"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04398212","Computer Vision Syndrome Visual Sequelae",,"Recruiting","No Results Available","Computer Vision Syndrome","Diagnostic Test: mfERG (multifocal-retinogram)","visual acuity|near vision","Sohag University","All","Child, Adult, Older Adult","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","5-10/4/2018","May 21, 2020","August 2020","October 2020","May 21, 2020",,"May 27, 2020","Faculty of medicine, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT04398212"
2,"NCT04405648","Computer Vision Syndrome Prevalence Among University Students",,"Recruiting","No Results Available","Computer Vision Syndrome","Behavioral: CVS GROUP","Prevalence of CVS|Visual acuity|Refraction|Schirmer test|Tear Break Up Time (TBUT)","Sohag University","All","Child, Adult, Older Adult",,"650","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","4-8/1/2018","May 28, 2020","July 2020","August 2020","May 28, 2020",,"June 1, 2020","Faculty of medicine, Sohag, Egypt|Sohag Faculty of Medicine, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT04405648"
3,"NCT00920231","Computer Vision System for the Blind Veteran",,"Completed","Has Results","Blindness","Device: initial system|Device: modified system","Frequency of Device Failures Per Attempt to Complete a Navigation Course|Ability to Meet the Subjective Travel Needs of the Blind Subject","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","16","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","C6731-R","November 2011","December 2013","September 2015","June 15, 2009","April 2, 2015","January 22, 2016","Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00920231"
4,"NCT03831919","Trial of Hoya SYNC III Design Lenses","SYNCIII","Recruiting","No Results Available","Computer Vision Syndrome","Device: SYNC III|Device: single vision lenses","Change in CVS-Q|Change in heterophoria|Change in aligning prism|Change in near point of convergence|Change in amplitude of accommodation|Change in accommodative lag|Change in accommodative facility|Fusional reserves|Stereopsis","The Institute of Optometry, London","All","18 Years to 40 Years   (Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYNCIII","January 7, 2019","July 31, 2019","July 31, 2019","February 6, 2019",,"February 6, 2019","Institute of Optometry, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03831919"
5,"NCT04102631","A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy",,"Recruiting","No Results Available","Adenoma Detection Rate","Diagnostic Test: colonoscopy with assistance of Endo.Angel|Diagnostic Test: colonoscopy without assistance of Endo.Angel","Adenoma detection rate|The mean number of polyps per procedure|Polyp Detection Rate|The mean number of adenomas per procedure|Detection rate of large, small and minimal polyps|The mean number of large, small and minimal polyps per procedure|Detection rate of large, small and minimal adenomas|The mean number of large, small and minimal adenomas per procedure|Detection rate of adenoma in different sites|The mean number of adenomas in different sites per procedure|Time of colonoscopic withdrawal|Time of colonoscopic insertion|The rate of reaching the ileocecal region","Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1076","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","EA-18-002","August 30, 2019","November 30, 2019","December 31, 2019","September 25, 2019",,"September 25, 2019","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04102631"
6,"NCT03781583","SmartHMD for Improved Mobility",,"Recruiting","No Results Available","Low Vision|Orientation|Mobility Limitation|Navigation, Spatial|Visual Impairment","Device: No HMD used|Device: HMD worn but not active|Device: HMD worn and active","Mobility accuracy: Percentage Correct Alignment|Mobility accuracy: Veering|Mobility accuracy: Percentage Cue Usage|Detection of Signal|Time-to-Complete","James Weiland|University of Michigan","All","14 Years to 89 Years   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","HUM00141598","April 26, 2019","March 31, 2021","March 31, 2022","December 20, 2018",,"January 23, 2020","North Campus Research Complex, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03781583"
7,"NCT00338611","Convergence Insufficiency Treatment Trial (CITT)",,"Unknown status","No Results Available","Convergence Insufficiency|Binocular Vision Disorder","Behavioral: Home-based Pencil Push-Up Therapy|Behavioral: Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Behavioral: Office-based Vision Therapy/Orthoptics|Behavioral: Placebo Office-based Vision Therapy/Orthoptics","Measure of symptoms using a 15-item Convergence Insufficiency Symptom Survey|Eyes' ability to converge when performing close work","National Eye Institute (NEI)","All","9 Years to 18 Years   (Child, Adult)","Phase 3","221","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NEI-107","July 2005","September 2008","September 2009","June 20, 2006",,"March 25, 2010","University of Alabama at Birmingham School of Optometry, Birmingham, Alabama, United States|Southern California College of Optometry, Fullerton, California, United States|Ratner Children's Eye Center, La Jolla, California, United States|NOVA Southeastern University College of Optometry, Ft. Lauderdale, Florida, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|State University of New York College of Optometry, New York, New York, United States|The Ohio State University College of Optometry, Columbus, Ohio, United States|Pennsylvania College of Optometry, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00338611"
8,"NCT03705182","Prevention of Dermatitis in Epoxy Exposed Workers",,"Recruiting","No Results Available","Contact Dermatitis|Sensitization Dermatitis","Device: Fluorescence visualization (feedback)","Change in sensitization|Change in prevalence of dermatitis|Change in fluorescence levels|Change in number of fluorescence recordings","Aarhus University Hospital|Arbejdsmiljøforskningsfonden|Vestas Wind Power|Siemens Gamesa Renewable Energy|Skane University Hospital|Herning Hospital|National Research Centre for the Working Environment, Denmark|Aalborg University Hospital|University of Aarhus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Epoxy Vision","December 1, 2018","December 30, 2020","December 30, 2020","October 15, 2018",,"April 25, 2019","Department of Occupational medicine, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03705182"
9,"NCT04135716","A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy",,"Not yet recruiting","No Results Available","Adenoma","Diagnostic Test: Colonoscopy with assistance of Endo.Angel|Diagnostic Test: Colonoscopy without assistance of Endo.Angel","Adenoma detection rate|The mean number of polyps per procedure|Polyp Detection Rate|The mean number of adenomas per procedure|Detection rate of large, small and minimal polyps|The mean number of large, small and minimal polyps per procedure|Detection rate of large, small and minimal adenomas","Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1076","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","EA-18-003","November 28, 2019","March 1, 2020","July 1, 2020","October 23, 2019",,"October 23, 2019","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04135716"
10,"NCT04319055","AI-Assisted Facial Surgical Planning",,"Completed","No Results Available","Facial Plastic and Reconstructive Surgery|Periocular Diseases|Orbital Diseases|Artificial Intelligence",,"The model performance is evaluated by accuracy|AUC (Area Under the Curve)|ROC (Receiver Operating Characteristics) curve.|An Artificial Intelligence Approach to Identifying Facial, Periocular, and Orbital Diseases","National Taiwan University Hospital|Stanford University","All","20 Years to 65 Years   (Adult, Older Adult)",,"17932","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","201908066RIND","January 1, 2009","December 31, 2018","July 30, 2019","March 24, 2020",,"March 24, 2020","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04319055"
11,"NCT02879591","Enhancing Social Interaction With an AlterEgo Artificial Agent","ALTEREGO","Unknown status","No Results Available","Schizophrenia","Other: Social Skills training with Avatar therapist","number of patient enhancing social intercation|number of patient accepting avatar therapy|questionnaire for Faisability of avatar therapy","University Hospital, Montpellier|Université Montpellier|Ecole Polytechnique Fédérale de Lausanne|University of Bristol|DEUTSCHES FORSCHUNGSZENTRUM FUER KUENSTLICHE","All","18 Years to 60 Years   (Adult)","Not Applicable","246","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","U 9038","April 2014","September 2016","September 2016","August 25, 2016",,"August 25, 2016","Service Universitaire de psychiatrie adulte, University Hospital of Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02879591"
12,"NCT02243670","Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy",,"Completed","No Results Available","Opiate Addiction|Medication Non-adherence|Addiction|Opioid Dependence","Device: AiCure monitoring and intervention","To evaluate the feasibility and acceptability to participants and study staff in using AiCure to monitor medication adherence.|To evaluate the acceptability of using AiCure to optimize care pathways.|To measure the reliability and validity of AiCure in detecting interruptions in treatment.|The degree of participant maximum craving (during the 24 hour period prior to the study visit) for opioids as measured by the Brief Substance Craving Scale (BSCS).|The change in participant's psychosocial well being over time as measured by the seven subscales of the Addiction Severity Index (ASI).","AiCure|Orexo AB|Montefiore Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIC-HHSN271201300036C-01|HHSN271201300036C","August 2016","March 2017","March 2017","September 18, 2014",,"September 12, 2017","Montefiore Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02243670"
13,"NCT04220242","Future of Colorectal Cancer Surgery","FOCCuS1","Recruiting","No Results Available","Colorectal Cancer|Surgery","Other: Video recordings with analysis thereafter applied|Other: Examination of microsections of tissue excised for the purposes of cancer resection|Other: Cancer organoid development and testing","Video recordings of Colorectal Cancer.|Analysis of video recordings|Biophysics visualisation software development|Biophysics model training|Validation of predictive accuracy biophysics-visualisation model|Coefficients of Variation|Microscopic Map of intratumoral fluorophore accumulation|Realtime delineation display of tumour area including margins","Mater Misericordiae University Hospital|Royal College of Surgeons, Ireland|IBM Research In Ireland","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","DT 2018 0240","December 30, 2019","December 1, 2022","March 1, 2023","January 7, 2020",,"January 7, 2020","Mater Misericordiae University Hospital, Dublin, Other (Non U.s.), Ireland",,"https://ClinicalTrials.gov/show/NCT04220242"
14,"NCT02546063","Carbohydrate Estimation Supported by the GoCARB System",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Carbohydrates","Other: Smartphone App","Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring|Composite of insulin-related parameters|Glucose-related parameters|Daily nutritional behavior in individuals with T1D|User satisfaction","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","100/15","August 2015","December 2015","December 2015","September 10, 2015",,"August 10, 2016","Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02546063"
15,"NCT03955614","Intelligent Operating Room","inOr","Recruiting","No Results Available","Surgery","Other: pedal-controlled GoSurgeryTM|Other: ML-controlled GoSurgeryTM|Other: NoGo","Does GosurgeryTM affect teamwork?|Does GoSurgeryTM affect surgical training overtime?|Does GoSurgeryTM affect delays in the operating theatre?|Does GoSUrgeryTM affect mental demand overtime when operating?|Does GoSurgeryTM affect operative timings?|Does GoSurgeryTM affect patient outcomes (the presence of complications )?|Does GoSurgeryTM affect patient outcomes (duration of hospital stay)?|How does GosurgeryTM affect team performance?|Evaluation of the Machine Learning algorithm to correctly detect operative steps of the procedures.|Does GoSurgeryTM influence cost of wasted equipment?","Imperial College London","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","19SM4984","October 4, 2019","October 2020","October 2020","May 20, 2019",,"October 10, 2019","Imperial College Hospitals NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03955614"
16,"NCT01387581","Does the Aid of MelaFind Affect Clinical Management Decisions",,"Completed","Has Results","Melanoma",,"Sensitivity|Specificity","MELA Sciences, Inc.","All","Child, Adult, Older Adult",,"227","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","20101","October 2011","March 2012","March 2012","July 4, 2011","November 14, 2014","November 14, 2014","MELA Sciences, Irvington, New York, United States",,"https://ClinicalTrials.gov/show/NCT01387581"
17,"NCT04079478","The AID Study: Artificial Intelligence for Colorectal Adenoma Detection","AID","Completed","No Results Available","Colon Cancer","Other: AI","Additional diagnostic yield obtained by AI-aided colonoscopy to the yield obtained by the Standard (high-definition) colonoscopy","Istituto Clinico Humanitas","All","40 Years to 80 Years   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2363","September 25, 2019","December 31, 2019","December 31, 2019","September 6, 2019",,"February 12, 2020","Endoscopy Unit, Humanitas Research Hospital, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04079478"
18,"NCT04260321","The AID Study 2: Artificial Intelligence for Colorectal Adenoma Detection 2",,"Recruiting","No Results Available","Colon Cancer","Device: AI","Non-inferiority of AI-aided colonoscopy in terms of ADR","Istituto Clinico Humanitas","All","40 Years to 80 Years   (Adult, Older Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2363-2","February 19, 2020","December 31, 2020","December 31, 2020","February 7, 2020",,"June 16, 2020","Fondazione Poliambulanza, Brescia, Italia, Italy|Endoscopy Unit, Humanitas Research Hospital, Rozzano, Milano, Italy|Ospedale Valduce, Como, Italy|Digestive Endoscopy Unit, Nuovo Regina Margherita Hospital, Rome, Italy|Ente Ospedaliero Cantonale, Ospedale Italiano, Lugano, Switzerland",,"https://ClinicalTrials.gov/show/NCT04260321"
19,"NCT04377217","Computerized Facial Recognition for Automated Diagnosis of the Facio-Scapulo-Humeral Muscular Dystrophy (FSMHD): Pilot Study","CV4 DIAGNOSIS","Not yet recruiting","No Results Available","Muscular Dystrophy, Facioscapulohumeral","Other: Video recording","Video recording","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-AOI-03","May 2020","December 2021","December 2021","May 6, 2020",,"May 6, 2020","Hopital Pasteur 2, Nice, France",,"https://ClinicalTrials.gov/show/NCT04377217"
20,"NCT03382951","Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH",,"Enrolling by invitation","No Results Available","Sedentary Lifestyle",,"Screen media use/viewing|The feasibility to recruit families to test the of the FLASH devices their home|The feasibility of the FLASH devices to be used in the family's home|The feasibility of the FLASH devices in children's homes to measure the amount of time a child spends viewing TV or other screens|The feasibility of the FLASH devices in children's homes for future studies","Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|William Marsh Rice University|Seattle Children's Hospital","All","6 Years to 65 Years   (Child, Adult, Older Adult)",,"448","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","H-40556|R01DK113269","October 19, 2017","March 30, 2021","February 28, 2022","December 26, 2017",,"February 12, 2020","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03382951"
21,"NCT03770832","Wearable Sensors and Video Recordings to Monitor Motor Development",,"Recruiting","No Results Available","Motor Delay|Neurodevelopmental Disorders|Developmental Disability",,"Three month clinical score estimation|Six month clinical score estimation|Prediction of neuromotor outcome using sensor and video data from 3 month time-point|Prediction of neuromotor outcome using sensor and video data from 6 month time-point|Prediction of neuromotor outcome using General Movements Assessment (GMA) scores|Prediction of neuromotor outcome using Alberta Infant Motor Scale (AIMS) scores|Prediction of neuromotor outcome using Hammersmith Infant Neurological Examination (HINE) scores|Prediction of neuromotor outcome using Test of Infant Motor Performance (TIMP) scores|Clinical score estimation|Prediction of neuromotor outcome at 2 years using sensor and video data from the remaining time-points","Shirley Ryan AbilityLab|Ann & Robert H Lurie Children's Hospital of Chicago|Northwestern University","All","up to 24 Months   (Child)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SX04202018","March 29, 2019","December 2023","December 2023","December 10, 2018",,"March 19, 2020","Shirley Ryan AbilityLab, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03770832"
22,"NCT03936413","Artificial Intelligence in Echocardiography",,"Not yet recruiting","No Results Available","Cardiovascular Diseases","Device: Bay Labs EchoGPS Echcoardiogram|Device: Native Terason Echocardiogram","Echocardiogram image acquisition quality|Educational outcome","New York Presbyterian Hospital|Caption Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NYPresbyterianH","May 1, 2019","June 30, 2020","June 30, 2020","May 3, 2019",,"May 3, 2019",,,"https://ClinicalTrials.gov/show/NCT03936413"
23,"NCT02981758","Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)","ADOPT","Completed","No Results Available","Post-partum Hemorrhage (PPH)",,"Quantification of blood loss during vaginal deliveries|Comparison of quantified blood loss (hemoglobin loss) using the The Triton™ System of mobile imaging with computer vision and learning algorithms compared to estimations of blood loss given by the provider.|Comparison of quantified blood loss (hemoglobin loss) using the The Triton™","Hackensack Meridian Health","Female","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Pro2016-0184","July 2016","July 2018","September 2019","December 5, 2016",,"February 11, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02981758"
24,"NCT04321200","PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability",,"Not yet recruiting","No Results Available","Pediatric ALL|Infant Development|Neurodevelopmental Disorders","Diagnostic Test: PANDA Gym|Other: Mobile App","Prechtl's General Movements Assessment (GMA)|The Test of Infant Motor Performance (TIMP)|Alberta Infant Motor Scale (AIMS)|Hammersmith Infant Neurological Examination (HINE)","University of Pennsylvania|Children's Hospital of Philadelphia","All","up to 6 Months   (Child)",,"1700","Other","Observational","Observational Model: Other|Time Perspective: Prospective","833180","August 1, 2020","August 1, 2023","July 1, 2024","March 25, 2020",,"March 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04321200"
25,"NCT03345693","Use of MoTrack Therapy in At-Home Hand Rehabilitation",,"Recruiting","No Results Available","Hand Injuries","Device: MoTrack Therapy","Compliance|Patient Ability to Understand the Prescribed Exercises From the Device|Prediction of Patient Improvement|Patient Hand Recovery|Patient Satisfaction|Therapist Satisfaction","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00106559","November 10, 2017","July 2020","July 2020","November 17, 2017",,"July 23, 2019","Johns Hopkins Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03345693"
26,"NCT04068688","Tailoring Treatment Targets for Early Autism Intervention in Africa",,"Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Early Start Denver Model (ESDM)","Supported joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Coordinated joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Symbol-infused joint engagement measured by the Joint Engagement Rating Inventory (JERI)|Fluency and connectedness measured by the Joint Engagement Rating Inventory (JERI)|Shared routines and rituals measured by the Joint Engagement Rating Inventory (JERI)|Scaffolding measured by the Joint Engagement Rating Inventory (JERI)|Following in on a child's focus measured by the Joint Engagement Rating Inventory (JERI)|Caregiver affect measured by the Joint Engagement Rating Inventory (JERI)|Initiation of joint attention measured by the Early Social Communication Scales (ESCS)|Response to joint attention measured by the Early Social Communication Scales (ESCS)|Language and Communication developmental quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Personal-Social-Emotional developmental quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Socialization subscale standard score on the Vineland Adaptive Behavior Scales - Socialization subscale standard score on the Vineland Adaptive Behavior Scales - 3rd edition (VABS-3)|Communication subscale standard score on the Vineland Adaptive Behavior Scales - 3rd edition (VABS-3)|Affective response measured by the SenseToKnow App|Social referencing measured by the SenseToKnow App|Gaze patterns measured by the SenseToKnow App|Postural sway measured by the SenseToKnow App","Duke University|University of Cape Town","All","18 Months to 72 Months   (Child)","Not Applicable","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00103045","September 1, 2019","July 31, 2021","July 31, 2021","August 28, 2019",,"October 9, 2019","University of Cape Town, Cape Town, West Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT04068688"
27,"NCT04309097","Reducing Eye Strain and Anxiety Using a Digital Intervention During Online Learning Class Recess Among Children at Home: A Randomized Controlled Trial","RESILIENT","Completed","No Results Available","Anxiety|Digital Eye Strain","Behavioral: Digital intervention|Behavioral: Information-only intervention","Change in anxiety|Change in syndromes of digital eye strain|Change in sleeping quality|Changes in time (hour) spent on different near work activities","Sun Yat-sen University","All","Child, Adult, Older Adult","Not Applicable","954","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020KYPJ045","March 16, 2020","March 29, 2020","March 29, 2020","March 16, 2020",,"May 12, 2020","Secondary schools, Zhaoqing, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04309097"
28,"NCT02996669","Autism Biomarker Consortium for Clinical Trials","ABC-CT","Completed","No Results Available","Autism Spectrum Disorder",,"NEPSY-II|Video Tracking|Aberrant Behavior Checklist (ABC)|Autism Impact Measure (AIM) Frequency|Autism Impact Measure (AIM) Impact|Child and Adolescent Symptom Inventory 5 (CASI-5)|PDD Behavior Inventory (PDD-BI)|Social Responsiveness Scale 2 (SRS-2) Total Score|Cognitive Assessment|Resting State EEG|Faces EEG|Visual Evoked Potentials (VEPs) EEG|Biological Motion EEG|Eye-tracking (ET) Biological Motion Task|Eye-tracking (ET) Activity Monitoring Task|Eye-tracking (ET) Interactive Social Task (IST)|Eye-tracking (ET) Pupillary Light Reflex Task|Eye-tracking (ET) Visual Search/Static Social Scenes Task","Yale University|Boston Children’s Hospital|Duke University|University of California, Los Angeles|University of Washington|Food and Drug Administration (FDA)|National Institute of Mental Health (NIMH)","All","6 Years to 11 Years   (Child)",,"399","Other|U.S. Fed|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1509016477|U01FD006888|U19MH108206","October 2016","May 13, 2019","May 13, 2019","December 19, 2016",,"March 5, 2020","Yale University Child Study Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02996669"
29,"NCT02798848","CREATE - Children Reading With Electronic Assistance To Educate","CREATE","Unknown status","No Results Available","Vision, Low|Child|Adolescent Development","Device: Tablet computer","acceptance/usage, measured as ordinal variable by participant diary|accessibility measured as ordinal variable as score on a touch-based game, ""Piano Tiles""|recruitment rates into the trial|Cardiff Visual Ability Questionnaire for Children (CVAQC) score|LV Prasad Functional Vision Questionnaire|Impact of Vision Impairment for Children (IVI_C) Questionnaire|Neale Analysis of Reading Ability (NARA)|International Reading Speed Texts (IREST)","University College, London|L.V. Prasad Eye Institute","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","15/0570","March 2016","December 2016","February 2017","June 14, 2016",,"June 14, 2016","Meera and L B Deshpande Centre for Sight Enhancement, L V Prasad Eye Institute, Hyderabad, India|South Essex Partnership Foundation Trust - Child Development Centre Bedford, Bedford, United Kingdom|Moorfields Eye Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02798848"
30,"NCT03908918","Mind and Body:A Clinical Trial Evaluation of a Smartphone App-based Mindfulness Intervention",,"Completed","No Results Available","Psychological Stress|Psychological Distress|Rehabilitation","Other: Mindfulness app","Outcome: Cost of treatment; Measure: Duration of stay|Outcome: Health services utilization; measure: survey questions|Outcome: Cost of treatment; Measure: Discharge destination|Outcome: Cost of treatment; Measure: Alternate Level of Care (ALC) assignment.|Outcome: Cost of treatment; Measure: National Rehabilitation Reporting System (NRS) assessments.|Outcome: Cost of treatment; Measure: Rehabilitation Patient Group (RPG)|Outcome: Cost of treatment; Measure: number of clinic visits|Outcome: stress; Measure: NIH Toolbox Perceived Stress Fixed Form (Age 18+ v2.0)|Outcome: Impact on health-related quality of life; Measure: PROMIS57|Outcome: clinician reported quality of patient appointment time; measure: purpose designed survey questions|Outcome: Mood; Measure: The Am app's mood measure|Outcome: Psychological flexibility; Measure: The Acceptance & Action Questionnaire-II|Outcome: User engagement; Measure: The Am app's user analytics - meditation choice and frequency|Outcome: Mood, stress and heart rate; Measure: The Am app's biometric measures (Heart Rate)|Outcome: Mood, stress and heart rate; Measure: The Am app's biometric measures (respiratory rate)|Outcome: Mood, stress and heart rate; Measure: The Am app's biometric measures (relative blood oxygen saturation)|Outcome: Stress; Measure: The Am app's stress measure|Outcome: Stress; Measure: The Am app's intent for practicing mindfulness measure|Outcome: User engagement; Measure: The Am app's points structure","Providence Healthcare","All","40 Years and older   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","123","April 1, 2019","September 30, 2019","September 30, 2019","April 9, 2019",,"December 18, 2019","Providence Healthcare, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03908918"
31,"NCT04242836","Development and Validation of a Digital Optotype for Near Vision in Greek Language.","DeDART","Completed","No Results Available","Presbyopia|Low Vision|Near Vision","Diagnostic Test: MNREAD testing","Reading Acuity (RA)|Maximum Reading Speed (MRS)|Critical Print Size (CPS)|Accessibility Index (ACC)|Intraclass Correlation Coefficients (ICCs) for study participants|Test-retest Intraclass Correlation Coefficients (ICCs)","Democritus University of Thrace","All","18 Years to 75 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ES3/Th2/27-03-2019","March 28, 2019","June 28, 2019","November 28, 2019","January 27, 2020",,"January 27, 2020","University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece",,"https://ClinicalTrials.gov/show/NCT04242836"
32,"NCT03760055","Assessment of Visual Function With a Portable Brain-computer Interface",,"Enrolling by invitation","No Results Available","Glaucoma|Age Related Macular Degeneration|Optic Neuropathy|Retinal Degeneration","Device: nGoggle","Device accuracy to detect visual field loss|Device accuracy to detect structural neural loss|Device accuracy to detect objective functional loss|Assessment of repeatability|Patients' satisfaction","NGoggle|Duke University|National Eye Institute (NEI)","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Industry|Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00100894|R42EY027651","February 11, 2019","January 2024","January 2024","November 30, 2018",,"February 27, 2020","Duke University Eye Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03760055"
33,"NCT03782181","Use of Whole Body Vibration in Patients With Fibromyalgia",,"Completed","Has Results","Fibromyalgia","Device: Whole body vibration platform","Pressure Pain Thresholds|Vibration Thresholds|Berg Scale|Six-minute Walking Test (6MWT)|Dynamometer|Analysis of the Romberg's Balance Test With the CvMob Software|Gait Task|Fibromyalgia Impact Questionnaire (FIQ)|Visual Analogue Pain Scale (VAS)|Quality of Life Index (QLI)","University of the Balearic Islands","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IB 2586/15 PI","January 7, 2019","March 25, 2019","June 28, 2019","December 20, 2018","January 29, 2020","February 13, 2020","University of Balearic Islands, Palma de Mallorca, Balearic Islands, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03782181/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03782181"
34,"NCT00678860","Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires",,"Completed","No Results Available","Eye Disease",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"147","NIH","Observational","Time Perspective: Prospective","080135|08-EI-0135","May 9, 2008",,"October 31, 2011","May 16, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00678860"
35,"NCT03894670","Evaluation of Methods for Measuring Gastrointestinal Transit and Food Reward in Healthy Individuals - The PRESET Study","PRESET","Completed","No Results Available","Healthy Participants","Other: Standard mixed breakfast meal|Other: SmartBar™","Gastric emptying time (minutes)|Small bowel transit time (minutes)|Large bowel transit time (minutes)|Total gastrointestinal transit time (minutes)|Motility index (arbitrary unit)|Metabolites|Hormones|Attention measured using eye tracking|Arousal measured using galvanic skin response|Emotions measured using facial expression analysis|Food choice|Implicit wanting|Explicit liking|Explicit wanting|Subjective appetite|Self-reported gastrointestinal symptoms (part 1)|Self-reported gastrointestinal symptoms (part 2)|Self-reported gastrointestinal symptoms (part 3)|Self-reported autonomic symptoms|Body weight (kg)|Body mass index (kg/m^2)|Fat mass (kg)|Fat percentage (%)|Fat free mass (kg)|Waist circumference (cm)|Hip circumference (cm)|Mean amplitude of glycaemic excursions (MAGE)|Continuous overall net glycaemic action (CONGA)|Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)|Mean glucose concentrations|Standard deviation of glucose concentrations|Variation coefficients of glucose concentrations|Resting energy expenditure (kcal/day)|Substrate oxidation (respiratory exchange ratio)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Heart rate (bpm)|Heart rate response to standing up from the supine position|Heart rate response to inhalation and exhalation|Heart rate response to forced exhalation during rest (valsalva maneuver)|Microbiome content and diversity|Physical activity (time spent at different intensities)|Physical activity (counts/min)|Physical activity energy expenditure (kcal/day)|Physical activity (MET hours)|Timing of physical activity (hh:mm)|Energy intake (kcal/day)|Macronutrient intake (energy percentage)|Timing of dietary intake (hh:mm)|Sleep timing (hh:mm)|Sleep duration (minutes)|Sleep variability (minutes)|Sleep onset latency (minutes)|Sleep efficiency (%)|Wakefulness (minutes)|HbA1c (mmol/mol and %)|Insulin sensitivity (indices)|Insulin resistance (indices)","Kristine Færch|University of Copenhagen|iMotions A/S|University of Leeds|Aalborg University Hospital|Steno Diabetes Center Copenhagen","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-18026293","October 16, 2018","May 24, 2019","May 24, 2019","March 28, 2019",,"June 18, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT03894670"
36,"NCT03854656","Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes","RESET","Recruiting","No Results Available","Overweight and Obesity|PreDiabetes","Other: Time-restricted eating","Change in body weight (kg)|Body weight (kg)|Body mass index (kg/m^2)|Fat mass (kg)|Fat free mass (kg)|Fat percentage (%)|Waist circumference (cm)|Hip circumference (cm)|HbA1c (mmol/mol and %)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Heart rate (bpm)|Resting energy expenditure (kcal/day)|Substrate oxidation (respiratory exchange ratio)|Metabolites|Hormones|Circulating proteins that associate with low-grade inflammation and lipid metabolism|Respiratory and glycolytic capacities of isolated peripheral blood mononuclear cells (PBMCs)|Heart rate response to standing up from the supine position|Heart rate response to inhalation and exhalation|Heart rate response to forced exhalation during rest (valsalva maneuver)|Gastric emptying time (hours and minutes)|Small bowel transit time (hours and minutes)|Large bowel transit time (hours and minutes)|Total gastrointestinal transit time (hours and minutes)|Motility index|Attention measured using eye tracking|Emotions measured using facial expression analyses|Arousal measured using galvanic skin response|Food choice|Implicit wanting|Explicit liking|Explicit wanting|Insulin sensitivity (indices)|Insulin resistance (indices)|Subjective appetite|Mean amplitude of glycaemic excursions (MAGE)|Continuous overall net glycaemic action (CONGA)|Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)|Mean glucose concentrations|Standard deviation of glucose concentrations|Variation coefficients of glucose concentrations|Physical activity (time spent at different intensities)|Physical activity (counts/min)|Physical activity energy expenditure (kcal/day)|Physical activity (MET hours)|Timing of physical activity (hh:mm)|Energy intake (kcal/day)|Macronutrient intake (energy percentage)|Timing of dietary intake (hh:mm)|Sleep timing (hh:mm)|Sleep duration (min)|Sleep variability (min)|Sleep onset latency (min)|Sleep efficiency (%)|Wakefulness (min)|Self-reported gastrointestinal symptoms (part 1)|Self-reported gastrointestinal symptoms (part 2)|Self-reported gastrointestinal symptoms (part 3)|Self-reported autonomic symptoms|Self-reported control over eating|Self-reported sleepiness|Self-reported sleep quality|Self-reported chronotype|Self-reported physical activity|Self-reported overall health and wellbeing|Self-reported eating behavior|Self-reported night eating|Daily eating/drinking window (hh:min)|Microbiome content and diversity|Motivation for participation (qualitative methods)|Feasibility of the intervention (qualitative methods)|Satisfaction with the intervention (qualitative methods)","Kristine Færch|University of Copenhagen|Aalborg University Hospital|iMotions A/S|University of Leeds|Salk Institute for Biological Studies|Steno Diabetes Center Copenhagen","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NNF17OC0027822","February 25, 2019","June 2020","August 2020","February 26, 2019",,"November 25, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT03854656"
37,"NCT03986619","Evaluation of Methods for Measuring Food Reward and Food-related Behavior in Healthy Individuals","PRESET","Completed","No Results Available","Healthy Participants",,"Gaze duration bias (ratio)|Attention|Arousal|Emotions|Food choice|Reaction time (ms)|Implicit wanting|Explicit liking|Explicit wanting|Subjective appetite|Body weight (kg)|Body mass index (kg/m^2)|Fat mass (kg)|Fat percentage (%)|Fat free mass (kg)|Waist circumference (cm)|Hip circumference (cm)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Heart rate (bpm)|HbA1c (mmol/mol and %)|Sleep quality|Sleepiness|Self-reported health|Physical activity|Chronotype|Night eating|Eating behavior|Control over eating|Socioeconomic status|Total energy intake (kcal or kJ)|Energy intake from specific food categories (kcal or kJ)","Steno Diabetes Center Copenhagen|University of Copenhagen|University of Leeds|Aalborg University Hospital|iMotions A/S","All","30 Years to 70 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","H-18026293_substudy","October 16, 2018","August 29, 2019","August 29, 2019","June 14, 2019",,"September 4, 2019","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT03986619"
38,"NCT02862405","Perception of Objects and Natural Scenes in People With Vision Loss (ACTIVIS)","ACTIVIS","Completed","No Results Available","Vision Loss","Other: vision tests","Comparison of performances in visual tests between different groups according to error rate|Comparison of performances in visual tests between different groups according to answer time|Estimation of the score of visual acuity by the logMAR chart|Measure of lesion size|Pearson correlation coefficient to determine the correlation between the performance parameters during visual tests (error rate and answer time) and clinical parameters (visual acuity and lesion size)","Lille Catholic University|University Hospital, Lille","All","18 Years to 90 Years   (Adult, Older Adult)",,"260","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","RC-P009","March 2011","March 2015","March 2015","August 11, 2016",,"August 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02862405"
39,"NCT02925884","Effects of Gunnar Computer Glasses on Viewing Comfort and Performance",,"Terminated","No Results Available","Dry Eye|Eye Strain|Visual Acuity|Color Perception|Reading","Device: Gunnar OTC Glasses Condition","Subjective rating of Gunnar computer glasses preference|Viewing discomfort|Visual acuity|Color perception|Reading|Dry eye measurements","Pacific University|Gunnar Optiks","All","18 Years to 42 Years   (Adult)","Not Applicable","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","PUIRB075-13|Gunnar2013","June 2013","September 2013","September 2013","October 6, 2016",,"October 6, 2016","Vision Performance Institute, Pacific University, Forest Grove, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02925884"
40,"NCT02775396","Effects of Wearing Progressive Addition Lens on Working Distance and Refractive Status in Adult Computer Users",,"Completed","No Results Available","Video Game Play Using Handheld Computer","Device: Spectacle lens","Change in near working distance measured by an automatic ultrasound sensor|Change in refractive status measured by an automatic refractometer","The Hong Kong Polytechnic University|Carl Zeiss","All","18 Years to 40 Years   (Adult)","Not Applicable","64","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","P14-0085","September 2014","March 2015","April 2015","May 17, 2016",,"May 17, 2016",,,"https://ClinicalTrials.gov/show/NCT02775396"
41,"NCT03214484","The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients",,"Unknown status","No Results Available","Macular Degeneration Exudative Eye Bilateral","Other: By comparing the evolution of the visual acuity curves.|Other: By comparing the evolution of the curves.","Visual acuity","Hospital St. Joseph, Marseille, France","All","50 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Sight Study","June 2, 2017","December 2017","June 2018","July 11, 2017",,"July 11, 2017","Hopital Saint Joseph, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03214484"
42,"NCT02464241","Evaluation of Different Color Vision Tests in Children",,"Completed","No Results Available","Color Perception","Other: only examination","Percentage of correct answers per child per test.","University of Zurich","All","4 Years to 10 Years   (Child)",,"71","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KEK-ZH-Nr. 2014-0340","January 2015","August 2018","November 2018","June 8, 2015",,"November 26, 2018","University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02464241"
43,"NCT03151200","Visual Functional Connectivity and Visual Improvement After TMS/Binocular Treatment",,"Enrolling by invitation","No Results Available","Amblyopia","Device: Computer based binocular treatment|Device: Transcranial magnetic stimulation","Improvement of visual acuity in amblyopic eyes after TMS/binocular treatment|Improvement of stereovision and reduction in suppression in amblyopic patients after TMS/binocular treatment","University of Manitoba|University of Waterloo|McGill University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","B2014:117 (HS18266)","January 30, 2014","December 2019","December 2020","May 12, 2017",,"April 18, 2019","VGH Adult Medical Clinic, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03151200"
44,"NCT01515943","Convergence Insufficiency Treatment Study (CITS)",,"Completed","Has Results","Convergence Insufficiency","Other: Active home-based computer vergence/accommodative therapy|Procedure: Near target push-ups|Other: Placebo home-based computer vergence/accommodative therapy|Procedure: Placebo yoked prism flippers","Treatment Group Comparison of the Percentage of Participants Classified as an Overall Success at 12 Weeks - HB-C Versus HB-PU|Treatment Group Comparison of the Percentage of Participants Classified as an Overall Success at 12 Weeks - HB-C Versus HB-P|Number of Participants Classified as Having Met Success Criteria Based on CI Signs/Symptoms at 12 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria Based on the Mean NPC Break at 12 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria Based on the Mean PFV Blur at 12 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria for Both Clinical Measures at 12 Weeks by Treatment Group|Number of Participants Classified as Having Improved in All 3 Outcomes Measures From Baseline to 12 Weeks by Treatment Group|Number of Participants Classified as an Overall Success Based on the 3 Outcomes Measures From Baseline to 6 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria Based on CI Signs/Symptoms at 6 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria Based on the Mean NPC Break at 6 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria Based on the Mean PFV Blur at 6 Weeks by Treatment Group|Number of Participants Classified as Having Met Success Criteria for Both Clinical Measures at 6 Weeks by Treatment Group|Number of Participants Classified as Having Improved in All 3 Outcomes Measures From Baseline to 6 Weeks by Treatment Group","Jaeb Center for Health Research|Pediatric Eye Disease Investigator Group|National Eye Institute (NEI)","All","9 Years to 17 Years   (Child)","Not Applicable","204","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CITS|2U10EY011751","June 2012","January 2015","January 2015","January 24, 2012","August 5, 2016","April 12, 2017","Everett & Hurite Ophthalmic Association, Cranberry TWP, Pennsylvania, United States|Pennsylvania College of Optometry, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01515943"
45,"NCT02279446","Development of a Validated Chart for Intermediate Vision Assessment",,"Unknown status","No Results Available","Myopia|Hyperopia|Presbyopia|Astigmatism","Other: Intermediate Visual acuity (IVA) assessment","Intermediate Visual Acuity (IVA)","Democritus University of Thrace","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Time Perspective: Cross-Sectional","263/13-10-2014","October 2014","October 2014","April 2015","October 31, 2014",,"October 31, 2014","Eye Institute Of thrace, Alexandroupolis, Evros, Greece",,"https://ClinicalTrials.gov/show/NCT02279446"
46,"NCT04142307","Biofeedback in Idiopathic Infantile Nystagmus Syndrome",,"Recruiting","No Results Available","Low Vision in Children","Device: Biofeedback Training|Device: Sham - simulated BT","Changes in Best Corrected Visual Acuity for Distance Vision across BT sessions and post BT|Changes in Fixation Stability (Bivariate contour ellipse area) across BT sessions and post BT|Changes in Contrast Sensitivity for near vision across BT sessions and post BT|Changes in Stereopsis for near vision across BT and post BT|Changes in Quality of Life Parental Questionnaire across BT and post BT|Changes in Reading speed across BT sessions and post BT","Monica Daibert Nido|University of Toronto","All","5 Years to 17 Years   (Child)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Biofeedback Low Vision","January 30, 2019","October 15, 2019","January 30, 2020","October 29, 2019",,"October 29, 2019","CNIB, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04142307"
47,"NCT01799707","Vision Restoration Training in Glaucoma","gVRT","Completed","No Results Available","Glaucoma","Behavioral: vision restoration training|Behavioral: Discrimination Training","Detection accuracy change in percent over baseline of the visual field|change in visual stimulus perimetric detection rate|improvement of reaction time","University of Magdeburg","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VRT 03-2003","July 2004","August 2007","March 2013","February 27, 2013",,"July 9, 2019",,,"https://ClinicalTrials.gov/show/NCT01799707"
48,"NCT02840305","Brain Bases of Natural Scenes's Visual Perception of Natural Scenes","SCENES","Completed","No Results Available","Healthy Volunteer","Other: Evaluation of visual function|Other: Magnetic Resonance Imaging","Identify brain bases of natural scenes's visual perception of the natural scenes","University Hospital, Grenoble","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","38RC11.221","April 2012","March 2016","August 2016","July 21, 2016",,"January 18, 2017","UniversityHospitalGrenoble, La Tronche, France",,"https://ClinicalTrials.gov/show/NCT02840305"
49,"NCT02020252","Effect of Multi-Media Enrollment",,"Unknown status","No Results Available","Lung Cancer","Other: Touchscreen Computer Program","Change in attitudes, knowledge, and clinical trial decision making after use of interactive multimedia learning program","University of Chicago","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Other|Time Perspective: Prospective","IRB13-1233","November 26, 2013","October 2018","November 2018","December 24, 2013",,"January 4, 2018","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02020252"
50,"NCT01414023","Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder","CCT-OC","Completed","No Results Available","Obsessive Compulsive Disorder","Behavioral: Cognitive Control Training|Behavioral: Peripheral Vision Task","OCI-R scores|BDNF serum levels","Boston University Charles River Campus","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BU-2487","July 2011","July 2012","July 2012","August 11, 2011",,"May 18, 2020","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01414023"
51,"NCT03275753","Visual Function Tests in Age-related Macular Degeneration",,"Recruiting","No Results Available","Age Related Macular Degeneration","Other: Visual Function Tests","Critical flicker fusion|Dark adaptation|Reading Tests|Color vision function|Shape discrimination","ORA, Inc.","All","60 Years to 99 Years   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","17-270-0001","September 21, 2017","December 2019","December 2019","September 8, 2017",,"October 30, 2018","Andover Eye Associates, Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03275753"
52,"NCT00013936","A Novel Acuity Testing Method",,"Completed","No Results Available","Vision Disorder",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"500","NIH","Observational",,"010136|01-EI-0136","March 2001",,"October 2002","April 4, 2001",,"March 4, 2008","National Eye Institute (NEI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00013936"
53,"NCT04111068","Improving Vision in Adults With Macular Degeneration",,"Recruiting","No Results Available","Macular Degeneration","Device: anodal tDCS Active Stimulation|Device: anodal tDCS Sham/Placebo Stimulation","Rapid Serial Visual Presentation (RSVP) Reading Pre-Test|Rapid Serial Visual Presentation (RSVP) Reading Post-Test 1 (during stimulation)|Rapid Serial Visual Presentation (RSVP) Reading Post-Test 2 (5 min after stimulation)|Rapid Serial Visual Presentation (RSVP) Reading Post-Test 3 (30 min after stimulation)|Uncrowded Visual Acuity Pre-Test|Uncrowded Visual Acuity Post-Test 1 (during stimulation)|Uncrowded Visual Acuity Post-Test 2 (5 min after Stimulation)|Uncrowded Visual Acuity Post-Test 3 (30 min after Stimulation)|Crowded Visual Acuity Pre-Test|Crowded Visual Acuity Post-Test 1 (during stimulation)|Crowded Visual Acuity Post-Test 2 (5 min after stimulation)|Crowded Visual Acuity Post-Test 3 (30 min after stimulation)","University of Waterloo|The Hong Kong Polytechnic University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VSBrainStim1","December 1, 2019","March 2020","March 2020","October 1, 2019",,"December 18, 2019","University of Waterloo, Waterloo, Ontario, Canada|The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04111068/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04111068"
54,"NCT02821403","Effects of Blue-light Blocking Lens on Visual Functions",,"Completed","Has Results","Effects of Blue-light Blocking Lens on Visual Functions","Device: clear lens with regular coating|Device: regular coating lens with yellow tint|Device: clear lens with blue-light blocking coating","Contrast Sensitivity as Assessed by Mars Contrast Sensitivity Chart|Color Vision as Assessed by the Farnsworth Munsell 100 Hue Test|Self-assessment of Lens Performance Through Questionnaire","The Hong Kong Polytechnic University","All","18 Years to 55 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","HSEARS20140512001-03","July 2014","May 2015","May 2015","July 1, 2016","April 7, 2017","April 7, 2017",,,"https://ClinicalTrials.gov/show/NCT02821403"
55,"NCT03748368","Computer-based Tutorial for the Informed Consent Process for Cataract Surgery in Turkish or Serbian Speaking Patients",,"Recruiting","No Results Available","Cataract","Other: Cataract presentation|Other: Placebo presentation","Number of correctly answered questions between study group and control group|Usability of the touchscreen device","Prim. Prof. Dr. Oliver Findl, MBA|Vienna Institute for Research in Ocular Surgery","All","21 Years to 105 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","CatInfo SK/TK","January 1, 2017","May 1, 2020","July 1, 2020","November 20, 2018",,"October 2, 2019","Vienna Institute for Research in Ocular Surgery (VIROS), Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03748368"
56,"NCT04142164","Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections",,"Recruiting","No Results Available","Age-related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema","Other: MacInfo presentation|Other: Placebo presentation","Number of correctly answered questions between study group and control group|Usability of the touchscreen device","Prim. Prof. Dr. Oliver Findl, MBA|Vienna Institute for Research in Ocular Surgery","All","21 Years to 105 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","MacInfo","October 24, 2019","January 1, 2021","May 1, 2021","October 29, 2019",,"October 30, 2019","Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04142164"
57,"NCT01454141","Cognitive Control Training for Depression",,"Completed","No Results Available","Depression","Other: Cognitive Control Training|Other: Peripheral Vision Task","Change in Beck Depression Inventory|Change in Positive and Negative Affective Scale (PANAS)|Emotional Response and Recovery Task|Changes in Visual Analog Scales","Boston University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BU-2182E","July 2010","June 2011","June 2011","October 18, 2011",,"October 18, 2011","Boston University, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01454141"
58,"NCT02494908","Evidence of Neuroplasticity After Performing a Cognitive Task in Idiopathic Parkinson's Disease Patients",,"Unknown status","No Results Available","Parkinson Disease","Behavioral: Playing a computer game simulating a car race","seeing evidence of microstructural brain tissue changes in Diffusion Tensor Imaging (DTI) MRI","Dr. Sharon Hassin|Bar-Ilan University, Israel|Tel Aviv University|Sheba Medical Center","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2372-15-SMC","July 2015","January 2018","July 2018","July 10, 2015",,"July 10, 2015","Movement Disorders Institute, Sheba Medical center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT02494908"
59,"NCT00475254","Stress and Vision Fluctuations in Retinitis Pigmentosa",,"Completed","No Results Available","Retinitis Pigmentosa",,"Vision test reliability across multiple test administrations in relation to psychological and external factors","Johns Hopkins University|National Institute of Nursing Research (NINR)|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)",,"50","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","K23EY018356","August 2007","April 2011","April 2011","May 21, 2007",,"April 6, 2011","Johns Hopkins WiImer Eye Insitute's Lions Vision Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00475254"
60,"NCT03703180","Vision Assessment With the Quick Contrast Sensitivity Function (qCSF) Method in Healthy Controls and MS","VICTOR2","Recruiting","No Results Available","Multiple Sclerosis",,"Correlation between ganglion cell / inner plexiform layer (GCIPL) thickness loss and area under the log CSF curve change over two years|Correlation between retinal nerve fibre layer (RNFL) thickness loss and area under the log CSF curve change over two years|Longitudinal correlation between visual quality of life and contrast vision","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","inims-victor2","January 29, 2018","February 2021","February 2021","October 11, 2018",,"October 22, 2018","Institute of Neuroimmunology and MS, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03703180"
61,"NCT04276610","Words on the Brain: Can Reading Rehabilitation for Age-Related Vision Impairment Improve Cognitive Functioning?","WOTB","Recruiting","No Results Available","Age-related Macular Degeneration|Dementia|Low Vision|Low Vision Aids|Hearing Loss|Reading Problem|Cognitive Impairment","Behavioral: Low Vision Reading Rehabilitation","Rey Auditory Verbal Learning Test (RAVLT)|Letter Number Sequencing task|Montreal Cognitive Assessment - full or blind version|1-n-back task|Minnesota Reading Test (MNRead)|Depression, Anxiety and Stress Scale|Canadian Digit Triplet Test|Magnetic Resonance Imaging (MRI) - for subset of participants","Université de Montréal|Fonds de la Recherche en Santé du Québec|Canadian Institutes of Health Research (CIHR)","All","65 Years and older   (Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRIR-1284-1217","May 16, 2017","May 16, 2023","May 16, 2023","February 19, 2020",,"February 20, 2020","Institut Nazareth et Louis-Braille du CISSS de la Montérégie-Centre, Longueuil, Quebec, Canada|Centre de réadaptation Lethbridge-Layton-Mackay du CIUSSS du Centre-Ouest-de-l'Île-de-Montréal, Montreal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04276610/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04276610/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04276610"
62,"NCT00318045","Effects of Optical Blur on Performance and Comfort of Computer Users",,"Unknown status","No Results Available","Refractive Error","Device: Eyeglass lenses","Visual comfort|Productivity (correct output per hour)","Vision Council of America","All","19 Years and older   (Adult, Older Adult)","Phase 3","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","X050208014","October 2005",,"April 2006","April 25, 2006",,"April 25, 2006","School of Optometry, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00318045"
63,"NCT02679716","Reconstruction of Pathological Changes of the Ophthalmic Artery in Patients With Retinal Artery Occlusion",,"Completed","No Results Available","Retinal Artery Occlusion","Other: MRI of the cerebral arteries","Pathological changes in subjects with retinal artery occlusions|number of patients with preexisting stroke","Vienna Institute for Research in Ocular Surgery","All","21 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","RAO","December 2014","July 31, 2017","July 31, 2018","February 10, 2016",,"October 22, 2019","Vienna Institute for Research in Ocular Surgery, Vienna, Austria|Hanusch-Krankenhaus, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02679716"
64,"NCT02023957","A Pilot With Interactive Computer-assisted Screening for Mental Health in Primary Care","iCAS","Completed","No Results Available","Mental Health Disorders","Behavioral: Interactive computer-assisted screening (iCAS)","Clinician Detection (probable, sub-clinical, confirmed) of major depression or generalized anxiety or post-traumatic stress disorder or alcohol dependence|Patient discussion on mental health|Patient intention to see a mental health counselor|Patient satisfaction with health services|Patient enablement to cope with these conditions|Patient adherence to follow-up advice and referrals to mental health support","York University|Canadian Institutes of Health Research (CIHR)|North York General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","e2013 - 291","November 2013","May 2014","May 2014","December 30, 2013",,"June 3, 2016","York University, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02023957"
65,"NCT02983305","Optical Head-Mounted Display Technology for Low Vision Rehabilitation",,"Completed","Has Results","Retinal Dystrophies|Healthy","Device: Head-Mounted Display","Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared)|Change in Gait Speed Compared to Baseline (Measured in Seconds)","University of Michigan","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00110408","June 26, 2017","November 21, 2018","November 21, 2018","December 6, 2016","October 9, 2019","October 9, 2019","Kellogg Eye Center, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02983305/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02983305"
66,"NCT01872000","Binocular Vision in Monocular Pseudophakia","BVMP","Terminated","No Results Available","Cataract","Procedure: Cataract surgery","Extent of binocular vision at near working distance following IOL implantation.|Change in visual acuity and subjective visual comfort at distance, intermediate and near working distances following IOL implantation.","University of Oxford|Oxford University Hospitals NHS Trust","All","18 Years to 45 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BVMP2013","April 2013","October 2018","October 2018","June 7, 2013",,"June 13, 2019","Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom|Stoke Mandeville Hospital, Aylesbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01872000"
67,"NCT03884985","Eye Movements, Visual Perception and Attention",,"Recruiting","No Results Available","Vision","Other: Visual stimulation","Average Performance in Visual tasks|Microsaccades rate","University of Rochester|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RSRB00069578|R01EY029788-01","January 1, 2015","February 1, 2023","February 1, 2023","March 21, 2019",,"March 16, 2020","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03884985"
68,"NCT03160131","Rehabilitation of Visual Function After Brain Injury","IBOS-NVT","Not yet recruiting","No Results Available","Stroke, Ischemic|Brain Injuries|Stroke Hemorrhagic|Traumatic Brain Injury","Device: Neuro Vision Technology","Ability to complete a mobility route|Time to complete a mobility route|National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)|Short Form (36) Health Survey (SF-36)|Montreal Cognitive Assessment (MoCA)|Fatigue Severity Scale-7|Multidimensional Fatigue Inventory 20 (MFI-20)|Test of Attentional Performance (TAP) Test 2.3: Visual Field|Behavioral Inattention Test (BIT)|Rey-Osterrieth's complex figure test|Modified Barthel-100 Index|Hemisphere differences","University Hospital, Gentofte, Copenhagen|The Institute for the Blind and Partially Sighted (IBOS)|Copenhagen University Hospital at Herlev","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-17001534","August 1, 2017","July 31, 2019","July 31, 2020","May 19, 2017",,"May 19, 2017","The Institute for the Blind and Partially Sighted (IBOS), Copenhagen, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT03160131"
69,"NCT01300949","Spaeth/Richman Contrast Sensitivity Test","SPARCS","Completed","Has Results","Glaucoma","Diagnostic Test: Spaeth/Richman Contrast Sensitivity Test|Diagnostic Test: Pelli-Robson Contrast Sensitivity Chart","Contrast Sensitivity, Another Means of Testing Vision","Wills Eye|Pfizer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","314","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-998","January 2010","April 2014","April 2014","February 23, 2011","November 8, 2018","December 11, 2018","Wills Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01300949"
70,"NCT00782444","Computer Navigation vs Conventional Technique in Knee Arthroplasty","CAOS","Active, not recruiting","No Results Available","Knee Osteoarthritis|Rheumatoid Arthritis","Procedure: Computer navigated knee replacement|Procedure: Conventional knee replacement","longevity of the implant|Function of the knee|Bleeding|complications","Haukeland University Hospital|The Research Council of Norway","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007/12587","January 2009","December 2020","December 2020","October 31, 2008",,"April 7, 2020","Haukeland university hospital, Bergen, Norway|Haugesund hospital, Haugesund, Norway|Haugesund sanitetsforenings revmatismesykehus, Haugesund, Norway|Lovisenberg diakonale sykehus, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00782444"
71,"NCT03997890","Clinical Outcomes of Patients Bilaterally Implanted With the TECNIS® Symfony or TECNIS® Symfony Toric Extended Range of Vision IOL",,"Completed","No Results Available","Cataract","Procedure: Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs","Visual outcome|Spectacle use|Photic phenomena|Patient Satisfaction","Yonsei University","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","96","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-2016-0029","July 13, 2016","January 18, 2018","January 18, 2018","June 25, 2019",,"June 27, 2019","Department of Ophthalmology, Yonsei Univeristy College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03997890"
72,"NCT03794752","Visual Enhancement Device in Low Vision Patients","Evergaze","Terminated","No Results Available","Macular Degeneration, Age-Related|Diabetic Retinopathy","Device: Head-Mounted Visual Enhancement Device","Change in best corrected visual acuity (BCVA) compared from baseline with and without the head-mounted electronic visual enhancement device|Change in best corrected near visual acuity (BCNVA) from baseline with and without the head-mounted electronic visual enhancement device|Change in reading speed from baseline compared with and without the head-mounted electronic visual enhancement device|Change in response speed to identify facial expressions from baseline compared with and without the head-mounted electronic visual enhancement device|Change in response speed to visual-motor skills to identify shapes and objects from baseline compared with and without the head-mounted electronic visual enhancement device|Change in score measured on a rating scale to assess difficulty with visual function from baseline compared with and without the head-mounted electronic visual enhancement device","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STU 012014-015","February 2015","December 28, 2018","December 28, 2018","January 7, 2019",,"February 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03794752"
73,"NCT02614651","AUgmented REality for the Visually Impaired - Part 1","AUREVI 1","Completed","No Results Available","Retinitis Pigmentosa|Glaucoma","Procedure: Find visual comfort threshold related to light intensity|Procedure: Find the size of the visual field|Procedure: Effectiveness of brightness control|Procedure: Performance of color correction|Device: Vuzix Wrap 1200DX virtural reality glasses","The maximum brightness value for visual comfort (THRESHOLD_MAX)|The minimum value of the perceptible light contrast in low light perceptible (THRESHOLD_MIN)|The speed of light change adaptation within a pre-specified range (getting dimmer)|The speed of light change adaptation within a pre-specified range (getting brighter)|Optimal range (in degrees) of the visual field provided by the device ""RV glasses + camera""|Response time in seconds|Number of correct responses","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LOCAL/2015/IMGD-01|2016-A00099-42","May 2016","April 20, 2017","May 29, 2017","November 25, 2015",,"July 19, 2017","CHRU de Nîmes - Hôpital Universitaire Carémea, Nîmes Cedex 09, France",,"https://ClinicalTrials.gov/show/NCT02614651"
74,"NCT03685968","King Vision® and GlideScope® in Difficult Airways",,"Completed","Has Results","Airway Management","Device: Video laryngoscopes","Overall Successful Tracheal Intubation for All 3 Video Laryngoscopes - GSAVL, KVChVL and KVNChVL|First-attempt Successful Intubation for All 3 Video Laryngoscopes - GSAVL, KVChVL and KVNChVL","The University of Texas Health Science Center, Houston|King Systems Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","225","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HSC-MS-13-0024","March 6, 2013","November 17, 2015","December 17, 2015","September 26, 2018","January 4, 2019","January 8, 2019",,,"https://ClinicalTrials.gov/show/NCT03685968"
75,"NCT03589859","Computerized Vestibular Rehabilitation",,"Active, not recruiting","No Results Available","Vestibular Diseases",,"Vestibulo-ocular reflex gain","VA Office of Research and Development","All","18 Years to 75 Years   (Adult, Older Adult)",,"30","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","C2892-P","December 1, 2018","November 30, 2020","November 30, 2020","July 18, 2018",,"April 16, 2020","Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03589859"
76,"NCT00685074","Computer-based Brief Intervention for Perinatal Substance Abuse",,"Completed","No Results Available","Substance Abuse","Behavioral: Computer-based Motivational Interviewing|Behavioral: Time control","Drug use at 3 months|Drug use at 6 months","Wayne State University|National Institute on Drug Abuse (NIDA)","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","143","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MES-III|5R01DA021329-04|DA021329-01","September 2007","March 2011","March 2011","May 28, 2008",,"October 14, 2011","Hutzel Women's Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00685074"
77,"NCT04067050","A Clinical Study of the Comfilcon A Asphere Soft Contact Lens in Users of Digital Devices",,"Completed","No Results Available","Ametropia","Device: comfilcon A asphere|Device: Spectacles","Symptom of Burning|Symptom of Itching|Symptom of Feeling of Foreign Body|Symptom of Tearing|Symptom of Excessive Blinking|Symptom of Eye Redness|Symptom of Eye Pain|Symptom of Heavy Eyelids|Symptom of Dryness|Symptom of Blurred Vision|Symptom of Double Vision|Symptom of Difficulty Focusing For Near Vision|Symptom of Increased Sensitivity to Light|Symptom of Colored Halos Around Objects|Symptom of Feeling That Sight is Worsening|Symptom of headache","Coopervision, Inc.","All","18 Years to 35 Years   (Adult)","Not Applicable","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","EX-MKTG-105","July 4, 2019","February 28, 2020","March 30, 2020","August 26, 2019",,"May 5, 2020","Eurolens Research - The University of Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04067050"
78,"NCT03098927","Mirror Neuron Network Based Motor Imagery Training to Improve Brain Computer Interface Performance in Spinal Cord Injury Patients","BCI","Withdrawn","No Results Available","Spinal Cord Injuries","Behavioral: Motor imagery training","Change in motor imagery performance|Cortical signal generation (Mirror Neuron Network activation)","The Cleveland Clinic|National Aeronautics and Space Administration (NASA)|MetroHealth Medical Center","All","18 Years to 45 Years   (Adult)","Not Applicable","0","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-041","September 1, 2014","November 30, 2017","November 30, 2017","April 4, 2017",,"December 14, 2017","The Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03098927"
79,"NCT00013351","Restricted Useful Field View as a Risk Factor in Older Adults",,"Completed","No Results Available","Vision Impairment","Procedure: Prevention of Falls",,"US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)",,"150","U.S. Fed","Observational","Time Perspective: Prospective","C1830R","April 1998",,"March 2001","March 16, 2001",,"January 21, 2009","VAMC, Decatur, Decatur, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00013351"
80,"NCT04332783","Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search",,"Recruiting","No Results Available","Vision","Other: No Intervention","Serial Dependence Assessment","University of California, Berkeley","All","18 Years and older   (Adult, Older Adult)",,"1650","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","1R01CA236793","April 1, 2019","March 30, 2025","March 30, 2025","April 3, 2020",,"May 15, 2020","University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT04332783"
81,"NCT01669031","Randomized Controlled Trial on Visual Field Training",,"Unknown status","No Results Available","Glaucoma","Other: Practice program","The absolute value of the difference in mean deviation of the first and second visual field exam|Difference in the absolute number of altered points in the visual field with a total deviation below the 0.5 percentile|Difference in the percentage of false positives, false negatives, and fixation losses at the first and second exam between control and intervention group|Difference in the time required to complete the first and second exam|Difference in the proportion of unreliable visual fields at the first and second exam between control and intervention groups","Oftalmologia Hospital Sotero del Rio","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Oftalmo_Glaucoma_002","August 2012","May 2013","May 2013","August 20, 2012",,"August 20, 2012","Hospital Sótero del Río, Santiago, Puente Alto, Chile",,"https://ClinicalTrials.gov/show/NCT01669031"
82,"NCT02988154","Simulation Efficacy in Neurosurgical Education","SENSE","Unknown status","No Results Available","Educational|Simulation|Hydrocephalus|Intraventricular Hemorrhage","Other: Simulation training|Other: ''See one, do one'' approach","Accuracy of catheter placement|Speed of performing the procedure|Subjective survey","Johannes Gutenberg University Mainz|University of Oxford","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Other|Time Perspective: Prospective","SimLab_SSP_01","June 2016","January 2017",,"December 9, 2016",,"January 20, 2017","University of Mainz / Department of Neurosurgery, Mainz, Rheinland Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT02988154"
83,"NCT02431156","Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Mini-monovision Correction",,"Unknown status","No Results Available","Presbyopia","Other: Assessment of visual capacity","Assessment of Visual capacity (VC)|Visual capacity for activities that require distant vision (DVC)|Visual capacity for activities that require intermediate vision (IVC)|Visual capacity for activities that require near vision (NVC)","Democritus University of Thrace","All","50 Years to 60 Years   (Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PseudoPresbADL","March 2015","June 2015","June 2015","April 30, 2015",,"April 30, 2015","Eye Institute Of thrace, Alexandroupolis, Evros, Greece",,"https://ClinicalTrials.gov/show/NCT02431156"
84,"NCT02559063","Vision-based Speed of Processing Cognitive Training and Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment","Behavioral: Vision-based speed of processing training|Behavioral: Mental leisure activities","Attention and processing speed test (UFOV)|Cognitive control and working memory (EXAMINER)|instrumental activities of daily living (TIADL)|mean of functional connectivity in default mode network|mean of structural connectivity in default mode network","University of Rochester|National Institute of Nursing Research (NINR)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","84","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","1R01NR015452","January 12, 2016","October 9, 2018","July 1, 2019","September 24, 2015",,"October 2, 2019","University of Rochester Memory Care Program, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02559063"
85,"NCT01617408","Brain Stimulation and Vision Testing",,"Recruiting","No Results Available","Transcranial Magnetic Stimulation (TMS)|Visual System|fMRI|Dorsal Pathway|Ventral Pathway",,"Online behavioral TMS experiments: performance accuracy, sensitivity and reaction time (RT); Offline fMRI TBS experiments: taskperformance as well as reduced neuronal activity","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"345","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","120128|12-M-0128","March 4, 2013",,,"June 12, 2012",,"June 11, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01617408"
86,"NCT04334369","Contact Lens and Myopia Control in Optometry School Students",,"Active, not recruiting","No Results Available","Myopia, Progressive","Device: Proclear Single Vision Contact Lenses manufactured by CooperVision|Device: Proclear Multifocal Contact Lenses manufactured by CooperVision","Contact Lenses and Myopia Progression","University of the Incarnate Word","All","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","RSO myopia control","December 12, 2018","August 2023","August 2024","April 6, 2020",,"April 6, 2020","Bowden Eye Care & Health Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04334369"
87,"NCT02988570","Study on the Phenotype of Language in Preterm Born Children at 5 Years of Age","EPILANG2","Completed","No Results Available","Preterm Children","Behavioral: computer-evaluation of the language","Evaluation of comprehension of words and phrases level|Evaluation of production of words and phrases level|Evaluation of judgment of sentences level","University Hospital, Rouen","All","5 Years to 6 Years   (Child)","Not Applicable","49","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016/338/HP","November 10, 2016","March 31, 2017","March 31, 2017","December 9, 2016",,"April 30, 2018","Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT02988570"
88,"NCT03873844","Improving Thinking in Everyday Life: Pilot Study A",,"Recruiting","No Results Available","Cognitive Impairment","Behavioral: Speed of Processing Training|Behavioral: Transfer Package from CI Therapy","Cognitive Task Activity Log (CTAL)|Useful Field of View (UFOV)","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300002814","March 15, 2019","March 15, 2022","March 15, 2025","March 14, 2019",,"June 19, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03873844"
89,"NCT00549406","Visual Training Program to Improve Balance and Prevent Falls in Older Adults",,"Completed","No Results Available","Accidental Falls|Musculoskeletal Equilibrium","Procedure: computerized visual training|Procedure: computerized word puzzles|Procedure: video-game based visual training","ability to use peripheral vision to recover balance by grasping a handhold|natural gaze and balance-recovery behavior (in responding to a sudden unpredictable balance perturbation while walking in an unfamiliar environment); clinical balance measures; visual-processing measures","Sunnybrook Health Sciences Centre|Ontario Neurotrauma Foundation|Canadian Institutes of Health Research (CIHR)","All","64 Years to 80 Years   (Adult, Older Adult)","Phase 1","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2007-PREV-INT-452|CIHR grant# MOP-13355","June 2008","July 2011","February 2012","October 25, 2007",,"December 23, 2014","Centre for Studies in Aging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00549406"
90,"NCT01691027","Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas","VRT","Completed","Has Results","Scotoma, Central|Central Visual Impairment","Behavioral: Visuo-motor training","Improvement in Eye-hand Coordination|Stylus to Eclipse Area","VA Office of Research and Development","All","55 Years to 95 Years   (Adult, Older Adult)","Not Applicable","4","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C1000-R","July 2013","July 2015","December 2015","September 24, 2012","February 23, 2018","February 23, 2018","Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01691027"
91,"NCT04450966","Adolescent Substance Use Prevention Intervention Research Study in Pediatric Primary Care","ASPIRE","Not yet recruiting","No Results Available","Heavy Drinking|Driving Under the Influence|Riding With Driver Under the Influence","Behavioral: Computer-facilitated Screening and Brief Intervention","Any heavy episodic drinking day during past 3 months|Any riding/driving risk","Boston Children’s Hospital|American Academy of Pediatrics|Children's Hospital of Philadelphia","All","14 Years to 17 Years   (Child)","Not Applicable","1268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NIAAA_1R01AA027253-01A1","May 1, 2021","September 30, 2024","March 30, 2025","June 30, 2020",,"June 30, 2020","American Academy of Pediatrics, Itasca, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04450966"
92,"NCT02405143","Restoration of Vision After Stroke","REVIS","Unknown status","No Results Available","Stroke|Infarction; Posterior Cerebral Artery|Hemianopsia","Device: Active tACS using DC-Stimulator MC|Device: Sham stimulation using DC-Stimulator MC","Improved detection in the visual field defined as the percentage change of the stimulus detection rate in High-resolution perimetry (HRP)|The change in extent of visual fields in standard automated perimetry","Helsinki University Central Hospital|Academy of Finland","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UAK1010001","April 2015","June 2016","June 2017","April 1, 2015",,"April 1, 2015","Helsinki University Central Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT02405143"
93,"NCT02821767","Natural History, Pathogenesis, and Outcome of Ocular Disorders",,"Recruiting","No Results Available","Eye Disease",,"No formal outcomes will be measured; however, the clinical assessments of enrolled participants can be used to measure theresponse to standard treatment.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"1000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","160134|16-EI-0134","November 2, 2016","July 1, 2026","July 1, 2026","July 4, 2016",,"April 24, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02821767"
94,"NCT03248388","Argus II/ORCAM Device Study",,"Recruiting","No Results Available","Retinitis Pigmentosa","Device: Argus II Eyeglasses|Device: ORCAM","Number of Subjects Who Are Able to Use the ORCAM device With the Argus II Device at the End of the Study","Mayo Clinic|Second Sight Medical Products","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","17-003289","August 31, 2017","December 2021","December 2021","August 14, 2017",,"June 4, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03248388"
95,"NCT02640196","Videolaryngoscopes for Double Lumen Tube Intubations in Simulated Easy and Difficult Airway",,"Completed","No Results Available","Staff Anaesthesiologists|Limited Experience in Using Videolaryngoscopes","Device: Macintosh|Device: GlideScope|Device: Airtraq|Device: King Vision","Time to achieve successful double lumen tube intubation|Best view during laryngoscopy using the classification described by Cormack and Lehane|Difficulty of intubation using a Visual Analog Scale (VAS)|Number of first-pass success|Number of the required optimisation manoeuvers","Dammam University","All","23 Years to 65 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","ANESTH-03-15","March 2015","May 2015","June 2015","December 28, 2015",,"December 28, 2015","Dammam University KFHU, Al-Khobar, EP, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02640196"
96,"NCT01427829","Computer-assisted Psychosocial Risk Assessment (CaPRA) for Refugee Health and Settlement","CaPRA","Completed","No Results Available","Computer|Screening|Decision Support System|Primary Care|Psychosocial|Refugees","Behavioral: Computer-assisted Psychosocial Risk Assessment (CaPRA)","Patient intention to visit a psychosocial counselor|Patient satisfaction|Patient acceptability","University of Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","FA-25340","July 2010","October 2010","October 2010","September 2, 2011",,"September 2, 2011",,,"https://ClinicalTrials.gov/show/NCT01427829"
97,"NCT03925337","Computer Aided Detection of Polyps in the Colon",,"Recruiting","No Results Available","Polyp, Adenomatous|Colo-rectal Cancer","Device: Computer Aided Diagnostic Software","Adenoma Miss Rate (AMR)|Polyp Miss Rate (PMR)|Amplified adenoma detection rate|Advanced adenoma miss rate determination|Colonoscope segmental withdrawal time determination|Total procedure time determination|Rate of adverse event determination","Beth Israel Deaconess Medical Center","All","22 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018P000564","May 7, 2019","December 2020","December 2020","April 24, 2019",,"June 22, 2020","University of Chicago, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|NYU Langone, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03925337"
98,"NCT03058172","Study of Olfaction / Vision Interactions in Expert and Novice Populations",,"Unknown status","No Results Available","Healthy","Other: Odor presentation (for participants' perception)|Other: Image presentation (for participants' perception)","Brain activity|Genotyping|Olfactory abilities|Perception|Response times","Hospices Civils de Lyon","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL16_0685","April 15, 2016","March 15, 2019","April 15, 2019","February 20, 2017",,"February 23, 2018","Infirmerie Protestante, Caluire et Cuire, France",,"https://ClinicalTrials.gov/show/NCT03058172"
99,"NCT01567748","In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms",,"Completed","No Results Available","Coronary Artery Disease","Procedure: BP Measurements at aorta, radial and femoral locations","Validate ITF Methodology","University of Alberta","All","18 Years to 80 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","00021889","January 2012","April 2014","April 2014","March 30, 2012",,"December 5, 2014","University of Alberta Hospital/Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01567748"
100,"NCT01663155","Chest Imaging, Breath, and Biomarkers in a Screening Trial",,"Completed","No Results Available","Lung Cancer","Device: chest x-ray with or without CAD, lose dose CT scan","The sensitivities of chest x-ray with CAD and chest CT|Disease-specific mortality between screening with chest x-ray and CAD versus no screening|All-cause mortality rate between screening with chest x-ray and CAD versus no screening|Length of time between randomization and the incidence of symptomatic advanced lung cancer for screened subjects versus controls|Does lung cancer screening with chest x-rays and computer aided detection (CAD) reduce the incidence of symptomatic advanced lung cancer in a high risk population|The quality of life between screening with chest x-ray and CAD versus no screening.","The Cleveland Clinic","All","40 Years to 75 Years   (Adult, Older Adult)",,"1424","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-455|State of Ohio grant|06-055","September 2008","May 2014","May 2014","August 13, 2012",,"May 18, 2017","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01663155"
101,"NCT00579293","Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer",,"Completed","No Results Available","Childhood Cancer",,,"Memorial Sloan Kettering Cancer Center","All","18 Years to 49 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-098","August 2004","July 2008","July 2008","December 24, 2007",,"July 28, 2008","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00579293"
102,"NCT00006422","Evaluation and Treatment of Pediatric Eye Diseases",,"Completed","No Results Available","Ocular Motility Disorder","Procedure: current standard of care treatments",,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Not Applicable","150","NIH","Interventional",,"010023|01-EI-0023","October 2000",,"October 2002","October 30, 2000",,"March 4, 2008","National Eye Institute (NEI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00006422"
103,"NCT01013935","A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]","CARE+ Spanish","Completed","No Results Available","HIV Infections","Other: CARE+ Spanish computer counseling session|Other: CARE+ Spanish brief computer risk assessment session","ART adherence|HIV-1 viral load|Sexual risks|Clinic visit adherence|Qualitative exit interviews with patients (n=75) to assess technology uptake factors, cultural/linguistic acceptability, and suggestions for ongoing use among older vs. younger, and US-born vs. foreign-born Latino groups|Two focus groups with providers (n≤30) to assess perceived technology barriers/facilitators","New York University|St. Luke's-Roosevelt Hospital Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","556","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","1RC1MH088307","June 2010","July 2013","July 2013","November 16, 2009",,"September 28, 2018","St. Luke's Roosevelt, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01013935"
104,"NCT01282827","Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve)",,"Completed","No Results Available","Low Vision","Device: rtACS (verum condition)|Device: placebo stimulation","Detection accuracy (DA) change in percent over baseline within defective visual field sectors|Visual Parameters 1|Visual Parameters 2|Visual Parameters 3|Visual Parameters 4|EEG parameters","University of Magdeburg|EBS Technologies GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EBS-optnerv-BCT","November 2006","March 2010","March 2010","January 25, 2011",,"January 26, 2011","Klinik für Neurologie, Charité Campus Mitte, Universitätsmedizin Berlin, Berlin, Germany|Institut für Medizinische Psychologie, Leipziger Str. 44, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01282827"
105,"NCT00151151","The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)",,"Completed","No Results Available","Pregnancy|Sexually Transmitted Diseases","Behavioral: Computer-Assisted Motivational Intervention|Behavioral: Didactic Educational Counseling","Self-reported sexual and contraceptive behaviors recorded by a 90-day timeline follow back interview at 9 and 18 months compared to baseline|Stage of readiness to be abstinent, use condoms, spermicide, and hormonal contraception based on a computerized assessment|Reported drug and alcohol use recorded by a 90-day timeline follow back interview","University of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years to 21 Years   (Child, Adult)","Not Applicable","660","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0405473|HD41058","February 2003","December 2007","December 2007","September 8, 2005",,"September 13, 2011","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00151151"
106,"NCT00111293","Attention and Visual Perception",,"Completed","No Results Available","Focal Lesions|Focal Brain Lesion",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"8","NIH","Observational",,"050157|05-M-0157","May 16, 2005",,"May 14, 2010","May 19, 2005",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00111293"
107,"NCT01378455","Effectiveness of Handwriting Training Program on Handwriting Performance in Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Other: interactive computerized handwriting training program|Other: traditional handwriting training program","Body function and structure|Activities and participation|Quality of life|Computer Analysis for Chinese Handwriting(CACH)","Chang Gung Memorial Hospital","All","6 Years to 12 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","98-3193B","March 2010","March 2012","February 2015","June 22, 2011",,"October 5, 2016","Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01378455"
108,"NCT00672828","Interactive Computer Program or Brochure in Increasing Colorectal Cancer Screening Among African Americans","PACT","Completed","No Results Available","Colorectal Cancer","Behavioral: Non-tailored CRC screening brochure|Behavioral: Interactive computer intervention","Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion|Self-reported CRC discussion and screening test recommendation from provider on intervention/clinic visit date|Provider documentation of CRC discussion and screening test recommendation on intervention/clinic visit date|Self-reported CRC health beliefs|Self-reported stage of CRC screening test adoption","Indiana University|National Cancer Institute (NCI)","All","51 Years to 80 Years   (Adult, Older Adult)","Not Applicable","693","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IUSN-0604-01B|CDR0000584262|5R01CA115983-05","January 2008","April 2012","April 2012","May 6, 2008",,"August 20, 2013","Indiana University School of Nursing, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00672828"
109,"NCT01509794","Psychophysiological Indicators of Performance in Computer-Based Simulation",,"Completed","No Results Available","Healthy","Other: Low Valence|Other: High Valence","Engagement with simulation|Cognitive performance","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","2011-P-000906","November 2011","March 2013","March 2013","January 13, 2012",,"March 29, 2013","Massachusetts General Hospital, Division of Postgraduate Medical Education, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01509794"
110,"NCT03502603","Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses",,"Recruiting","No Results Available","Cerebral Neurological Illness","Diagnostic Test: Railroad Test|Diagnostic Test: Swamp Test|Diagnostic Test: Presidents Recognition Test|Diagnostic Test: Judgment of Line Orientation|Diagnostic Test: Symbol Span subtest of the Wechsler Memory Scale-IV|Diagnostic Test: Information subtest of the Wechsler Adult Intelligence Scale-IV:|Diagnostic Test: Digit Span subtest of the Wechsler Adult Intelligence Scale-I|Diagnostic Test: Reading subtest of the Wide Range Achievement Test|Diagnostic Test: Symbol Digit Modalities Test:|Diagnostic Test: Dot Counting Test","Score on Railroad Test|Score on Swamp Test|Score on President Recognition Test","NYU Langone Health","All","21 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-01677","May 10, 2019","December 1, 2020","December 1, 2020","April 18, 2018",,"December 23, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03502603"
111,"NCT01144104","Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study","AMEP2","Completed","No Results Available","Depression","Behavioral: Public Service Announcement|Behavioral: Interactive Multi-Media Computer Program|Behavioral: Sleep Hygiene Video","Process of Care|Patient Outcomes|Toxicity|Direct or indirect patient requests for depression treatment","University of California, Davis|National Institute of Mental Health (NIMH)","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","925","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","200917591|1R01MH079387-01A1","June 2010","November 2011","June 2014","June 15, 2010",,"May 30, 2017","Sutter Health - Elk Grove Family Medicine, Elk Grove, California, United States|VA Northern California Healthcare System, Mather, California, United States|Kaiser Permanente - Point West, Sacramento, California, United States|University of California, Davis, Sacramento, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01144104"
112,"NCT01202344","Computer Prediction of Restenosis Following Peripheral Angioplasty",,"Suspended","No Results Available","Peripheral Angioplasty","Other: Additional x-ray images","Simulation Accuracy|Logistic Regression Analysis","Dheeraj Rajan|University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-0335-BE","September 2010","December 2020","December 2020","September 15, 2010",,"March 24, 2020","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01202344"
113,"NCT01702727","I-BiT - Evaluation of a Novel Binocular Treatment System (I-BiTTM) in Children With Amblyopia","I-BiT","Completed","No Results Available","Amblyopia","Device: I-BiTTM game|Device: Non-I-BiTTM game|Device: I-BiTTM DVD","Change from baseline in visual acuity","Nottingham University Hospitals NHS Trust|Wellcome Trust","All","4 Years to 8 Years   (Child)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10OY006","June 2012","November 2013","November 2013","October 8, 2012",,"November 22, 2016","Cambridge University Hospitals NHS Trust, Cambridge, Cambridgeshire, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01702727"
114,"NCT03761992","Measurement of the Effect of Gingko Biloba Extract on Ocular and Nailfold Blood-flow in NTG",,"Recruiting","No Results Available","Normal Tension Glaucoma","Dietary Supplement: Gingko Baloba|Other: Placebo","Primary Outcome - Measure of Blood Vessel by Optical Cohrence Tomography Angiography (OCTA)|Secondary Outcome - Measure of Blood Flow and Velocity by Nailfold Capillaroscopy (NFC)","Robert Ritch, MD, LLC.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NFC Gingko","November 19, 2018","November 2020","December 2020","December 3, 2018",,"March 17, 2020","New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03761992"
115,"NCT02507895","Effect of Brain-Computer Interfaced-Assisted Motor Imagery for Gait Retraining in Stroke Patients",,"Completed","No Results Available","Stroke","Device: MI-BCI","changes of "" gait parameters measured by "" from baseline to post-training and 4-6 weeks after training|Changes of ""cortical excitability measured by TMS"" from baseline to post-training and 4-6 weeks after training|changes of "" cortical excitability measured by fMRI/DTI"" from baseline to post-training and 4-6 weeks after training|Mobility changes from baseline to post-training and 4-6 weeks after training, as measured by ""timed up-and-go test""|changes of walking speed measured by ""10 metre walk test"", from baseline to post-training and 4-6 weeks after training","National University Hospital, Singapore|National University Health System, Singapore|Agency for Science, Technology and Research","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCI-LL2012/00658","October 2013","November 2017","January 2018","July 24, 2015",,"May 17, 2018","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02507895"
116,"NCT03235856","Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE","REDCAKE","Unknown status","No Results Available","Keratoconus",,"To obtain a database, containing at least two valid corneal Scheimpflug measurements recorded at least 5 months apart, of 1500 keratoconus patients.|To develop software to automatically detect keratoconus and estimate the keratoconus progression speed|To improve the predictive model for keratoconus progression speed so it can work using only one single measurement","University Hospital, Antwerp|European Vision Institute Clinical Research Network","All","12 Years to 40 Years   (Child, Adult)",,"1500","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","ECR-AS-2017-12","September 1, 2017","May 25, 2018","January 1, 2019","August 1, 2017",,"May 2, 2018","Antwerp University Hospital, Edegem, Belgium",,"https://ClinicalTrials.gov/show/NCT03235856"
117,"NCT03350919","Visual Restoration for Hemianopia",,"Completed","No Results Available","Stroke Induced Vision Loss|Hemianopia|Quadrantanopia","Device: Training in the blind field|Device: Training in the intact field","24-2 Humphrey PMD","University of Rochester|Envision Solutions, LLC","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","69879","March 15, 2018","December 3, 2019","December 3, 2019","November 22, 2017",,"January 22, 2020","Bascom Palmer Eye Institute, University of Miami Health Services, Miami, Florida, United States|Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States|Scheie Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03350919"
118,"NCT01015989","Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya","CARE+ Kenya","Completed","No Results Available","HIV Infections","Other: CARE+ Kenya brief computer risk assessment session|Other: CARE+ Kenya computer counseling session","ART adherence will be measured by HIV-1 viral load, electronic monitoring, pharmacy refill, self-report, and clinic attendance|HIV transmission risk will be measured by self-reported unprotected sex with HIV negative/unknown partner, and trends in Chlamydia trachomatis, Neisseria gonorrhoeae, and T. vaginalis.|We will conduct economic evaluation to compare CARE+ Kenya vs. standard of care.|Qualitative exit interviews with patients|Two focus groups with providers","New York University|Indiana University|Moi University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","1R01MH085577","September 2011","July 2012","June 2014","November 18, 2009",,"September 28, 2018","AMPATH at Burnt Forest Health Centre, Burnt Forest, Rift Valley, Kenya|AMPATH Module 1, Eldoret, Kenya",,"https://ClinicalTrials.gov/show/NCT01015989"
119,"NCT01652963","Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills",,"Unknown status","No Results Available","Intellectual Disabilities","Other: Reed and Clements Training Task","Cognitive mediation skills|Emotion recognition skills","University of East Anglia","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","UEA-6345832-MED1|12/EE/0284","July 2012","August 2013","August 2013","July 30, 2012",,"November 21, 2012","NCH&C NHS Trust Learning Disability Services, Norwich, Norfolk, United Kingdom|Nansa, Norwich, Norfolk, United Kingdom|Genesis - Orwell Mencap, Ipswich, Suffolk, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01652963"
120,"NCT00469612","Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment",,"Terminated","Has Results","Myopia","Device: NeuroVision's NVC treatment for Low Myopia","Visual Acuity|Contrast Sensitivity Function|Refractive Error","Ohio State University","All","18 Years to 59 Years   (Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2006H0045","June 2007","December 1, 2009","December 1, 2009","May 4, 2007","September 25, 2018","September 25, 2018","College of Optometry, The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00469612"
121,"NCT03431441","Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style",,"Completed","Has Results","Visual Acuity","Device: JJVC Marketed Contact Lens","LogMAR Objective Vision (High Illumination/High Contrast)","Johnson & Johnson Vision Care, Inc.","Female","18 Years to 39 Years   (Adult)","Not Applicable","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-6180","January 16, 2018","February 14, 2018","February 14, 2018","February 13, 2018","March 5, 2019","March 5, 2019","VRC East, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03431441/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03431441"
122,"NCT01954680","Retrain Your Brain in Children/Adolescents With Bipolar Disorder: A Pilot Study","COGFLEX","Unknown status","No Results Available","Bipolar Disorder|Pediatric Bipolar Disorder|Childhood-onset Bipolar Disorder","Behavioral: COGFLEX-skill building levels|Behavioral: COGFLEX-control condition","Change in functional magnetic resonance imaging (fMRI) brain activation|Change in Clinician global Impression Improvement-Irritability","Bradley Hospital|National Institute of Mental Health (NIMH)","All","7 Years to 17 Years   (Child)","Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","0195-07 COGFLEX|R21MH096850|R33MH096850","August 2013","September 2018","September 2018","October 7, 2013",,"January 18, 2018","Bradley Hospital, East Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01954680"
123,"NCT04302701","Dichoptic Treatment vs. Patching for Moderate Anisometropic Amblyopia",,"Not yet recruiting","No Results Available","Amblyopia|Anisometropia","Other: Dichoptic treatment using virtual reality|Other: Patching","Visual acuity at 10 weeks|Compliance to treatment|Number of patients developing misalignment|Regression of amblyopic eye visual acuity|Changes in visual acuity in the sound eye|Changes in near stereopsis","Cairo University","All","6 Years to 35 Years   (Child, Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dichoptic-123","June 1, 2020","September 30, 2021","December 31, 2021","March 10, 2020",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302701"
124,"NCT01351844","The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer","CEASE","Terminated","No Results Available","Breast Cancer|Arthralgia","Behavioral: Education and exercise intervention|Behavioral: Education and General Exercise","Feasibility|Grip Strength","George Washington University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2010-548","May 2011","May 2013","May 2013","May 11, 2011",,"August 30, 2017","Victoria Shanmugam, Washington, D.C., District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT01351844"
125,"NCT02641470","The Effect of DA9301 on Tablet Computer-Induced Asthenopia",,"Completed","No Results Available","Asthenopia","Dietary Supplement: DA9301 (Vaccinium uliginosum extract)|Dietary Supplement: Placebo","Change of the modified questionnaire scores proposed by Ames et al.","Namyi Gu|DongGuk University","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DA9301_01","January 2014","February 2014",,"December 29, 2015",,"December 29, 2015",,,"https://ClinicalTrials.gov/show/NCT02641470"
126,"NCT03417557","Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses",,"Completed","Has Results","Presbyopia","Device: Comfilcon A lens (test)|Device: Omafilcon B lens (control)","Visual Acuity|Subjective Assessment of Visual Performance: Distance Day-time Navigation Tasks for Vision Quality and Clarity|Subjective Assessment of Visual Performance: Intermediate / Computer Task for Vision Quality and Clarity|Subjective Assessment of Visual Performance: Near Vision for Vision Quality and Clarity","Coopervision, Inc.","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CV-18-10","January 12, 2018","April 3, 2018","April 3, 2018","January 31, 2018","February 10, 2020","May 4, 2020","Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University, Bloomington, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03417557/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03417557"
127,"NCT01815398","Cognitive Skills Training for Homeless Youth",,"Completed","No Results Available","Affective Disorders|Anxiety Disorders|Attention Deficit Disorder|Substance Abuse","Behavioral: Cognitive Remediation|Behavioral: Computer Skills Training","Global Cognition Score|Vocational outcome","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 22 Years   (Adult)","Not Applicable","188","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#6586|1R21MH092569-01A1","July 2012","December 2015","January 2017","March 21, 2013",,"March 28, 2017","Covenant House New York, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT01815398"
128,"NCT02604953","Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and ""Normal"" Patients",,"Completed","No Results Available","Glaucoma","Diagnostic Test: Short Duration Transient Visual Evoked Potential (SDtVEP)|Diagnostic Test: Pattern electroretinogram (PERG)","Short Duration Transient Visual Evoked Potential (SD- tVEP)","Wills Eye","All","21 Years to 80 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-358","July 2014","June 2015","July 2015","November 16, 2015",,"December 2, 2017",,,"https://ClinicalTrials.gov/show/NCT02604953"
129,"NCT00025844","Fear Conditioning Using Computer-Generated Virtual Reality",,"Completed","No Results Available","Anxiety Disorder",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","7 Years to 50 Years   (Child, Adult)",,"202","NIH","Observational",,"020003|02-M-0003","October 22, 2001",,"April 10, 2012","October 28, 2001",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00025844"
130,"NCT04213079","Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity Storage",,"Recruiting","No Results Available","Mal de Debarquement Syndrome (MdDS)","Device: re-adaptation of the vestibulo-ocular reflex|Device: Habituation of velocity storage of the vestibulo-ocular reflex","Subjective symptoms self-report|Change in Static posturography|Visual Vertigo Analogue Scale (VVAS)|Dizziness Handicap Inventory (DHI) questionnaire","Icahn School of Medicine at Mount Sinai|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","18 Years to 78 Years   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GCO-19-0348|1R21DC018390-01","June 2020","December 2020","September 2021","December 30, 2019",,"May 19, 2020","Vestibular Testing Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04213079"
131,"NCT00809835","Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse",,"Completed","Has Results","Cocaine Dependence","Drug: Galantamine|Behavioral: Computer Assisted Cognitive Behavioral Therapy (CBT)","Cocaine Use|Cocaine Abstinence|Cognitive Function","Yale University|National Institute on Drug Abuse (NIDA)","All","18 Years to 50 Years   (Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0708002943|R01DA015969-13","December 2007","January 2015","January 2015","December 17, 2008","June 12, 2017","January 30, 2019","Kinsella Treatment Center (KTC), Bridgeport, Connecticut, United States|Regional Network of Programs, Stratford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00809835"
132,"NCT03316196","Cognitive Training for PTSD",,"Recruiting","No Results Available","Posttraumatic Stress Disorder","Behavioral: COGENT COGNITIVE TRAINING|Behavioral: Non training computer condition","Clinician Administered PTSD Scale - reexperiencing|Delis-Kaplan Executive Functioning System|Reading Span fMRI task (baseline to week 8)|Emotion Regulation fMRI task (baseline to week 8)|Clinician Administered PTSD Scale diagnosis","VA Office of Research and Development","All","21 Years to 55 Years   (Adult)","Not Applicable","100","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MHBB-023-17S|CX001600-01A1","June 13, 2018","July 29, 2022","September 30, 2022","October 20, 2017",,"May 11, 2020","VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03316196"
133,"NCT01173614","Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes","Gullstrand","Completed","No Results Available","Normal Subjects, Ametropia",,"to obtain a predetermined number of valid ocular biometry measurements per participating site|To obtain a predetermined number of valid visual function measurements per participating site|Provide a reference database for research purposes","European Vision Institute Clinical Research Network","All","Child, Adult, Older Adult",,"1646","Other","Observational","Time Perspective: Prospective","ECR-CCRS-2010-01","January 2011","June 2015","June 2016","August 2, 2010",,"June 15, 2016","VISSUM - Instituto Oftalmológico de Alicante, Alicante, Spain",,"https://ClinicalTrials.gov/show/NCT01173614"
134,"NCT00386776","Patient Computer Dialog in Primary Care",,"Completed","Has Results","Patient Computer Dialog","Other: Computer-based medical history","Patient Post Medical History Assessment Questionnaire|Patient Post Visit Questionnaire|Physician Post Visit Questionnaire|Number of Office Visits by Patients|Time Per Visit|Number of Telephone Calls and E-mail Messages Between Patients and Physicians|Completeness of Patients' Problem Lists","Beth Israel Deaconess Medical Center|National Library of Medicine (NLM)","All","18 Years and older   (Adult, Older Adult)","Phase 3","45","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2004P-000420|R01LM008255-01A1","January 2005","January 2011","January 2011","October 12, 2006","June 10, 2013","June 20, 2013","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00386776"
135,"NCT02483273","Alterations of Conjunctival Microcirculation in Brain Dead Patients",,"Completed","No Results Available","Brain Death",,"Microvascular flow index (MFI) of ocular conjunctiva.|Total vessel density (TVD) of ocular concunctiva.|Perfused vessel density (PVD) of ocular conjunctiva.|Microvascular flow index (MFI) of sublingual mucosa.|Total vessel density (TVD) of sublingual mucosa.|Perfused vessel density (PVD) of sublingual mucosa.","Lithuanian University of Health Sciences","All","18 Years and older   (Adult, Older Adult)",,"22","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","P1-BE-2-19/2011","May 2011","September 2015","March 2016","June 26, 2015",,"March 3, 2016","Lithuanian University of Health Sciences, Kaunas, Lithuania",,"https://ClinicalTrials.gov/show/NCT02483273"
136,"NCT00955188","Computer-Based Tailored or Standard Information for Colorectal Cancer Screening",,"Completed","No Results Available","Colorectal Cancer","Other: computer-assisted intervention|Other: educational intervention|Other: medical chart review","Adherence to colorectal cancer screening at 12 months post-intervention|Elements of informed decision making|Knowledge about screening options|Decisional conflict and satisfaction|Intention to get screened","University of Michigan Rogel Cancer Center|National Cancer Institute (NCI)","All","50 Years to 79 Years   (Adult, Older Adult)",,"345","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000632080|R01CA131041|P30CA046592|H8000-32900-01","August 2004","April 2007","May 2008","August 10, 2009",,"December 21, 2012","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00955188"
137,"NCT00013117","Computer-Assisted Access to Specialist Expertise",,"Completed","No Results Available","Diabetes Mellitus","Behavioral: Telephone specialist consultation",,"US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","10000","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","VCR 99-008",,,"December 2002","March 16, 2001",,"April 7, 2015","Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00013117"
138,"NCT01946581","Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery",,"Unknown status","No Results Available","Cataract","Procedure: Cataract Surgery","Patient overall satisfaction post Cataract surgery","MDbackline, LLC","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Time Perspective: Retrospective","JH SAT 2013","May 2013","May 2014",,"September 19, 2013",,"September 19, 2013","Harvard Eye Associates, Laguna Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT01946581"
139,"NCT00104559","Computer-Generated Vs. Standard Informed Consent for HIV Research Studies",,"Unknown status","No Results Available","HIV Infections","Behavioral: iMIC-generated consent form and tutorial|Behavioral: Standard paper consent form","Clinical trial knowledge acquisition|Consent form usability|Volunteer satisfaction","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1R43AI058870-01","January 2005","July 2007","March 2009","March 2, 2005",,"September 26, 2008","The Circumplex Company, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00104559"
140,"NCT02017652","Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg","FORE-SIGHT","Completed","No Results Available","Bowel Motility",,"StO2 measurement from intestines, liver and flank at time of venous and arterial blood oxygen saturation.|Cerebral StO2 measurements from Fore-Sight FS-II monitor and Fore-Sight-I (FS-I) monitor.|Pulse and Tissue oxygen saturation and infant activity|Stool Interference Index over 24 hrs.","Sharp HealthCare","All","up to 7 Days   (Child)",,"19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FORE-SIGHT","December 2013","December 2014","December 2014","December 23, 2013",,"October 9, 2017","Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02017652"
141,"NCT04103775","Mechanisms of Cognitive Change","CTCS","Recruiting","No Results Available","Psychosis","Behavioral: Cognitive Remediation|Behavioral: Active Control","MATRICS Consensus Cognitive Battery (MCCB) Verbal Learning Subscale Scores|Academic Performance","Colorado State University","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","19-8509H","September 20, 2019","May 15, 2021","May 15, 2021","September 25, 2019",,"September 25, 2019","Colorado State University, Fort Collins, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04103775"
142,"NCT03057496","Collision Warning Device for Blind and Visually Impaired",,"Completed","No Results Available","Hemianopia|Hemianopsia|Peripheral Visual Field Defect|Blindness|Retinitis Pigmentosa|Glaucoma","Device: Collision warning device","Number of collision incidents in everyday device use","Massachusetts Eye and Ear Infirmary","All","18 Years and older   (Adult, Older Adult)","Not Applicable","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1007377","January 22, 2018","November 8, 2019","December 5, 2019","February 20, 2017",,"April 8, 2020","Schepens Eye Research Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03057496"
143,"NCT00242242","Moving a Paralyzed Hand Through Use of a Brain-Computer Interface",,"Terminated","No Results Available","Stroke",,,"National Institute of Neurological Disorders and Stroke (NINDS)|Center for Neuroscience and Regenerative Medicine (CNRM)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"110","NIH|U.S. Fed","Observational",,"060012|06-N-0012","October 17, 2005",,"July 23, 2013","October 19, 2005",,"November 25, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00242242"
144,"NCT00838721","Evaluation of Pascal Laser Trabeculoplaty","PLT","Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Other: laser trabeculoplasty","intraocular pressure","Santa Clara Valley Health & Hospital System|OptiMedica Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PASCAL-1","March 2008","March 2010","March 2010","February 6, 2009",,"October 14, 2016","Santa Clara Valley Medical Center, San Jose, California, United States",,"https://ClinicalTrials.gov/show/NCT00838721"
145,"NCT02471287","Genetics of Inherited Eye Disease",,"Recruiting","No Results Available","Genetic Eye Disease",,"Establish Cohort|Determine the genetic cause(s) and molecular pathogenesis|Suggest best clinical outcome measures|Provide a mechanism for collecting biological samples|Revealing systematic comorbidities","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"1250","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150128|15-EI-0128","June 22, 2015","September 1, 2022","September 1, 2022","June 15, 2015",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02471287"
146,"NCT01791946","Binocular Treatment of Amblyopia Before and After Strabismus Surgery",,"Completed","No Results Available","Amblyopia|Strabismus","Procedure: Binocular Treatment|Procedure: Sham Binocular Treatment","The primary outcome variable is a composite of the difference in visual acuity and stereo vision measurements taken before binocular treatment and strabismus surgery versus after binocular treatment and strabismus surgery.","Massachusetts Eye and Ear Infirmary","All","18 Years to 60 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","12-186H","January 2013","September 2016","September 2016","February 15, 2013",,"January 13, 2017","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01791946"
147,"NCT04271943","THE EFFECT OF AEROBIC AND GAME BASED EXERCISES ON COGNITIVE FUNCTIONS IN DEMENTIA",,"Active, not recruiting","No Results Available","Dementia","Behavioral: Computer Based Exercises|Dietary Supplement: Aerobic Exercises","MONTREAL COGNITIVE ASSESSMENT|STROOP TEST|NOTTINGHAM HEALTH PROFILE|DIGIT SPAN TEST","Istanbul Medipol University Hospital","All","65 Years and older   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D1170023","April 20, 2019","September 2020","July 2021","February 17, 2020",,"June 16, 2020","Guvencetin, Istanbul, Sisli, Turkey",,"https://ClinicalTrials.gov/show/NCT04271943"
148,"NCT02622178","How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?",,"Completed","Has Results","Glaucoma Diagnosis","Diagnostic Test: Optical Coherence Tomography|Diagnostic Test: Visual evoked potential","Visual Evoked Potential (VEP)|Retinal Nerve Fiber Layer Thickness","Wills Eye","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-125E","September 2011","December 2013","December 2013","December 4, 2015","November 15, 2018","November 15, 2018","Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02622178"
149,"NCT00731796","Testing of a Functional Outcome Measure for Those With Visual Field Defects","FOM","Suspended","No Results Available","Hemianopsia, Homonymous","Device: Functional Outcome Measure","Determine the ability of a Functional Outcome Measure to distinguish visual impairment in those with retrochiasmatic insults and visual field defects compared to those without visual field defects|Identify the correlation between the degree of functional impairment and the amount of visual field loss|Determine the ability of a Functional Outcome Measure to detect change after a rehabilitation intervention","NovaVision, Inc.","All","18 Years and older   (Adult, Older Adult)",,"190","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NUSRPFOM01","September 2007","December 2009","December 2009","August 11, 2008",,"March 8, 2011","NovaVision, Inc., Boca Raton, Florida, United States|University of Miami Bascom Palmer, Miami, Florida, United States|Emory University School of Medicine Atlanta VA Medical Center Research, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00731796"
150,"NCT02656953","The Impact of Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Neck Complaints",,"Completed","No Results Available","Neck Pain","Device: VDU lenses (Zeiss® Officelens Plus)|Device: Progressive lenses (Zeiss® Multifocal Precision Plus)","Change in functionality using the Neck disability index (NDI)|Change in visual complaints using the Visual Fatigue Questionnaire|Change in muscle elasticity by using the MyotonPRO® device|Change in muscle stiffness by using the MyotonPRO® device|Change in muscle tone by using the MyotonPRO® device|Change in pressure pain threshold by using the WagnerTM FDX 50 hand-held pressure algometer|Change in head posture during a VDU task by means of 2D video analysis","University Ghent","All","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","20150115","March 2015","December 2015","May 2016","January 15, 2016",,"April 18, 2017",,,"https://ClinicalTrials.gov/show/NCT02656953"
151,"NCT02822612","The EASE Study - Human Factor and Usability Testing of a Binocular OCT System","EASE","Completed","Has Results","Glaucoma|Retinal Disease|Strabismus|Healthy Volunteers","Device: Binocular OCT prototype","Total Examination Time|Number of Participants With Subjective Ratings ≥ 4 on Post-Test Questionnaire|Number of Participants That Presented Gradable Data, by Examination Type","University College, London","All","18 Years to 100 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","15/LO/1756","May 2016","October 2016","October 2016","July 4, 2016","March 26, 2020","March 26, 2020","Moorfields Eye Hospital NHS FT, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02822612"
152,"NCT02265354","Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System","S4S","Active, not recruiting","No Results Available","Tobacco Smoking","Behavioral: Collective-Intelligence computer tailored health communication|Behavioral: Rule-based computer tailored health communication","Repeated Use of website measure|30-day point prevalent smoking cessation at six months","University of Massachusetts, Worcester|University of Massachusetts, Amherst|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Not Applicable","260","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H00002005|K07CA172677","January 11, 2017","December 28, 2017","June 28, 2020","October 15, 2014",,"December 12, 2019","UMass Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02265354"
153,"NCT02810847","The Use of Interactive Binocular Treatment (I-BiT) for the Management of Anisometropic, Strabismic and Mixed Amblyopia in Children Aged 3.5 - 12 Years","I-BiT Plus","Unknown status","No Results Available","Amblyopia|Strabismus","Device: I-Bit plus","The change of visual acuity from baseline to week six post randomisation visit between the two arms in each group.|Successful delivery and installation of equipment to patients' homes, and any reasons for failure|The ability of the patients to use the equipment in their home (unsupervised) setting and any reasons why not. Ocular alignment Stereoacuity Proportion of patients completing course|The time taken by the patients to use the equipment in their home (unsupervised) setting.|The robustness of the equipment by measuring failure / breakage rate.|Completeness of outcome measures will be assessed via the frequency of missing data.|The recruitment rate and reasons for not taking part.|The retention rate and reasons for drop out.|Any problems encountered with the randomisation process.|The standard deviation in visual acuity at 6 weeks; this will inform sample size calculations for a future trial to assess effectiveness of the I-BiT™ system.|Change in visual acuity in the amblyopic eye from baseline to weeks 3 and 10 post randomisation between the two arms.|Change in stereoacuity from baseline to week 3 post randomisation between the two arms.|Change in stereoacuity from week 3 to weeks 6 and 10 for the I-BiT treated groups.|Change in binocular status and ocular alignment from baseline to week 6 post randomisation between the two arms in each group.|Change in binocular status and ocular alignment from week 6 to week 10 for the I-BiT treated groups.|Quality of life questionnaire at week 6.|Proportion of patients completing course of treatment (defined as minimum of 18 hours in total, which equates to 30 minutes per day 6 days per week for six weeks).|The change in visual acuity, and angle of strabismus between weeks 3, 6 and 10 for the I-BiT treated groups.","Nottingham University Hospitals NHS Trust|National Institute for Health Research, United Kingdom|Wellcome Trust","All","42 Months to 9 Years   (Child)","Not Applicable","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13OY006","June 2016","December 2017","December 2017","June 23, 2016",,"June 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02810847"
154,"NCT01881399","Fluorescence Versus Intraoperative Cholangiography in the Visualization of Biliary Tree Anatomy","FLARIOC","Completed","No Results Available","Cholelithiasis|Gallbladder Polyps","Device: Fluorescence cholangiography (da Vinci surgical system)|Other: Virtual cholangiography|Procedure: Conventional IOC","To evaluate the ability of a ICG-fluorescence guidance in visualizing the biliary anatomy and to compare accuracy to conventional intraoperative cholangiography|To evaluate the ability of fluorescence-based imaging in visualizing the biliary tree anatomy|To evaluate the ability of enhanced reality in visualizing the biliary anatomy intra-operatively, especially the cysticocholedochal junction|To evaluate time required for the visualization of biliary tree anatomy for each modality : fluorescence, enhanced reality, conventional intraoperative cholangiography","IHU Strasbourg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-004|2012-A01664-39","November 2013","June 2016","June 2016","June 19, 2013",,"March 14, 2018","Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT01881399"
155,"NCT00714441","Reducing Distress and Improving Self-Care in Diabetes","REDEEM","Completed","No Results Available","Diabetes Type 2","Behavioral: Lifestyle and Activities Education Program (LEAP-AHEAD)|Behavioral: Computer Automated Self-Management (CASM)|Behavioral: Computer Automated Self-Management and Problem Solving Therapy (CAPS)","Diet. Starting the Conversation is a 9 items measure of eating patterns (including 2 items from the NCI Fruit and Vegetable Screener). NCI Percent Energy from Fat Screen (PFAT) contains 17 items concerning frequency of intake for 15 food groups.|Physical Activity. The CHAMPS (28 items) will be used to measure physical activity.|Medication Adherence. Medication taking will be assessed by the Hill-Bone Medication Adherence scale. Questions will also cover smoking and alcohol use.|Distress. Patient distress will be assessed across several measures including: the 20-item CES-D, the 17-item DDS, the PHQ8, and screening items from the SCID to rule out psychosis.|HbA1C|Blood Pressure|Fasting glucose|Lipids","University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","392","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2R01DK061937-05A1","July 2008","November 2011","November 2011","July 14, 2008",,"April 19, 2012","UC San Francisco, Family and Community Medicine Dept., San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00714441"
156,"NCT03021512","Functional Assessment of ADL in Patients Who Underwent Bifocal and Trifocal Presbyopic Correction",,"Unknown status","No Results Available","Presbyopia","Procedure: Phaco with Restor|Procedure: Phaco with Panoptix","Visual Capacity (VC)|Distant Visual Capacity (DVC)|Intermediate Visual Capacity (IVC)|Near Visual Capacity (NVC)","Democritus University of Thrace","All","50 Years to 65 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","299/13-1-2017","January 2017","January 2018","January 2018","January 16, 2017",,"January 16, 2017","Democritus University of Thrace, Alexandhroupolis, Evros, Greece",,"https://ClinicalTrials.gov/show/NCT03021512"
157,"NCT03839732","Observer Variability in Scoring Abdominal Aortic Calcifications and Vertebral Morphometry","CALCIFY2D","Recruiting","No Results Available","Vascular Calcification|Vertebral Fracture","Diagnostic Test: Score of abdominal aorta calcifications","Observer variability in scoring Vascular Calcification at the abdominal aorta|Observer variability in scoring Vertebral Fractures at the lumbar spine|Accuracy of computer assisted VC score|Accuracy of computer assisted QVM","Istituto Ortopedico Rizzoli|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|University of Padova","All","20 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CE AVEC 695/2018/Oss/IOR","November 28, 2018","October 2019","November 2019","February 15, 2019",,"February 15, 2019","Istituto Ortopedico Rizzoli, Bologna, BO, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03839732/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03839732"
158,"NCT00166062","Safety and Effectiveness of Computer Screening for Intimate Partner Violence",,"Completed","No Results Available","Domestic Violence|Perpetration","Procedure: Screening patients for IPV","Adverse events in the ED|Increased violence at follow up","Emory University|Centers for Disease Control and Prevention|National Institutes of Health (NIH)","All","18 Years to 55 Years   (Adult)","Not Applicable",,"Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single","0304-2003|R49/CCR423113-03","January 2004","December 2006","December 2007","September 14, 2005",,"September 20, 2013","Grady Memorial Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00166062"
159,"NCT04208633","Correlation Between Sulcus Anatomy and Other Parameters After Horizontal & Vertical Intraocular Lens (IOLs) Placements",,"Completed","No Results Available","Cataract|Pseudophakia","Procedure: Horizontal placement of the intraocular lens in the capsular bag|Procedure: Vertical placement of the intraocular lens in the capsular bag","Sulcus diameter versus anterior chamber dimension|Changes in sulcus diameter in 4 axes in eyes with vertical and horizontal placement of IOLs|Changes in anterior chamber depth following cataract extraction|Changes in anterior chamber diameter following cataract extraction|Rotation of the IOL in degrees from it's primary placement at 4-6 weeks at postoperative follow up.|To explore any relationship between demographics in relation to sulcus anatomy","Brighton and Sussex University Hospitals NHS Trust","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","145273","September 14, 2016","January 5, 2019","January 5, 2019","December 23, 2019",,"December 23, 2019","Brighton & Sussex University Hospitals NHS Trust, Brighton, Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04208633"
160,"NCT01518426","Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population","3Electrods","Completed","No Results Available","Attitude to Computers","Device: EEG Recording (Emotiv)","Wilcoxon statistic (Area Under the Curve)","Centre d'Investigation Clinique et Technologique 805|National Research Agency, France","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2011-A00102-39","June 2012","July 2012","July 2012","January 26, 2012",,"May 6, 2014","Raymond Poincaré Hospital, Garches, Paris Area, France",,"https://ClinicalTrials.gov/show/NCT01518426"
161,"NCT02737696","Computer-based Prescription Opioid Abuse Prevention for Adolescents",,"Completed","No Results Available","Opioid Related Disorders","Behavioral: Web-based prescription opioid prevention for adolescents|Behavioral: JustThinkTwice.gov website (DEA)","Negative attitudes and perceived risk associated with their misuse|Intentions to use prescription opioids|Rates of prescription opioid use.|Knowledge about key issues relevant to prescription opioid abuse among youth|Skill acquisition relevant to preventing misuse of prescription opioids (decision making/refusal skills)","Dartmouth-Hitchcock Medical Center","All","12 Years to 17 Years   (Child)","Not Applicable","431","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","00028283","May 15, 2017","March 18, 2018","September 18, 2018","April 14, 2016",,"September 26, 2018","Center for Technology and Behavioral Health, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT02737696"
162,"NCT04289571","Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease",,"Recruiting","No Results Available","Cone-Rod Degeneration|Rod-Cone Degeneration","Diagnostic Test: VR Motility Tool","VR mobility test parameters|Feasibility of the tool|Effect of prior game play","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","5 Years and older   (Child, Adult, Older Adult)","Phase 1","165","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","200026|20-EI-0026","July 14, 2020","December 31, 2022","August 15, 2024","February 28, 2020",,"July 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Sydney Eye Hospital at the University of Sydney, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT04289571"
163,"NCT03505606","New Visual Acuity and Crowding Tests for Better Detection of Amblyopia",,"Recruiting","No Results Available","Amblyopia","Diagnostic Test: Visual acuity tests","Visual Acuity","Anglia Ruskin University","All","3 Years to 11 Years   (Child)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FST/FREP/17/739","January 1, 2019","December 2020","December 2020","April 23, 2018",,"February 1, 2019","Anglia Ruskin University Eye Clinic, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03505606"
164,"NCT03796936","3MDR to Treat PTSD With mTBI (3MDR)","3MDR","Recruiting","No Results Available","Posttraumatic Stress Disorder|Traumatic Brain Injury","Behavioral: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy","Change in PTSD Checklist for DSM5 (PCL-5) score|Change in Neurobehavioral Symptom Inventory (NSI) score|Change in Patient Health Questionnaire depression module (PHQ-9) score|Change in Insomnia Severity Index (ISI) score","Walter Reed National Military Medical Center|Uniformed Services University of the Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WRNMMC-2018-0201","January 11, 2019","December 2020","December 2020","January 8, 2019",,"January 25, 2019","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03796936"
165,"NCT02337647","Evaluation of the Distortion Correction Data Collection (DCDC) App Software",,"Completed","No Results Available","Age-related Macular Degeneration","Other: DCDC App","Functionality of the Distortion Correction Data Collection App (DCDC), as measured by successful usage of the app by subjects.","University of Nebraska","All","55 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","625-14","June 2014","March 2016","June 2016","January 13, 2015",,"September 25, 2017","Truhlsen Eye Institute, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02337647"
166,"NCT02839395","The Effects of Acute vs. Chronic of Screen Illumination on: Sleep Efficacy and Architecture, Physiology, Emotion and Behavior: Possible Effect on Human Health",,"Completed","No Results Available","Sleep|Emotion","Other: No intervention- base line|Other: Acute|Other: Chronic","body temperature|Melatonin secretion|sleepiness|BSI Questionnaire|Subjective sleepiness|attention|total Sleep time|Sleep efficiency|sleep latency to sleep stage1|sleep latency to sleep stage2|wake %TIB|REM %TIB|staege1%TIB|stage2%TIB|stage4%TIB","Assuta Medical Center","All","20 Years to 45 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","0005-16-ASMC","August 2016","October 2016","December 2016","July 21, 2016",,"January 9, 2018",,,"https://ClinicalTrials.gov/show/NCT02839395"
167,"NCT02177669","Test-Retest Variability of Quick Contrast Sensitivity Function Testing",,"Completed","No Results Available","Healthy","Other: quick Contrast Sensitivity Function test","95% coefficient of repeatability across subjects","Nova Southeastern University|Adaptive Sensory Technology","All","20 Years to 89 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","05291468Exp|R21EY023720|Adaptive Sensory Technology","June 2014","November 2016","November 2016","June 30, 2014",,"April 11, 2017","Nova Southeastern University; College of Optometry, Fort Lauderdale, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02177669"
168,"NCT04235803","Telemedicine Follow-up for Routine, Low-Risk Oculoplastic Surgery",,"Not yet recruiting","No Results Available","Eyelid Diseases|Ptosis, Eyelid|Blepharoptosis|Dermatochalasis|Ectropion|Entropion|Eyelid Tumor|Skin Cancer, Eyelid|Floppy Eyelid Syndrome","Other: Telemedicine follow-up","FACE-Q 'Satisfaction with Outcome'|FACE-Q 'Early Life Impact'|FACE-Q 'Satisfaction with Doctor'|Late post-operative complications|Time burden","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Eye plastic telemedicine","July 1, 2020","March 2021","June 2021","January 22, 2020",,"June 1, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04235803"
169,"NCT03640130","Peripheral Reading",,"Enrolling by invitation","No Results Available","Central Visual Impairment","Behavioral: Gaze-contingent text enhancement","Reading speed|Reading accuracy|Efficiency of eye movement","University of Houston","All","Child, Adult, Older Adult","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY00001096","November 1, 2018","March 1, 2019","March 1, 2019","August 21, 2018",,"November 14, 2018","University of Houston, College of Optometry, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03640130"
170,"NCT03765476","Validation of a Training Program for Patients With Alcohol Use Disorder",,"Recruiting","No Results Available","Alcohol Use Disorder","Behavioral: SALIENCE|Behavioral: TAU","Change in alcohol craving|Change in attentional bias|Change in alcohol interference|Change in approach-avoidance tendencies|Relapse","Central Institute of Mental Health, Mannheim","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","125","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SALIENCE","July 1, 2018","December 31, 2020","December 31, 2020","December 5, 2018",,"April 27, 2020","Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit, Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03765476"
171,"NCT01344044","Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Device: BCI","Attention Deficit Hyperactivity Disorder Rating Scale (ADHD Rating Scale) 4th Edition","National Healthcare Group, Singapore|Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|Singapore Clinical Research Institute","All","6 Years to 12 Years   (Child)","Phase 2|Phase 3","192","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DSRB Domain A/09/395","January 2011","May 13, 2016","May 13, 2016","April 28, 2011",,"March 30, 2017","Child Guidance Clinic, Institute of Mental Health, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01344044"
172,"NCT01270126","Trial of Alternating Current Stimulation in Optic Neuropathy","SCT_optnerve","Completed","Has Results","Optic Nerve Diseases|Optic Nerve Injuries|Optic Neuropathies","Device: Repetitive transorbital alternating current stimulation","Detection Accuracy (DA) Change in Percent Over Baseline Within Defective Visual Field Sectors|Other Visual and EEG Parameters","University of Magdeburg|EBS Technologies GmbH","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","EBS_optnerve_SCT","November 2006","December 2010","December 2010","January 5, 2011","September 4, 2013","September 16, 2013","Institute of Medical Psychology, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01270126"
173,"NCT01583101","Child Health Improvement Through Computer Automation (CHICA) Highlighting Study",,"Completed","Has Results","Physician Behavior","Other: Receiving Highlighted Prompts|Other: Receiving Non-highlighted Prompts","The Number of Prompts That Were Responded to","Indiana University","All","Child, Adult, Older Adult","Not Applicable","2237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","CHICA_Highlight_Study","April 2012","October 2012","October 2012","April 23, 2012","March 23, 2017","May 15, 2017","IUMG Clinic System, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01583101"
174,"NCT03409978","Smartphone App for Analysis of General Movements in Young Infants",,"Completed","No Results Available","Cerebral Palsy","Device: in-Motion app","Percentage of recordings that movement video recordings fulfil requirements needed for observation and classification of fidgety general movements|Ease of use of the In-Motion App in score on the Software usability scale (SUS) as part of a questionnaire sent to users two weeks after received video recordings|Correlation between computer-based software estimates by smartphone videos performed by parents at home and standard videos performed at the hospital follow-up clinic","St. Olavs Hospital|Norwegian University of Science and Technology|University of Illinois at Chicago|Ann & Robert H Lurie Children's Hospital of Chicago|Christian Medical College, Vellore, India|University Ghent|Hillerod Hospital, Denmark","All","12 Weeks to 17 Weeks   (Child)",,"86","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2017/913","March 5, 2018","December 20, 2019","December 20, 2019","January 25, 2018",,"February 19, 2020","Ghent University, Ghent, Belgium|Hillerød Hospital, Copenhagen, Denmark|St Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT03409978"
175,"NCT01149590","Scottish COmputed Tomography of the HEART Trial","SCOT-HEART","Completed","No Results Available","Angina Pectoris|Coronary Heart Disease","Procedure: Computer Tomography Angiography","Proportion of patients diagnosed with angina pectoris secondary to coronary heart disease|Symptoms|Diagnosis|Investigations|Treatment|Long-term outcome","University of Edinburgh|NHS Lothian|Chief Scientist Office of the Scottish Government","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","4138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CZH/4/588","November 2010","May 2015","May 2015","June 23, 2010",,"April 10, 2017","Borders General Hospital, Melrose, Borders, United Kingdom|Victoria Hospital, Kirkcaldy, Fife, United Kingdom|Ninewells Hospital, Dundee, Tayside, United Kingdom|University Hospital Ayr, Ayr, United Kingdom|Royal Infirmary Edinburgh, Edinburgh, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Western Infirmary Glasgow, Glasgow, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Forth Valley Royal, Larbert, United Kingdom|St John's Hosptial, Livingston, United Kingdom|Royal Alexandra Hospital, Paisley, United Kingdom|Perth Royal Infirmary, Perth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01149590"
176,"NCT00655096","Screening for Research Participants",,"Recruiting","No Results Available","Eye Diseases",,"Cscertain eligibility","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"10000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","080102|08-EI-0102","August 20, 2008",,,"April 9, 2008",,"July 8, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00655096"
177,"NCT00842413","Investigating the Role of the Premotor Cortex in Higher Cognitive Functions",,"Terminated","No Results Available","Brain Injury|Chronic",,,"Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P060605","May 2007","September 2007","September 2007","February 12, 2009",,"February 12, 2009","Hôpital de la Pitié-Salpétrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT00842413"
178,"NCT03407066","Perception, Sensation, Cognition and Action in Humans",,"Recruiting","No Results Available","Normal Physiology",,"MRI, fMRI|MEG|Behavioral measures","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"10200","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","180046|18-EI-0046","March 26, 2019","December 31, 2025","December 31, 2025","January 23, 2018",,"May 12, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03407066"
179,"NCT02599350","Assessing Gas Exchange in Intensive Care Patients on a Ventilator",,"Completed","No Results Available","Mechanical Ventilation Complication",,,"University of Aberdeen","All","16 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09/MRE00/32","May 2009","July 2012","August 2012","November 6, 2015",,"November 6, 2015","Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02599350"
180,"NCT01169948","320 Multidetector Computed Tomography Prior to Coronary Artery Bypass Surgery",,"Withdrawn","No Results Available","Coronary Disease","Radiation: Computed tomography scan","Coronary artery stenosis defined qualitatively by trained observers and quantitatively by computer software|Myocardial perfusion defects defined qualitatively by trained observers and quantitatively by computer software","University of Edinburgh","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2009/R/CAR/17","June 2010",,,"July 26, 2010",,"March 14, 2013","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01169948"
181,"NCT02421146","The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study",,"Completed","Has Results","Chronic Schizophrenia","Device: Transcranial direct current stimulation|Device: Transcranial direct current stimulation - Sham","Cognition on the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) Scale|Cognition on the RBANS ( Repeatable Battery for the Assessment of Neuropsychological Status) Scale. Change Between 26th Day and Baseline.","Northwell Health","All","18 Years to 60 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","14-623","April 2015","September 12, 2016","September 12, 2016","April 20, 2015","April 30, 2018","April 30, 2018","Zucker Hillside Hospital, Glen Oaks, New York, United States",,"https://ClinicalTrials.gov/show/NCT02421146"
182,"NCT01418820","Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions",,"Completed","No Results Available","Complete Hemianopia|Incomplete Hemianopia|Scotoma|Quadrantanopia|Stroke|Hemorrhage|Brain Trauma","Device: Verum stimulation|Device: Placebo stimulation","detection accuracy (%) in visual field measures over baseline|detection accuracy (%) in the intact visual field over baseline|visual acuity (LogRAD)|EEG parameters|conventional perimetry|reaction time (ms)","University of Magdeburg|EBS Technologies GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EBS-PP-2011-02-16-001","March 2011","December 2013","December 2013","August 17, 2011",,"July 5, 2019","Inst. f. Medical Psychology, Univ. of Magdeburg, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01418820"
183,"NCT01771575","The Use of the PoNS™ Device in the Treatment of Blunt and Blast Induced Vestibular Disorders",,"Withdrawn","No Results Available","Hearing and Vestibular Disorders","Other: Placebo device|Device: PoNS™ device","Change in Sensory Organization Test score|Change in Vestibular-Ocular Reflex scores","United States Naval Medical Center, San Diego|The Geneva Foundation","All","18 Years to 40 Years   (Adult)","Not Applicable","0","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NMCSD.2013.0011","July 2013","September 2014","September 2014","January 18, 2013",,"August 19, 2016","Naval Medical Center, San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01771575"
184,"NCT00673764","The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance",,"Completed","Has Results","Dry Eye","Other: Systane Ultra Lubricant Eye Drops|Other: Optive Lubricant Eye Drops","Time at Best Corrected Visual Acuity|Functional Blink Rate Time (Time Between Blinks)","Alcon Research","All","18 Months and older   (Child, Adult, Older Adult)","Not Applicable","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-07-24","May 2008","June 2008","June 2008","May 7, 2008","February 10, 2010","February 2, 2012","North Andover, North Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00673764"
185,"NCT03524196","Service-user Experiences of Text-based Conversations With a Computer About Their Difficulties",,"Completed","No Results Available","Psychological","Other: Manage Your Life Online (MYLO)","MOL helpfulness ratings questionnaire.|Reorganisation of Conflict Scale (RoC)|Patient Health Questionnaire (PHQ-9)|Generalised Anxiety Disorder Questionnaire (GAD-7)|Psychological Outcome Profiles questionnaire (PSYCHLOPS)|Qualitative feedback about the MYLO interface|Frequency of MYLO use|Duration of MYLO use","University of Manchester","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","238389","November 19, 2018","May 1, 2019","July 11, 2019","May 14, 2018",,"September 25, 2019","University of Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03524196"
186,"NCT00001864","Amblyopia (Lazy Eye) Treatment Study",,"Completed","No Results Available","Amblyopia|Anisometropia|Strabismus","Drug: Atropine|Device: Patch",,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 3","20","NIH","Interventional","Primary Purpose: Treatment","990110|99-EI-0110","May 1999",,"November 2001","May 22, 2002",,"March 4, 2008","National Eye Institute (NEI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001864"
187,"NCT02929979","Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder",,"Completed","No Results Available","Alcohol Use Disorder|PTSD|Cognitive Dysfunction","Behavioral: Cognitive Training|Behavioral: Cognitive training placebo control","The WAIS-IV (Wechsler, 2008) Processing Speed Index|Trail Making Test (TMT) - Part A|Computerized Approach Avoidance Tasks for Alcohol and Threat|The Revised Hopkins Verbal Learning Test|The Brief Visual Memory Test Revised|The Wechsler Adult Intelligence Scale-IV Working Memory Index|The Conners' Continuous Performance Task II|The Color-Word Interference Test (DKEFS)|The Iowa Gambling Task|The Delay Discounting Task|Trail Making Test (TMT) - Part B|The Wisconsin Card Sorting Test - computer version 4 Research Edition|The Tower Test (DKEFS)|Alcohol Use|Functional Status - Inventory of Psychosocial Functioning|PTSD Symptom Severity","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","93","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1492-W|1IK2RX001492-01A1","January 1, 2015","July 21, 2019","July 21, 2019","October 11, 2016",,"July 24, 2019","VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02929979"
188,"NCT02481752","The Effect of AAT Training in Smokers",,"Completed","No Results Available","Tobacco Use","Other: Approach Avoidance Training|Other: SHAM Training","Reaction Time on Approach Avoidance Task|Motivation to Quit Smoking as assessed by having participants rate their motivation to quit smoking on a scale of 1 to 10 (1 being not motivated at all and 10 being extremely motivated to quit).|Number of Days Abstinent as assessed by daily cigarette count during a self-guided quit attempt.|Self Efficacy as assessed by the Relapse Situation Self-Efficacy questionnaire.|Urge to Smoke as assessed by the QSU-brief (Questionnaire of Smoking Urges).","University of Texas at Austin","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","2015-02-0023","July 2015","March 2016","March 2016","June 25, 2015",,"August 18, 2016","University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02481752"
189,"NCT00684320","Attention Disengagement Training for Social Phobia","SPAttn","Completed","Has Results","Social Anxiety Disorder","Behavioral: Attention Disengagement Training (ADT)|Behavioral: Placebo Condition","Liebowitz Social Anxiety Scale (LSAS)|Social Phobia and Anxiety Inventory","San Diego State University|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R34MH073004-03","September 2006","August 2011","August 2011","May 26, 2008","May 1, 2014","May 1, 2014","San Diego State University, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00684320"
190,"NCT01421498","Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","OPUS-1","Completed","Has Results","Keratoconjunctivitis Sicca|Dry Eye Disease","Drug: Lifitegrast|Drug: Placebo","Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84|Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84","Shire","All","18 Years and older   (Adult, Older Adult)","Phase 3","588","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1118-KCS-200","August 29, 2011","April 28, 2012","April 28, 2012","August 22, 2011","February 24, 2017","December 19, 2018","OPUS-1 Investigational Site, Waterbury, Connecticut, United States|OPUS-1 Investigational Site, Louisville, Kentucky, United States|OPUS-1 Investigational Site, Augusta, Maine, United States|OPUS-1 Investigational Site, Lewiston, Maine, United States|OPUS-1 Investigational Site, Andover, Massachusetts, United States|OPUS-1 Investigational Site, Lancaster, Massachusetts, United States|OPUS-1 Investigational Site, Quincy, Massachusetts, United States|OPUS-1 Investigational Site, Wakefield, Massachusetts, United States|OPUS-1 Investigational Site, Winchester, Massachusetts, United States|OPUS-1 Investigational Site, Derry, New Hampshire, United States|OPUS-1 Investigational Site, Manchester, New Hampshire, United States|OPUS-1 Investigational Site, Memphis, Tennessee, United States|OPUS-1 Investigational Site, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01421498"
191,"NCT04241575","Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages",,"Recruiting","No Results Available","Fatty Liver, Nonalcoholic|Diabetes Mellitus, Type 2","Diagnostic Test: Simple fibrosis scores and electronic reminder messages","Action on suspected advanced liver fibrosis|Referral for specialist care|Inappropriate referral for specialist care|Confirmed diagnosis of advanced liver fibrosis","Chinese University of Hong Kong","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","952","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Screening","NAFLD-NIT-RCT","February 1, 2020","April 30, 2023","April 30, 2023","January 27, 2020",,"January 27, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04241575"
192,"NCT02261857","3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea",,"Completed","No Results Available","Sleep Apnea, Obstructive|Craniofacial Abnormalities|Pediatric Disorder","Device: Personalized continuous positive airway pressure (CPAP) mask","Change in CPAP Compliance at 1 month|Change in CPAP Leak Rate at 1 month|Change in residual AHI on CPAP at 1 month|Change in time spent in large leak on CPAP at 1 month|Change in Quality of Life via OSA-18 questionnaire|Safety outcomes: Comfort at baseline|Safety outcomes: Comfort at 1 month|Safety outcomes: Skin reaction at 1 month|Change in Quality of Life via PSQ questionnaire|Safety outcomes: durability at 1 month|Safety outcomes: Skin reaction at 12 months|Safety outcomes: Durability at 12 months","Glenn Green|American Academy of Otolaryngology-Head and Neck Surgery Foundation|University of Michigan","All","1 Year to 18 Years   (Child, Adult)","Early Phase 1","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00078727","September 2013","September 2017","September 2017","October 10, 2014",,"April 16, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02261857"
193,"NCT02564978","Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration",,"Recruiting","No Results Available","Age- Related Macular Degeneration","Drug: Minocycline","Difference in the rates of GA area expansion in the study eye between the run-in phase of the study and following IP initiation.|Changes in: GA area expansion based on digital grading of color fundus images, best-corrected visual acuity (BCVA), low-luminance VA, central retinal thickness on OCT, and macular sensitivity on microperimetry.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","55 Years and older   (Adult, Older Adult)","Phase 2","60","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150202|15-EI-0202","December 14, 2016","December 31, 2024","December 31, 2024","October 1, 2015",,"March 6, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Bristol Eye Hospital, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02564978"
194,"NCT00806559","Space and Interaction Trial: Room Design and Patient-physician Interaction","SIT","Completed","No Results Available","Internal Medicine Patients|Participating Staff","Other: Re-designed room|Other: Control room","Patient and Clinician Interaction variables (duration of the encounter, patient sense of control in encounter, patient's ability to access information from the computer monitor and the quality of the verbal and non-verbal interaction).|Patient experience of the clinical encounter. The following variables will be measured: patient satisfaction with the room, patient satisfaction with the encounter and the quality of the relationship.","Mayo Clinic|Steelcase","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","07-000135","July 2007","April 2008","April 2008","December 11, 2008",,"December 14, 2011","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00806559"
195,"NCT02915068","Feasibility of a Clinician Training Program to Improve Patient-provider Communication in the Presence of Health IT Systems in the Exam Room",,"Completed","No Results Available","Asthma","Behavioral: EHR-Physician Asthma Care Education Program","Change from baseline patient report of physician performance at 3 and 6 months|Change from baseline patient satisfaction at 3 and 6 months|Change from baseline asthma control at 3 and 6 months|Change from baseline asthma-related quality of life at 3 and 6 months","University of Michigan|Agency for Healthcare Research and Quality (AHRQ)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","126","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","HUM00100232","June 2015","August 31, 2017","August 31, 2017","September 26, 2016",,"September 14, 2017","Integrated Health Associates ClinSite Research, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02915068"
196,"NCT04186104","Artificial Intelligence in Children's Clinic",,"Recruiting","No Results Available","Artificial Intelligence|Outpatient","Other: Routine diagnostic process|Other: Artificial intelligence assisted diagnosis process","Evaluate the efficiency of the two processes|Evaluate patients' rate of satisfaction for medical processes|Evaluate rate of single visit and rate of return visit|Economic measurements|Work efficiency of doctors|Evaluate the accuracy of examination items prescribed by the AI system and inexperienced physicians","Shanghai Jiao Tong University School of Medicine","All","2 Months to 18 Years   (Child, Adult)","Not Applicable","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","SCMCIRB-K2019020-2","March 21, 2020","June 30, 2020","December 31, 2020","December 4, 2019",,"May 21, 2020","Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Shanghai Children's Medical Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04186104"
197,"NCT02983552","Binocular Dig Rush Game Treatment for Amblyopia","ATS20","Active, not recruiting","No Results Available","Amblyopia","Other: iPad®|Other: Spectacle correction","Mean change in amblyopic-eye VA|VA Improvement at 4 Weeks Defined as a Binary Outcome|VA Improvement at 8 Weeks Defined as a Binary Outcome|Stereoacuity|Treatment Compliance with Binocular Therapy|Treatment Compliance with Binocular Therapy at 8 weeks|Fellow-eye Contrast with Binocular Therapy|Fellow-eye Contrast with Binocular Therapy at 8 Weeks|VA in Fellow Eye|VA in Fellow Eye at 8 Weeks|Ocular Alignment|Ocular Alignment at 8 Weeks|Diplopia|Diplopia at 8 Weeks|Adverse Symptoms|Adverse Symptoms at 8 Weeks","Jaeb Center for Health Research|Pediatric Eye Disease Investigator Group|National Eye Institute (NEI)","All","4 Years to 12 Years   (Child)","Not Applicable","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ATS20|2U10EY011751","March 2, 2017","July 2020","August 2020","December 6, 2016",,"June 9, 2020","UAB Pediatric Eye Care; Birmingham Health Care, Birmingham, Alabama, United States|Midwestern University Eye Institute, Glendale, Arizona, United States|University Eye Center at Ketchum Health, Anaheim, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Saddleback Eye Medical Associates, Mission Viejo, California, United States|Western University College of Optometry, Pomona, California, United States|Yale University, New Haven, Connecticut, United States|Nova Southeastern University College of Optometry, The Eye Institute, Fort Lauderdale, Florida, United States|University of Florida Shands Hospital, Gainesville, Florida, United States|The Emory Eye Center, Atlanta, Georgia, United States|St Luke's Hospital, Boise, Idaho, United States|Ticho Eye Associates, Chicago Ridge, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Illinois College of Optometry, Chicago, Illinois, United States|Progressive Eye Care, Lisle, Illinois, United States|Advanced Vision Center, Schaumburg, Illinois, United States|Pediatric Eye Associates, Wilmette, Illinois, United States|Indiana School of Optometry, Bloomington, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Wilmer Eye Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Michigan College of Optometry at Ferris State Univ, Big Rapids, Michigan, United States|Helen DeVos Children's Hospital Pediatric Ophthalmology, Grand Rapids, Michigan, United States|Pediatric Ophthalmology, P.C., Grand Rapids, Michigan, United States|University of Minnesota-Minnesota Lions Children's Eye Clinic, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Saint Louis University Institute, Saint Louis, Missouri, United States|St. Louis Children's Hospital Eye Center, Saint Louis, Missouri, United States|U of MO St. Louis College of Optometry, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Concord Ophthalmologic Associates, Concord, New Hampshire, United States|Michael F. Gallaway, O.D., P.C., Marlton, New Jersey, United States|State University of New York, College of Optometry, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Eye Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Pediatric Ophthalmology Associates, Inc., Columbus, Ohio, United States|The Ohio State University College of Optometry, Columbus, Ohio, United States|Eye Care Associates, Inc., Poland, Ohio, United States|Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma, United States|Pacific University College of Optometry, Portland, Oregon, United States|OHSU Casey Eye Institute, Portland, Oregon, United States|Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States|Conestoga Eye, Lancaster, Pennsylvania, United States|Pediatric Eye Specialists, Chattanooga, Tennessee, United States|Southern College of Optometry, Memphis, Tennessee, United States|Texas Children's Hospital - Dept. Of Ophthalmology, Houston, Texas, United States|University of Houston College of Optometry, Houston, Texas, United States|Texas Tech University Health Science Center, Lubbock, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|Houston Eye Associates, The Woodlands, Texas, United States|Virginia Pediatric Eye Center, Norfolk, Virginia, United States|Seattle Children's Hospital, University of Washington, Seattle, Washington, United States|Northwest Pediatric Ophthalmology, P.S., Spokane, Washington, United States|Spokane Eye Clinical Research, Spokane, Washington, United States|Marshall University, Huntington, West Virginia, United States|University of Wisconsin, University Station, Madison, Wisconsin, United States|Snowy Range Vision Center, Laramie, Wyoming, United States|Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02983552"
198,"NCT03405857","Effects of the Cognitive Enhancing ICT Contents in Patients With Mild Cognitive Impairment",,"Completed","No Results Available","Mild Cognitive Impairment","Other: Cognitive rehabilitation program","Change from baseline performance on Digit Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Auditory Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Trail Making Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Stroop test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Recognition test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Auditory Verbal Learning test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline score on Korean Version of Geriatric Depression Test Short Form (Depression scale) at 4 weeks and 8 weeks|Change from baseline activity on functional Near-Infrared Spectroscopy (fNIRS) at 4 weeks and 8 weeks","Samsung Medical Center","All","55 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-01-013-010","May 25, 2016","January 25, 2018","April 7, 2018","January 23, 2018",,"August 2, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03405857"
199,"NCT03401775","Evaluation of the Effects of the New Program for Cognitive Enhancement and Improvement in the Elderly",,"Completed","No Results Available","Aging","Other: Cognitive rehabilitation program","Change from baseline performance on Digit Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Auditory Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Trail Making Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Stroop test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Recognition test (Neuropsychological test) at 4 weeks and 8weeks|Change from baseline performance on Auditory Verbal Learning test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline score on Korean Version of Geriatric Depression Test Short Form (Depression scale) at 4 weeks and 8 weeks|Change from baseline activity on functional Near-Infrared Spectroscopy (fNIRS) at 4 weeks and 8 weeks","Samsung Medical Center","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015-10-080-005","December 23, 2015","December 15, 2016","December 15, 2016","January 17, 2018",,"January 17, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03401775"
200,"NCT03444961","CAREN Argus Rehab (CARE) Study","CARE","Completed","No Results Available","Retinitis Pigmentosa","Device: CAREN system training","Effects of CAREN virtual reality system on obstacle course navigation|Effects of CAREN virtual reality system on Timed Up and Go testing|Effects of CAREN virtual reality system on Activities-specific Balance Confidence (ABC) scale questionnaire|Effects of CAREN virtual reality system on square localization visual function test|Effects of CAREN virtual reality system on direction of motion visual function test.|Effects of CAREN virtual reality system on grating visual acuity visual function test|Effects of CAREN virtual reality system on gait assessment","The Cleveland Clinic","All","25 Years to 100 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-1355","January 30, 2018","June 20, 2018","June 20, 2018","February 26, 2018",,"December 3, 2018","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03444961"
201,"NCT01245504","Assessment of Socket Shapes Made by Central Fabrication Facilities",,"Completed","No Results Available","People With Lower Limb Amputation That Are Ambulatory","Other: Assessed for socket fit","Limb volume|Limb shape","University of Washington","Female","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","31673 E/B","November 2008","December 2011","December 2011","November 22, 2010",,"April 25, 2014","University of Washington, Bioengineering Department, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01245504"
202,"NCT02990897","Pilot Study of Health Information Technology for Chronic Kidney Disease Management",,"Active, not recruiting","No Results Available","Chronic Kidney Disease","Behavioral: clinical decision support message","Laboratory tests completed|Urine microalbumin to creatinine ratio test completed|Referral of patient from PCP to nephrologist|Doubling of serum creatinine|Initiation of hemodialysis","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","0","December 2015","January 2017","January 2021","December 13, 2016",,"July 9, 2020","North Shore Physicians Group, Danvers, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02990897"
203,"NCT02272959","Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth Who do Not Respond to CBT",,"Recruiting","No Results Available","Anxiety Disorders","Behavioral: Attention bias modification treatment (ABMT)|Behavioral: Attention Control Condition","The Pediatric Anxiety Rating Scale (PARS)|Anxiety Related Emotional Disorders - Child/Parent Version (SCARED-C/P)","Yair Bar-Haim|United States - Israel Binational Science Foundation|Schneider Children's Hospital|Sheba Medical Center|Tel Aviv University","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","loe140498ctil","January 2015","July 2019","July 2019","October 23, 2014",,"September 18, 2018","Tel-Aviv University, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT02272959"
204,"NCT03968965","Evaluation of 3D Machine-vision Image Guided Surgery Spine Navigation",,"Recruiting","No Results Available","Spinal Stenosis, Lumbar Region|Spondylolisthesis","Device: 3D MvIGS Spine Navigation|Other: 2D Fluoroscopy","Mean total length of operative time|Length of stay|Length of time for initial image processing|Length of time to place all screws|Length of time to confirm screw placement|Length of time to register images|Estimated Blood Loss (EBL)|Incidence of Malalignment|Complications|Measurement of 2D fluoroscopy radiation exposure","7D Surgical Inc.|Hospital for Special Surgery, New York","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","130","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0328","May 9, 2018","December 2020","January 2021","May 30, 2019",,"November 7, 2019","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03968965"
205,"NCT02058966","Pilot Study of Entacapone for Methamphetamine Abuse",,"Completed","Has Results","Methamphetamine Dependence","Drug: Entacapone|Drug: Methamphetamine|Drug: Placebo","Effect of Entacapone on Methamphetamine-induced Mood|Effect of Entacapone on Subjective Effects of Methamphetamine|Effect of Entacapone on Methamphetamine-induced Stimulation|Cognitive Function","Oregon Health and Science University|Portland VA Medical Center","All","18 Years to 45 Years   (Adult)","Early Phase 1","29","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","8874|1004805|3986","June 2014","June 2016","June 2016","February 11, 2014","September 12, 2019","September 12, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02058966"
206,"NCT03655782","Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain Injury",,"Not yet recruiting","No Results Available","MTBI - Mild Traumatic Brain Injury","Behavioral: PATH neurotraining|Behavioral: Orientation Discrimination","Change in Visual Working Memory|Change in Attention|Change in Cognitive Flexibility|Change in Auditory Working Memory|Change in Processing Speed|Change in Reading Speed|Change in DLPFC Function|Change in ACC Function|Change in Precuneus/PCC","Perception Dynamics Institute|University of California, San Diego|University of South Alabama","All","18 Years to 55 Years   (Adult)","Not Applicable","153","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","PerceptionDI","June 1, 2020","December 31, 2021","December 31, 2024","August 31, 2018",,"December 2, 2019","Pacific Center for Neurological Disease Neuroscience Research Institute, Poway, California, United States|University of California at San Diego, San Diego, California, United States|Perception Dynamics Institute, Solana Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03655782"
207,"NCT03345381","Impact of Breathing Exercises and Meditation on Quality of Life in Dry Eye Disease Patients: A Pilot Study",,"Not yet recruiting","No Results Available","Depression|Quality of Life|Dry Eye|Anxiety|Sleep","Other: SKY + ASTM + usual care|Other: Usual care","Change in Health Related Quality of Life (HRQoL)|Visual Function Score|Depression|State and Trait Anxiety|Sleep Quality|Community Integration|Canadian Dry Eye Assessment|Dry Eye Assessment","Lawson Health Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","110762","July 1, 2019","September 1, 2020","December 1, 2020","November 17, 2017",,"June 18, 2019","St. Joseph's Hospital, Ivey Eye Institute, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03345381"
208,"NCT03292705","Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment","CogT-PACT","Completed","No Results Available","Mild Cognitive Impairment","Behavioral: PEP|Behavioral: CCI","Attitudes Toward Computers Questionnaire Total score|Useful Field of View|Executive Function|Brief Visuospatial Memory Test|Activities of Daily Living-Prevention Instrument|Everyday Problems for Cognitive Challenged Elderly Test","University of Rochester","All","60 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R21AG054810","October 1, 2017","April 5, 2019","September 1, 2019","September 25, 2017",,"December 6, 2019","Brickstone/Saint John Meadow, Rochester, New York, United States|River Edge Manor, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03292705"
209,"NCT03706534","Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms",,"Active, not recruiting","No Results Available","Breast Cancer|Breast Lesions|Breast Mass","Device: Ultrasound Image review with CADe|Device: Ultrasound Image review with CADx|Device: Ultrasound Image manual review|Procedure: Biopsy","Concordance rate|Reporting time|Consensus|Accuracy|Sensitivity|Specificity|Area Under Curve","Samsung Medison|University of Rochester","All","19 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Device Feasibility","300.08-2018-Samsungmedison-S","September 20, 2018","November 30, 2019","January 31, 2020","October 16, 2018",,"October 29, 2019","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03706534"
210,"NCT03103828","Sharing and Talking About my Preferences","STAMPVA","Recruiting","No Results Available","Chronic Disease","Behavioral: Computer-Tailored Intervention|Behavioral: Motivational Interviewing|Behavioral: Motivational Enhancement Therapy","Completion of 4 ACP behaviors|Movement on each of 4 ACP behaviors","VA Connecticut Healthcare System","All","55 Years and older   (Adult, Older Adult)","Not Applicable","484","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","TF0025","October 2, 2017","March 31, 2021","March 31, 2021","April 6, 2017",,"January 9, 2020","VA Connecticut Healthcare System, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03103828"
211,"NCT04050046","Noninvasive Brain Stimulation to Enhance Cognitive Training in Older Adults","MINDS","Completed","No Results Available","Normal Aging","Device: Transcranial Direct Current Stimulation|Behavioral: Computer-based cognitive therapy (CBCT)","Change in Executive Function|Change in response to TMS","University of Pennsylvania","All","65 Years to 85 Years   (Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","822954","August 18, 2015","August 1, 2018","August 1, 2018","August 8, 2019",,"August 8, 2019",,,"https://ClinicalTrials.gov/show/NCT04050046"
212,"NCT00776737","Studies of Measures of Attention",,"Completed","No Results Available","Attention Deficit Disorder|Attention Deficit Hyperactivity Disorder",,,"National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC)","All","6 Years to 60 Years   (Child, Adult)",,"36","NIH","Observational","Time Perspective: Prospective","090002|09-DC-0002","October 16, 2008",,"January 14, 2011","October 21, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00776737"
213,"NCT03299400","Continuous Intraocular Pressure Patterns in Spine Surgery",,"Completed","No Results Available","Intraocular Pressure","Device: Contact lens sensor","Report the physiological changes of IOP patterns during prone spinal surgery|Correlate any intraoperative risk factors that may cause IOP fluctuations|Documentation of IOP changes after the surgery until the contact lens sensor is removed","The University of Hong Kong","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UW 16-207","May 9, 2016","May 9, 2017","May 9, 2017","October 3, 2017",,"May 6, 2020","Duchess of Kent Children's Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03299400"
214,"NCT03369054","Psychotherapy Trial With Transgender Clients",,"Completed","No Results Available","Transgender Persons, M01.777.500","Behavioral: Minority Stress Treatment|Behavioral: Treatment As usual","Measuring Weekly Change in the Outcome Questionnaire 45; Lambert et al., 2013|Measuring 3 month and 9 month Change in the Outcome Questionnaire 45; Lambert et al., 2013|Measuring 3 month and 9 month Change in the World Health Organization WHOQOL-BREF Quality of Life Assessment (WHOQOL-BREF); Power, 1998","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2017-0816|A171600|EDUC\COUNSELING PSYCH","December 1, 2017","January 10, 2019","January 10, 2019","December 11, 2017",,"December 24, 2019","University of Wisconsin Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03369054"
215,"NCT01078129","Cognitive Remediation Therapy and Schizophrenia",,"Completed","No Results Available","Schizophrenia","Behavioral: cognitive remediation therapy|Behavioral: non-CRT","cognitive deficits (attention/concentration, topological memory, logical reasoning, executive functions)|brain functioning (fMRI)|schizophrenia symptoms","Hôpital le Vinatier|University Hospital, Grenoble|University Hospital, Clermont-Ferrand","All","18 Years to 40 Years   (Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","2005-094B","January 2006","March 2008","December 2010","March 2, 2010",,"February 25, 2014","Hôpital le vinatier, Bron, France",,"https://ClinicalTrials.gov/show/NCT01078129"
216,"NCT02271373","Effect of Increasing Time Spent Outdoors on Myopia Prevention in School-Aged Children in Northeast China",,"Completed","No Results Available","Myopia","Behavioral: increasing time spent outdoors","Changes in uncorrected visual acuity|Questionnaire survey|Changes in ocular biometric parameters","Anhui Medical University","All","6 Years to 14 Years   (Child)","Not Applicable","3521","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","2013001","November 2012","November 2013","February 2014","October 22, 2014",,"October 23, 2014",,,"https://ClinicalTrials.gov/show/NCT02271373"
217,"NCT03655912","Binocular Visual Therapy and Video Games for Amblyopia Treatment.",,"Recruiting","No Results Available","Amblyopia","Device: Red/green glasses|Device: Electronic Tablet|Device: Eye patch","Best corrected visual acuity of the amblyopic eye|Best corrected visual acuity of the amblyopic eye two months after treatment suspension to determine lazy eye relapses|Stereopsis|Stereopsis two months after treatment suspension to determine lazy eye relapses","Universidad Autonoma de Nuevo Leon|Hospital Universitario Dr. Jose E. Gonzalez","All","4 Years to 10 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","OF17-00013","October 9, 2018","October 2020","December 2020","August 31, 2018",,"March 26, 2020","Departamento de Oftalmologia, Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT03655912"
218,"NCT00315939","Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes","BPK002","Completed","Has Results","Diabetes Mellitus, Type 1","Device: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Device: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)","Hemoglobin A1c|Frequency of Severe Hypoglycemia","Boris Kovatchev, PhD|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","12126","January 2006","December 2009","December 2009","April 19, 2006","September 9, 2014","September 18, 2014","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00315939"
219,"NCT03337230","Feasibility of a Social Media-based Weight Loss Program for Low Socioeconomic Status Individuals",,"Completed","No Results Available","Obesity","Behavioral: Physical Activity|Behavioral: Diet|Behavioral: Social Support","Ratio or participants screened to patients completing 12-week measures|Average score of adapted INSHAPE computer-based questionnaire|Number of eligible participants|Number of consented participants|Average change in Fitbit activity|Average change in International physical activity questionnaire (IPAQ) score|Average change in score of the National Cancer Institute's Automated Self-Administered 24-Hour (ASA24) dietary assessment web-based assessment tool|Change in weight|Change in waist circumference|Average change in social support score|Average change in weight loss self-efficacy score|Average change in dietary knowledge","Case Comprehensive Cancer Center","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CASE17Z17","October 31, 2017","May 27, 2018","May 27, 2018","November 8, 2017",,"January 3, 2020","Case Western Reserve Univeristy, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03337230"
220,"NCT04223336","A Web-enabled Integrated Care Pathway (ICP) for Addressing Multiple Modifiable Risk Factors as a Part of Smoking Cessation Treatment in Primary Care Settings.",,"Recruiting","No Results Available","Physical Activity|Fruits and Vegetable Consumption|Smoking Cessation","Behavioral: Brief physical activity and diet intervention","Smoking cessation - self-report questionnaire|Physical activity - self-report questionnaire|Fruits/vegetable consumption - self-report questionnaire","Centre for Addiction and Mental Health|Public Health Agency of Canada (PHAC)|Medical Psychiatry Alliance","All","Child, Adult, Older Adult","Not Applicable","5000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","119-2018","November 30, 2019","July 2020","February 2021","January 10, 2020",,"January 10, 2020","Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04223336"
221,"NCT02771431","The Use of Videoconferencing for Monitoring of Patients Post Urologic Surgery",,"Completed","No Results Available","Urology","Other: Tele-rounding in post operative care","Complication rates|length of inpatient stay|number of lab tests ordered|severity of complications|Additionally patient satisfaction will be looked at based on post-operative questionnaire.","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","14-659","February 2015","November 13, 2018","November 13, 2018","May 13, 2016",,"August 8, 2019","North Shore LIJ, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT02771431"
222,"NCT02580825","Biofeedback Gait Retraining to Reduce Lower Extremity Impact in Obese Children",,"Completed","No Results Available","Childhood Obesity","Behavioral: Biofeedback gait retraining|Behavioral: Exercise","GRF (ground reaction force)|Anthropometric measurements|VAS questionnaire|Physicians global assessment questionnaire|Postural deviations of the knee joint","Meir Medical Center","All","7 Years to 12 Years   (Child)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MeirMc0189-15CTIL","January 2016","August 2017","October 2017","October 20, 2015",,"March 21, 2018","the sports and health center for children and youth at ""Meir"" medical center, Kfar Sava, Israel",,"https://ClinicalTrials.gov/show/NCT02580825"
223,"NCT02911129","Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation",,"Completed","No Results Available","Normal Physiology|Stroke",,"Experiment 1: The primary outcome measure will be the change in the strength of the fronto-parietal resting state network (RSN) after rPA in neglect patients.|Experiments 2: The primary outcome measure will be the change in the strength of the fronto-parietal resting state network (RSN) after rPA or lPA or nPA.|Experiment 3: The primary outcome measure will be the change in the strength of the fronto-parietal resting state network (RSN) after cTBS over the PPC versus cTBS over the vertex.|Experiment 1: The change of preferred center and size in the different region of interest (ROI) in the parietal cortex, and the change in open loop pointing task performances after rPA.|Experiments 2: The change of preferred center and sizein the different region of interest (ROI) in the parietal cortex, and the change in open loop pointing task performances after rPA or lPA, or nPA|Experiments 3: The change in perceptual line bisection performances after r cTBS over PPC or cTBS over the vertex.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)",,"74","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160170|16-N-0170","November 4, 2016","May 7, 2020","May 7, 2020","September 22, 2016",,"June 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02911129"
224,"NCT01784627","Trial of Computerized SBI to Reduce Teen Alcohol Use",,"Withdrawn","No Results Available","Alcohol Abuse|Cannabis Abuse|Nicotine Dependence","Behavioral: c-ASBI","Days of alcohol use|Drinking initiation|Drinking cessation|Driving/Riding risk","Boston Children’s Hospital","All","9 Years to 20 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JK R01 PA-12-031","January 2015","October 2017","October 2017","February 6, 2013",,"October 7, 2016","Tufts Medical Center, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Longwood Pediatrics, Boston, Massachusetts, United States|East Boston Neighborhood Health Center, Boston, Massachusetts, United States|Cambridge Pediatrics, Cambridge, Massachusetts, United States|Lexington Pediatrics, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01784627"
225,"NCT02058550","Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy",,"Active, not recruiting","No Results Available","Cervical Cancer|Endometrial Cancer|Radiation Toxicity|Vaginal Cancer","Other: survey administration|Other: computer-assisted intervention|Behavioral: telephone-based intervention","Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation|Vaginal canal length|Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03","Stanford University|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB-29074|NCI-2013-02400|GYN0005|P30CA124435","September 2014","January 2019","September 2022","February 10, 2014",,"April 28, 2020","Stanford University, School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02058550"
226,"NCT03234725","Analysis of New Endoscopic Features and Variable Stiffness in Colonoscopy: Prospective Randomised Trial","ELUFIBLI","Completed","No Results Available","Colorectal Adenoma|Colorectal Adenomatous Polyp",,"diagnostic value of the computer algorithm|Number of detected serrated polyps|Number of detected polyps|the accuracy of the NICE (NBI International Colorectal Endoscopic) criteria using FICE versus BLI Eluxeo technology|Inter-observer agreement among the 5 experts|Cecal intubation rate|Propofol need for deep sedation|diagnostic interobserver variability based on the computer algorithm|the accuracy of the NICE criteria using FICE versus BLI Eluxeo technology with 50x optical zoom for differentiating between the non-neoplastic and neoplastic histotypes|Comparison of accuracy of BLI and LCI pictures|Improvement of adenoma detection rate by using LCI imaging comparing with that under white endoscopy|Time-to-cecum|Ancillary maneuvers to facilitate procedure","Bács-Kiskun County Teaching Hospital|Endo-Kapszula Privat Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Deep001","October 1, 2016","September 30, 2018","September 30, 2018","July 31, 2017",,"July 10, 2019","Bács Kiskun County and Teaching Hospital, Kecskemét, Nyiri Street 38, Hungary",,"https://ClinicalTrials.gov/show/NCT03234725"
227,"NCT04297735","Telemedicine Enabling Patients in Self-care Behaviors",,"Suspended","No Results Available","Arrythmia","Other: Standard of care group|Behavioral: Telemedicine group|Behavioral: Telemedicine","Time of recognition of an arrhythmia|Time of diagnosis of arrhythmia|Time to treatment initiation of arrhythmia|Change in self efficacy in medication use score as measured by the Medication Self Efficacy Tool (MUSE) survey|Change in functioning self efficacy score as measured by the 13 Item Shortened Function Self-efficacy Scale (FSES)|Change in self-efficacy of arrhythmia management score as measured by the Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmias (ASTA) survey","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HUM00156966","February 26, 2020","March 2022","March 2022","March 5, 2020",,"April 3, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04297735"
228,"NCT02200432","Patient Experience Recommender System for Persuasive Communication Tailoring","PERSPECT","Completed","No Results Available","Smoking Cessation","Other: PERSPeCT Recommender System","message influence","University of Massachusetts, Worcester","All","18 Years and older   (Adult, Older Adult)","Not Applicable","972","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","14762","May 2014","March 2015","June 2015","July 25, 2014",,"July 9, 2015","The University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02200432"
229,"NCT02582411","Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography",,"Completed","No Results Available","Healthy","Device: Laser Speckle Flowgraphy|Device: Doppler Optical Coherence Tomography","Relative flow volume (LSFG)|Systemic blood pressure|Intraocular pressure","Medical University of Vienna","All","18 Years to 80 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","OPHT-040415","August 2015","January 2016",,"October 21, 2015",,"February 25, 2016","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02582411"
230,"NCT04224298","Preliminary Study on Eye Features of Patients With Malignant Tumors",,"Enrolling by invitation","No Results Available","Human Characteristics",,"Model of white-eye ocular features in patients with malignant tumors","Beijing Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","WEIS","February 1, 2019","June 1, 2021","December 31, 2021","January 13, 2020",,"January 13, 2020","Yichen Dr. Xu, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04224298"
231,"NCT03581097","Educational Video and Peri-operative Anxiety",,"Completed","Has Results","Ambulatory Surgical Procedures|Anxiety Disorders","Other: Video Group","VAS-A Score Anxiety Level (Adapted Visual-Analogue Scale)|Degree of Satisfaction|Vital Parameters 1: Arterial Blood Pressure|Vital Parameters 2: Respiratory Rate|Vital Parameters 3: Heart Rate|First Subgroups Analyze: Anxious Patients|Second Subgroups Analyze: Higher Anxiety Score|Third Subgroup Analyze: First Experience With Surgery.","University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)","Not Applicable","93","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CERU-1801","February 1, 2013","May 30, 2013","June 10, 2018","July 10, 2018","September 13, 2019","September 13, 2019","Andrea Saporito MD, Bellinzona, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03581097/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03581097"
232,"NCT04067973","Impact of Prematurity on the Optic Nerve",,"Not yet recruiting","No Results Available","Ocular Surface Disease|Premature",,"Compare the thickness of the optical fibres measured in OCT RNFL between premature subjects and controls.|Compare the cup/disc ratio|eye length|Intraocular tension|Pachymetry|refractive measurements","Nantes University Hospital","All","5 Years to 10 Years   (Child)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RC19_0026","September 2, 2019","March 2, 2020","September 2, 2020","August 28, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04067973"
233,"NCT02741856","Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation","SCOPE2","Recruiting","No Results Available","Oesophageal Cancer","Drug: Carboplatin|Drug: Paclitaxel|Drug: Cisplatin|Drug: Capecitabine|Radiation: Radiotherapy","Primary endpoint phase II in squamous cell carcinoma comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint phase III in squamous cell carcinoma: Overall survival (OS) comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint in squamous cell carcinoma when switching chemotherapy|Primary endpoint phase in adenocarcinoma phase II comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint in adenocarcinoma when switching chemotherapy|Overall survival|Progression free survival|Quality of Life|Toxicity|Health economics","Lisette Nixon|Cancer Research UK|Velindre NHS Trust","All","17 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014/VCC/0015|2015-001740-11|Ethics Reference Number","November 4, 2016","April 2021","April 2023","April 18, 2016",,"October 25, 2018","Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Bristol Haematology & Oncology, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Kent and Canterbury, Canterbury, United Kingdom|Velindre Cancer Care Centre, Cardiff, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Derby Teaching Hospitals NHS Trust, Derby, United Kingdom|Glan Clwyd Hospital, Glan Clwyd, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|The Clatterbridge Cancer Centre nhs Foundation Trust, Liverpool, United Kingdom|Guy's and St Thomas', London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|North Middlesex Hospital, London, United Kingdom|The Royal Marsden Hospitals (Fulham), London, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom|Sheffield Teaching Hospitals - Weston Park Hospital, Sheffield, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom|The Royal Marsden Hospitals (Sutton, Surrey), Sutton, United Kingdom|Singleton Hospital, Swansea, United Kingdom|Worcestershire Royal Hospital, Worcester, United Kingdom|Wrexham Maelor, Wrexham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02741856"
234,"NCT04359108","Environmental Localization Mapping and Guidance for Visual Prosthesis Users","SLAM","Not yet recruiting","No Results Available","Retinitis Pigmentosa|Visual Impairment|Visual Prosthesis","Device: Navigation System for Users of a Visual Prosthesis","Accuracy as assessed as ratio of target identification success to total trials|Trial Time as assessed by mean time duration to identify target|Success in psychophysical judgments","Johns Hopkins University|Carnegie Mellon University|National Eye Institute (NEI)","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","35","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00228932|1R01EY029741-01A1","July 1, 2020","September 30, 2023","September 30, 2023","April 24, 2020",,"June 23, 2020","Johns Hopkins Medicine - Wilmer Eye Institute, Baltimore, Maryland, United States|Johns Hopkins Applied Physics Laboratory, Laurel, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04359108"
235,"NCT03291509","Remote Delivery of Weight Management for Adults With IDD",,"Recruiting","No Results Available","Obesity","Behavioral: Video Conference Meetings|Behavioral: In-person Meetings|Behavioral: Enhanced Stop Light Diet|Behavioral: Physical Activity","Change in weight|Change in Quality of Life|Cost analysis of study interventions","University of Kansas Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00140653|R01DK114121-01","February 21, 2018","July 2020","December 2021","September 25, 2017",,"March 26, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03291509"
236,"NCT02140164","Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa",,"Completed","Has Results","Retinitis Pigmentosa","Drug: Minocycline","Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment Values.|Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 12 Months Compared to the Average of the Pre-treatment Values|Changes in Amplitude of Photopic and Scotopic Responses on Electroretinogram (ERG) Testing at 6 Months as Compared to the Average of Pre-treatment Values|Changes in Amplitude of Photopic and Scotopic Responses on Electroretinogram (ERG) Testing at 12 Months as Compared to the Average of Pre-treatment Values|Change in Microperimetry at 6 Months as Compared to the Average of Pre-treatment Values|Change in Microperimetry at 12 Months as Compared to the Average of Pre-treatment Values|Change in Visual Field as Measured by HVF 30-2 Visual Field Testing at 6 Months as Compared to the Average of Pre-treatment Values|Change in Visual Field as Measured by HVF 30-2 Visual Field Testing at 12 Months as Compared to the Average of Pre-treatment Values|Number of Study Eyes Achieving a 15-letter or More Worsening in Electronic Visual Acuity (EVA) at 12 Months as Compared to Baseline|Number of Ocular Adverse Events|Number of Non-ocular Adverse Events|Number of Severe Adverse Events","National Eye Institute (NEI)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","7","NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140108|14-EI-0108","May 2014","November 2015","June 2016","May 16, 2014","January 16, 2017","December 5, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02140164"
237,"NCT03908515","Multi-center Clinical Observation of FCVB in Guangdong Province",,"Not yet recruiting","No Results Available","Retina Detachment|Eye Injuries|Eye Atrophy|Silicone Emulsion","Device: Foldable Capsular Vitreous Body (FCVB)","Corneal transverse diameter change|Ocular protrusion change|Visual acuity|Intraocular pressure|Local inflammatory response|Patients satisfaction","Sun Yat-sen University","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","FCVB 2019","May 1, 2019","May 31, 2019","May 31, 2020","April 9, 2019",,"April 16, 2019","Zhongshan Ophthalmic Center of Sun yat-sen Universtiy, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03908515"
238,"NCT03644914","Enhancing Reading Skills in 1st Grade Children",,"Completed","No Results Available","Literacy","Behavioral: 10-week Reading Program","Change in Test of Word Reading Efficiency (TOWRE) Score|Change in Inventory of Reading Occupations (IRO) Score","Columbia University","All","6 Years to 7 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR8813","February 15, 2019","June 21, 2019","June 30, 2019","August 23, 2018",,"July 9, 2019","NYC Elementary Public School (recruitment location), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03644914"
239,"NCT02562469","ACTIVATE: A Computerized Training Program for Children With ADHD",,"Completed","No Results Available","ADHD","Other: ACTIVATE","ADHD symptoms on the Disruptive Behavior Rating Scale","New York University","All","7 Years to 11 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTIVATE","September 2015","August 2017","August 2017","September 29, 2015",,"October 2, 2018","New York University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02562469"
240,"NCT03016156","Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma",,"Active, not recruiting","No Results Available","Retinoblastoma|Cataracts Infantile|Glaucoma, Congenital|Leucocoria","Other: CRADLE|Other: Red reflex testing","Rate of detection of leukocoria using CRADLE|Sensitivity of CRADLE versus ophthalmoscope to detect leukocoria|Specificity of CRADLE versus ophthalmoscope to detect leukocoria","St. Jude Children's Research Hospital","All","up to 7 Years   (Child)","Not Applicable","290","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","RBAPP","March 15, 2018","March 2021","March 2021","January 10, 2017",,"April 15, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03016156"
241,"NCT03727659","CONNECT for Depressed Cannabis Users Trial","CONNECT","Active, not recruiting","No Results Available","Substance Abuse|Depression","Behavioral: SHADE therapy + CONNECT FaceBook support","Change in illicit drug use between study visits and at follow up|Change in depression symptoms and severity between study visits and at follow up|Change in adherence to collateral psychiatric treatment between study visits and at follow up|Change in alcohol use between study visits and at follow up|Change in alcohol, tobacco and other drug use between study visits and at follow up","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONNECT","March 22, 2017","December 1, 2018","December 31, 2018","November 1, 2018",,"November 1, 2018","UCLA Integrated Substance Abuse Programs, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03727659"
242,"NCT01118988","Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents",,"Completed","Has Results","Irritable Bowel Syndrome (IBS)|Functional Abdominal Pain|Fibromyalgia|Complex Regional Pain Syndrome (CRPS)|Myofacial Pain|Chronic Daily Headaches|Migraine Headaches|Chronic Pain","Behavioral: Mentorship","Adherence to Physician Recommended CAM Therapies|Body Map and Pain Assessment|Pittsburgh Sleep Quality Index (PSQI)|Child Symptom Inventory (CSI)|Child Anxiety Sensitivity Inventory (CASI) - Child Report|Health Belief Scale (HBS) Short Version - Child Report|Emotion Regulation Questionnaire (ERQ) - Child Answer|Emotion Expression Scale for Children (EESC)|Functional Disability Inventory (FDI)|Revised Child Anxiety and Depression Scale (RCADS) Child Report|Beck Depression Inventory 2 (BDI-2) #18|Child Health Questionnaire - Child Report (CHQ)|Positive and Negative Affect Scale (PANAS)","University of California, Los Angeles","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R21HD057421-01A2","December 2009","June 2011","June 2011","May 7, 2010","March 9, 2016","September 30, 2016","UCLA Pediatric Pain Management Clinic, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01118988"
243,"NCT03188042","A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma",,"Recruiting","No Results Available","Glaucoma","Device: rtACS Stimulation|Device: Sham Intervention","Change in Optical coherence tomography (OCT)|Change in OCT angiography|Change in Magnetic resonance imaging (MRI)|Change in Visual acuity|Change in Contrast sensitivity|Change in Score on Assessment of Life Habits (LIFE-H), short form 3.1|Change in score on National Eye Institute Visual Functioning Questionnaire (VFQ-39)|Change in score on 36-Item Short Form Survey (SF-36)","NYU Langone Health","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-02005","December 14, 2017","March 2022","March 2022","June 15, 2017",,"May 8, 2020","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03188042"
244,"NCT02768896","Monitoring Brain Waves in Response to Visual and/or Auditory Stimulation in Parkinson's Disease Patients",,"Unknown status","No Results Available","Parkinson's Disease","Behavioral: Baseline|Behavioral: visual stimuli|Behavioral: Auditory stimuli|Behavioral: Visual and auditory stimuli","Voltage fluctuation resulting from brain activity after visual stimuli|Voltage fluctuation resulting from brain activity after auditory stimuli|Voltage fluctuation resulting from brain activity after visual and auditory stimuli","Rambam Health Care Campus|Technion, Israel Institute of Technology","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","0182-16RMB","June 2016","January 2018","February 2018","May 11, 2016",,"June 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02768896"
245,"NCT01163760","Clinical Evaluation of Two Daily Disposable Contact Lenses",,"Completed","Has Results","Refractive Error","Device: etafilcon A|Device: ocufilcon D","Lens Comfort|Comfort Throughout the Whole Day","Johnson & Johnson Vision Care, Inc.|Singapore Polytechnic University|Visioncare Research Ltd.","All","21 Years to 39 Years   (Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-0706|PRO-518","September 2007","September 2007","September 2007","July 16, 2010","July 16, 2010","June 19, 2018","Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01163760"
246,"NCT02621671","Communicating Multiple Disease Risks",,"Completed","No Results Available","Healthy","Behavioral: Cognitive interview|Other: Survey","Test eight images/visual displays that communicate risk estimates of five diseases associated with physical activity as measured by participants understanding of the images/visual displays|Most effective combination of strategies in communicating multiple disease risk estimates (Arm 2 only)|Time that it takes to complete the survey that accompanies the images (Arm 1 only)","Washington University School of Medicine","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","1191","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201501028","April 1, 2015","June 27, 2017","June 27, 2017","December 3, 2015",,"November 6, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02621671"
247,"NCT00904982","Randomized Trial of Interventions to Improve Warfarin Adherence","WIN3","Completed","Has Results","Atrial Fibrillation|Deep Vein Thrombosis|Dilated Cardiomyopathies","Behavioral: Financial Incentive and Med-eMonitor|Device: 2Med-eMonitor","Improved Warfarin Adherence/% Timeout of Target INR Range","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","809166","October 2009","May 2012","December 2013","May 20, 2009","March 16, 2017","March 16, 2017","Hospital of the University of Pennsylvania Anticoagulation Management Center, Philadelphia, Pennsylvania, United States|Philadelphia Veteran Affairs Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00904982"
248,"NCT04307108","Magic Glass Evaluation in People With Stroke",,"Recruiting","No Results Available","Stroke","Device: Magic Glass","the usability of the intervention;|the usability of the intervention|the acceptability of the intervention|the process requirements for the new care pathway;|the resource requirements for the new care pathway;|the intensity in Rehabilitation Therapy|the duration in Rehabilitation Therapy|Functional independence in the activities of daily living with respect to the modified Rankin Scale|Functional independence in the activities of daily living with respect to the Barthel Index|physical activity as measured by range of motion|cognitive function|Stroke specific quality of life|potential cost effectiveness of the solution","University of Ulster|Western Health and Social Care Trust|Southern Health and Social Care Trust|Tech 4 Care|miThings AB","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18/NI/0080","November 11, 2018","March 30, 2020","June 10, 2020","March 13, 2020",,"March 13, 2020","Neuro-rehabilitation Department of the University Hospital of Ancona., Ancona, Italy|Western Health and Social Care Trust, Derry, United Kingdom|Southern Health and Social Care Trust, Lurgan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04307108"
249,"NCT01153789","Study of Oculomotor Dysfunction Leading to Children Vertigo","VERVE","Completed","No Results Available","Vertigo|Headache|Anomaly of Vergence System|Accommodation Disorders|Orthoptic Rehabilitation","Procedure: orthoptic rehabilitation|Other: Orthoptic diagnostic","oculomotor complete evaluation (static and dynamic and accommodation), posturography test and a visual dynamic acuity test|free of symptoms","Assistance Publique - Hôpitaux de Paris|Centre National de la Recherche Scientifique, France","All","6 Years to 17 Years   (Child)","Not Applicable","183","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P081114","September 2010","February 2014","August 2014","June 30, 2010",,"December 4, 2014","ORL Service - Robert Debre Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT01153789"
250,"NCT01213004","Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers",,"Completed","No Results Available","Gastric Cancer|Lung Cancer","Procedure: respiration correlated CT scan","To determine whether motion-corrected cone-beam CT (CBCT) improves the localization accuracy|To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.|To determine whether motion-corrected cone-beam CT (CBCT) derived from a respiration correlated CT (RCCT) scan on the same day improves localization accuracy|To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT)","Memorial Sloan Kettering Cancer Center|University of North Carolina, Chapel Hill|Varian Medical Systems","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-146","September 2010","February 2018","February 2018","October 1, 2010",,"February 6, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01213004"
251,"NCT03491436","Pregnancy Remote Monitoring of Women at Risk for Gestational Diabetes",,"Withdrawn","No Results Available","Pregnancy Diabetic","Device: iHealth Align","Blood glucose sober|Weight once a day|blood glucose 2 hours after meal 1|blood glucose 2 hours after meal 2|blood glucose 2 hours after meal 3","Hasselt University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRM-001","May 1, 2017","December 31, 2017","December 31, 2017","April 9, 2018",,"April 9, 2018","Ziekenhuis Oost-Limburg, Genk, Belgium",,"https://ClinicalTrials.gov/show/NCT03491436"
252,"NCT00088712","Event Related Potentials in Infants and Adults",,"Completed","No Results Available","Healthy|Child Development",,"EEG response","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Months to 45 Years   (Child, Adult)",,"440","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","040250|04-CH-0250","July 28, 2004",,"August 26, 2019","August 2, 2004",,"September 10, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00088712"
253,"NCT03493958","RCT of Web-Based Behavioral Sleep Intervention for Individuals With Alcohol Use Disorder",,"Enrolling by invitation","No Results Available","Alcohol Dependence","Other: SHUTi Control|Behavioral: SHUTi","Phase II: Primary outcome measures include changes in insomnia severity over time and changes in actigraphy- recorded sleep efficiency over time.|Phase I: Assess the feasibility and acceptability of Internet-based CBT-I among individuals with AUD in recovery|TLFB and PACS|sleep disturbance, daytime sleepiness, anxiety/depression, fatigue, selfefficacy for sleep, dysfunctional beliefs about sleep, and functional outcomes|Actigraphy-generated measures","National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","17","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180079|18-CC-0079","March 5, 2019","December 31, 2021","December 31, 2021","April 11, 2018",,"May 4, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03493958"
254,"NCT01765972","Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear",,"Completed","Has Results","Corneal Swelling","Device: etafilcon A with Lacreon|Device: etafilcon A with Lacreon with print|Device: etafilcon A with print|Device: Spectacles (habitual)","Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit","Johnson & Johnson Vision Care, Inc.","All","18 Years to 45 Years   (Adult)","Not Applicable","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5252","December 2012","May 2013","May 2013","January 11, 2013","July 20, 2016","June 19, 2018","Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01765972"
255,"NCT02139722","Patient-Centered Care and Asian Americans",,"Completed","No Results Available","Hepatitis B|Hepatitis C|Liver Disease","Behavioral: Video Doctor, PA + PPN","EHR-documented hepatitis B surface antigen (HBsAg) test|Knowledge about hepatitis B virus (HBV) and hepatitis C virus (HCV)","University of California, San Francisco|San Francisco General Hospital|San Francisco Hep B Free Campaign","All","18 Years and older   (Adult, Older Adult)","Not Applicable","431","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening","AD-11-4615","January 2, 2014","May 28, 2017","July 30, 2017","May 15, 2014",,"October 26, 2017","San Francisco General Hospital, San Francisco, California, United States|UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02139722"
256,"NCT02759692","Clinical Evaluation of Two Approved Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: TEST Contact Lens|Device: CONTROL Contact Lens","Overall Comfort|Overall Quality of Vision|Individual Patient Reported Outcomes (Items 1-5)|Individual Patient Reported Outcomes (Items 6-10)|Individual Patient Reported Outcomes (Items 11-14)|Individual Patient Reported Outcomes (Items 15-17)","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","283","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5829","April 1, 2016","June 1, 2016","June 1, 2016","May 3, 2016","August 18, 2017","August 18, 2017","Becky Bizzle, OD, Montgomery, Alabama, United States|Complete Family Eye Care of Fruit Cove, Jacksonville, Florida, United States|Golden Family Eyecare, Sarasota, Florida, United States|St. Lucy's Vision Center, Tampa, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|VisualEyes, Inc., Roswell, Georgia, United States|Advantage Eyecare Associates, LLC, Neodesha, Kansas, United States|Sacco Eye Group, Vestal, New York, United States|Advanced Family Eye Care, Denver, North Carolina, United States|Total Eye Care PA, Memphis, Tennessee, United States|Brian Frazier, OD, Jacksonville, Texas, United States|Timothy R. Poling, OD, Salem, Virginia, United States|Ziegler Leffingwell Eyecare, West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02759692"
257,"NCT01922934","A Toolbox Approach to Obesity Treatment in Primary Care","Toolbox","Completed","Has Results","Obesity","Behavioral: Commercial weight loss program|Behavioral: Colorado Weigh|Dietary Supplement: Meal replacements|Drug: Obesity pharmacotherapy|Behavioral: Recreation center passes","Percentage of Participants Who Achieved >5% Weight Loss at 12 Months|Health Care Utilization - Non-study Clinic Visits|Health Care Utilization - Laboratory Measurements|Documentation of Obesity","Denver Health and Hospital Authority","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","4730","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GM3469","January 2014","August 2016","August 2016","August 14, 2013","August 18, 2017","August 18, 2017","Denver Health and Hospital Authority, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01922934"
258,"NCT02338973","Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)",,"Terminated","Has Results","Inherited Ophthalmic Diseases|Inherited Retinal Degeneration","Drug: Interferon gamma-1b","Number and Severity of IP-related AEs|Number of Participants Who Withdrew|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 1|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 2|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Day 3|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 2|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 5|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 8|Change in Best Corrected Visual Acuity (BCVA) From Baseline as Compared to Week 52|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 1|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 2|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Day 3|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 2|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 5|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 8|Change in Maximum Subretinal Fluid Volume From Baseline as Compared to Week 52|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 1|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 2|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Day 3|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 2|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 5|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 8|Change in Central Retinal Thickness as Measured on Cirrus OCT From Baseline as Compared to Week 52|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 1|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 2|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Day 3|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 2|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 5|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 8|Change in Central Retinal Thickness as Measured on Spectralis OCT From Baseline as Compared to Week 52|Change in Central Visual Field Sensitivity at Day 2 and Week 5 Compared to Baseline.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","4","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150052|15-EI-0052","January 14, 2015","June 1, 2018","July 26, 2018","January 15, 2015","August 6, 2019","August 13, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02338973/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02338973"
259,"NCT02415764","OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant",,"Completed","No Results Available","Psychosis|Schizoaffective Disorder|Schizophrenia","Behavioral: Behavioral/Attitudinal OnTrack Role-Playing Game","Changes in attitudes toward recovery|Sense of stigma and empowerment|Increased engagement in treatment|Attitudes toward the game","Center for Social Innovation, Massachusetts|Research Foundation for Mental Hygiene, Inc.","All","18 Years to 30 Years   (Adult)","Phase 1","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1R43MH105013-01","June 2015","March 2016","March 2016","April 14, 2015",,"July 27, 2016","Center for Social Innovation, Needham, Massachusetts, United States|New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02415764"
260,"NCT02479516","Community Health Assessment Program in the Philippines","CHAP-P","Unknown status","No Results Available","Diabetes","Behavioral: Community Health Assessment Program Philippines (CHAP-P)","Elevated HBA1c|Blood Pressure","McMaster University|Ateneo de Zamboanga University","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","APP242122","November 2015","October 2017","October 2017","June 24, 2015",,"June 24, 2015",,,"https://ClinicalTrials.gov/show/NCT02479516"
261,"NCT03397498","Computerized Cognitive Intervention in the Oldest-Old",,"Completed","No Results Available","Cognition|Dementia","Behavioral: CogniFit™|Behavioral: Control-games","Change in Global Cognition Composite|Change in Memory Function|Change in Logical Memory Story A|Change in Attention/Executive function score|Change in Language function score","Icahn School of Medicine at Mount Sinai","All","80 Years and older   (Older Adult)","Not Applicable","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","GCO 09-2339","March 10, 2011","December 16, 2014","December 16, 2014","January 12, 2018",,"January 12, 2018","Jewish Home Lifecare, New York, New York, United States|Icahn School of Medicine at Mount Sinia, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03397498"
262,"NCT01483937","Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium","SEMD","Completed","Has Results","Vestibular Diseases|Labyrinth Diseases|Ear Diseases|Otorhinolaryngologic Diseases|Traumatic Brain Injury","Device: Usual care physical therapy plus SEMD|Other: Usual care physical therapy only","Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Pre Test to Post Test 1 Sensory Organization Test (SOT).|Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Post Test 1 to Post Test 2 Sensory Organization Test (SOT).|Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Post Test 2 to Post Test 3 Sensory Organization Test (SOT).|Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change From Post Test 3 to Post Test 4 Sensory Organization Test (SOT).|Percent of Subjects Decreasing Fall Risk Measured by Functional Gait Assessment Pre Test to Post Test 2|Percent of Subjects Reporting Decrease in Self-report Fall(s) Occurrence Pre Test to Post Test 1|Percent of Subjects Decreasing Fall Risk Measured by Berg Balance Scale Pre Test to Post Test 2|Self-rated Disability Measured by Vestibular Rehabilitation Benefit Questionnaire Pre Test to Post Test 4|Head Shake Sensory Organization Test (HS_SOT)","Karen L Atkins|BalanceSense LLC","All","21 Years to 84 Years   (Adult, Older Adult)","Not Applicable","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10-221:1.2|W81XWH-10-C-0184-01","November 2011","May 2013","August 2013","December 2, 2011","June 27, 2014","June 27, 2014","England Physical Therapy, Garden Grove, California, United States|Florida Ear & Balance Center, Celebration, Florida, United States|Stevenson & Associates Physical Therapy, Fort Myers, Florida, United States|Brooks Balance Center, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01483937"
263,"NCT03901495","DD Assessment With Diaana #2","DiaanaRCT#2","Recruiting","No Results Available","Decision Making|Computer-assisted|General Practitioners|Patient Engagement","Other: Diaana","Differential diagnosis established by the resident physician|Consultation time|Patient satisfaction|Differential diagnosis estabished by Diaana","Adrien Schwitzguebel|University Hospital, Geneva","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UNIGE_Diaana","February 28, 2019","May 31, 2019","October 31, 2019","April 3, 2019",,"April 11, 2019","Geneva University Hospital, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT03901495"
264,"NCT03939650","Diagnosis Assessment With Diaana #3",,"Recruiting","No Results Available","Decision Making|Computer-assisted|General Practitioners|Patient Engagement","Device: Diaana","Accuracy of the diagnosis established by the resident physician|Consultation time|Patient satisfaction: Likert 1-4 scale|Differential diagnosis established by Diaana","Adrien Schwitzguebel|Hôpital de la Providence, Switzerland","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COLLINE_Diaana","January 31, 2020","January 31, 2020","January 31, 2020","May 7, 2019",,"October 29, 2019","La Colline Hospital Outpatient Unit, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT03939650"
265,"NCT04317417","MOST EMPOWER: Optimizing An Emotion Regulation Intervention","MOST EMPOWER","Not yet recruiting","No Results Available","Cancer","Behavioral: EMPOWER","Patient-Reported Outcomes Measurement Information System (PROMIS) Positive Affect Computer Adaptive Test (CAT) Questionnaire|Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Questionnaire|Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Questionnaire|Patient-Reported Outcomes Measurement Information System (PROMIS) Life Satisfaction Questionnaire","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 39 Years   (Adult)","Not Applicable","352","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00057993|WFBCCC 04220|R01CA242849-01","July 2020","July 2023","July 2023","March 23, 2020",,"June 16, 2020","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04317417"
266,"NCT02082743","Vision Care Intervention for Lower Grade School Children in Taiwan",,"Completed","No Results Available","Myopia|Outdoor Activity|Policy of Recess Outside Classroom","Behavioral: Outdoor activity in recess time","Cycloplegic refraction|Axial length","Chang Gung Memorial Hospital|Ministry of Health and Welfare, Taiwan","All","6 Years to 7 Years   (Child)","Not Applicable","1020","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C1020515|HPA-MHW-C1020515","October 2013","February 2015","February 2015","March 10, 2014",,"August 7, 2015","Department of Ophthamology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung university College of Medicine, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02082743"
267,"NCT01948674","Cognitive Stimulation in Adolescents",,"Completed","No Results Available","Substance Use Disorders","Behavioral: Computerized tasks","working memory (change from baseline)|timeline follow back (change from baseline)|delay discounting (change from baseline)|Stroop (change from baseline)|reading comprehension (change from baseline)|emotion regulation (change from baseline)|Go-No Go (change from baseline)|Global Appraisal of Individual Needs (change from baseline)","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","All","14 Years to 21 Years   (Child, Adult)","Phase 2","87","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NA_00080023|R21DA034942","October 2013","August 2015","August 2015","September 23, 2013",,"August 24, 2016","Mountain Manor Treatment Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01948674"
268,"NCT01641432","Computerized Attention Training for Individuals With Acquired Brain Injury",,"Completed","No Results Available","Acquired Brain Injury|Stroke|Hemispatial Neglect","Behavioral: Tonic and Phasic Attention Training|Behavioral: Active Comparator","Attention and Memory","Posit Science Corporation","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)","BPI-1002-2011","July 2011","July 2013",,"July 16, 2012",,"July 22, 2014","Brain Plasticity Institute, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01641432"
269,"NCT03994341","NEC Thermography Infrared Imaging Study",,"Recruiting","No Results Available","Necrotizing Enterocolitis","Diagnostic Test: A FLIR Thermovision a320M thermal IR camera","Region of interest inclusion|Accurate classification of heat distribution maps as NEC versus Normal","Ottawa Hospital Research Institute|Carleton Unniversity","All","26 Weeks to 42 Weeks   (Child)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NEC-01","August 13, 2019","June 1, 2021","June 1, 2022","June 21, 2019",,"September 6, 2019","Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03994341"
270,"NCT00685854","Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth",,"Completed","No Results Available","Macular Telangiectasia","Drug: Ranibizumab","Effect of intravitreal ranibizumab treatment on visual acuity|ETDRS BCVA, area of retinal leakage, retinal thickness, area of hypofluoresence, central retinal sensitivity","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080147|08-EI-0147","May 21, 2008","March 24, 2011","March 24, 2011","May 28, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00685854"
271,"NCT00685503","Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth",,"Completed","No Results Available","Neovascularization","Drug: Ranibizumab","Effect of intravitreal ranibizumab treatment on visual acuity.|ETDRS BCVA, area of retinal leakage, retinal thickness, area of hypofluoresence, central retinal sensitivity.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080146|08-EI-0146","May 21, 2008","April 12, 2011","April 12, 2011","May 28, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00685503"
272,"NCT00006411","Cornea Donor Study","CDS","Completed","Has Results","Corneal Disease|Fuch's Dystrophy|Pseudophakic Corneal Edema","Other: corneas assigned by donor age group","Graft Failure|Endothelial Cell Density (ECD)","National Eye Institute (NEI)|Eye Bank Association of America|Bausch & Lomb Incorporated|Tissue Banks International|Vision Share, Inc.|San Diego Eye Bank|The Cornea Society|Katena Products, Inc.|ViroMed Laboratories, Inc.|Midwest Eye Banks|Konan Medical, Inc.|Eye Bank for Sight Restoration|SightLife|Sight Society of Northeastern New York (Lions Eye Bank of Albany)|Lions Eye Bank of Oregon","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1090","NIH|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","NEI-80|5U10EY012358|3U10EY012358-11S1|5U10EY012728","January 10, 2000","December 31, 2012","July 2014","October 16, 2000","February 25, 2020","February 25, 2020","Jaeb Center for Health Research, Inc., Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00006411"
273,"NCT02368236","Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS)",,"Completed","No Results Available","Colorectal Neoplasms|Colonic Neoplasms","Behavioral: Tailored Printout","Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).|Participation in any type of colorectal cancer testing.|Testing difference in receipt of any type of colorectal cancer testing.","University of Texas Southwestern Medical Center|National Cancer Institute (NCI)","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","1012","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Screening","112010-132|R01CA122330","December 2008","February 2012","November 2012","February 23, 2015",,"July 30, 2018",,,"https://ClinicalTrials.gov/show/NCT02368236"
274,"NCT03561922","Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS",,"Terminated","No Results Available","Retinal Degeneration|Inherited Retinal Dystrophy Primarily Involving Sensory Retina","Device: RETINA IMPLANT Alpha AMS","Change in functional vision|Vision Related Quality of Life - Questionnaire|Visual Function - Questionnaire|Adverse Events|Measure of implant-mediated visual function","Retina Implant AG","All","18 Years to 78 Years   (Adult, Older Adult)","Not Applicable","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RI-FI-2017","September 4, 2018","April 5, 2019","April 5, 2019","June 19, 2018",,"April 19, 2019","Clinique Saint Jean, Montpellier, Hérault, France|Centre Hospitalier Universitaire La Milétrie de Poitiers, Poitiers, Vienne, France",,"https://ClinicalTrials.gov/show/NCT03561922"
275,"NCT01296945","Nutrition Knowledge for Spanish-speaking Parents",,"Completed","No Results Available","Obesity|Dental Caries","Other: Kiosk|Other: paper|Other: Kiosk PLUS paper|Other: Kiosk PLUS web","Knowledge score|knowledge score","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research","NA_00045360","February 2011","September 2011","September 2011","February 16, 2011",,"March 30, 2012","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01296945"
276,"NCT02966132","Interactive Mobile Doctor (iMD) for Asian Smokers","iMD","Completed","No Results Available","Smoking Cessation","Behavioral: iMD|Behavioral: NPA","abstinence|quite attempt|patient-provider discussion|EHR documented 5As","University of California, San Francisco|Asian Health Services","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRDRP 24AT-1301|24AT-1300","November 2016","June 2019","September 2019","November 17, 2016",,"May 5, 2020","Asian Health Services, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT02966132"
277,"NCT00422071","Detecting a Reward Signal in the Motor Cortex",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)",,"168","NIH","Observational",,"070063|07-N-0063","January 8, 2007",,"March 6, 2014","January 15, 2007",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00422071"
278,"NCT03617276","Reliability of Functional Outcome Measures in Neurofibromatosis 2",,"Completed","No Results Available","Neurofibromatosis 2",,"Modified nine hole peg test|Four square step test|Modified Clinical Test of Sensory Integration and Balance|Dynamic Visual Acuity test|The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2","Guy's and St Thomas' NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16/NW/0504","September 7, 2016","May 17, 2017","May 17, 2017","August 6, 2018",,"August 6, 2018","Neurofibromatosis Unit, Guys Hospital., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03617276"
279,"NCT02044484","HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission","APTcare","Unknown status","No Results Available","HIV","Behavioral: Multi-component intervention","Percentage of patients with suppressed HIV (≤ 200 copies/mL)|Percentage of patients without a gap in HIV primary care (without a gap > 6 months)|Change across time in log10 viral load values|HIV primary care appointment adherence","Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2794","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHHSTP-2468|CDC","January 2014","June 2015","October 2016","January 24, 2014",,"February 12, 2015","1917 Clinic, Brimingham, Alabama, United States|Owen Clinic, San Diego, California, United States|Jackson Memorial Hospital, Miami, Florida, United States|Boston Medical Center, Boston, Massachusetts, United States|Thomas Street Health Center, Houston, Texas, United States|Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02044484"
280,"NCT04213066","Stochastic Resonance Applied to Amblyopia Training and the Plasticity of Brain",,"Completed","No Results Available","Amblyopia|Amblyopia, Anisometropic","Device: Portable tablet","Visual acuity (VA)|Grating acuity (GA)|Contrast sensitivity (CS)|Visual evoked potential (VEP)|Total practice duration","National Cheng-Kung University Hospital|Chang Gung Memorial Hospital","All","4 Years to 8 Years   (Child)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A-BR-102-050-t","July 15, 2013","January 31, 2016","January 31, 2016","December 30, 2019",,"December 30, 2019",,,"https://ClinicalTrials.gov/show/NCT04213066"
281,"NCT01538615","Healthy Home Offerings Via the Mealtime Environment (HOME) Plus",,"Completed","Has Results","Obesity","Behavioral: HOME Plus intervention","Change in Child Body Mass Index (BMI Z-score)|Change in Target Children's Daily Intakes of Fruits and Vegetables|Change in Target Children's Hours of Screen Time (Television Viewing, Video and Computer Game Playing) Per Week|Change in Number of Fruits and Vegetables Available in the Home","University of Minnesota|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","8 Years and older   (Child, Adult, Older Adult)","Not Applicable","413","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20521|R01DK084000-01A2","July 2010","July 2015","June 2016","February 24, 2012","March 1, 2018","March 1, 2018","University of Minnesota, School of Nursing, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01538615"
282,"NCT03699644","Multimodal Ocular Imaging in Neurodegeneration",,"Suspended","No Results Available","Alzheimer Disease|Alzheimer Dementia|Frontotemporal Dementia","Device: Spectral-Domain Optical Coherence Tomography (SD-OCT)|Device: Magnetic Resonance Imaging (MRI)|Device: Positron Emission Tomography (PET)|Diagnostic Test: Comprehensive Ophthalmic Examination|Device: Fundus Photography","Presence of Retinal Thinning|Presence of Amyloid Plaque|Presence of Brain Pathology|Presence of Brain Metabolism|Presence of Macular Vascular Anomalies","University of Michigan","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00146956","January 4, 2019","December 2020","December 2020","October 9, 2018",,"May 27, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03699644"
283,"NCT02209116","Assessing QbTest Utility in ADHD: A Randomised Controlled Trial","AQUA2","Completed","No Results Available","Attention Deficit Hyperactivity Disorder (ADHD)","Other: Qb Test","Number of clinic appointments until correct diagnosis confirmed|Time to confirmation or exclusion of ADHD diagnosis (in days) and duration of clinic visits (in minutes).","University of Nottingham|National Institute for Health Research, United Kingdom","All","6 Years to 17 Years   (Child)","Not Applicable","267","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","CLAHRC-EM 14046","July 2014","June 2016","June 2016","August 5, 2014",,"June 22, 2016","Central Manchester University Hospitals NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Medway NHS Foundation Trust, Gillingham, Kent, United Kingdom|Bridgewater Community Healthcare NHS Trust, Wigan, Lancashire, United Kingdom|Leicestershire Partnership Nhs Trust, Leicester, Leicestershire, United Kingdom|United Lincolnshire Hospitals NHS Trust, Lincoln, Lincolnshire, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|Nottinghamshire Healthcare Nhs Trust, Nottingham, Nottinghamshire, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, Nottinghamshire, United Kingdom|Sussex Partnership NHS Foundation Trust, Worthing, Sussex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02209116"
284,"NCT03692624","Use of Heart Rate Variability (HRV) Biofeedback for Cancer Survivors",,"Completed","No Results Available","Cancer","Behavioral: Biofeedback","Reduced Pain|Reduced Stress|Reduced Fatigue|Reduced Depression|Reduced Insomnia","Prisma Health-Upstate|University of South Carolina","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00042898","May 10, 2015","April 19, 2017","February 7, 2020","October 2, 2018",,"March 6, 2020","Greenville Health System Cancer Institute, Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03692624"
285,"NCT00808496","The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis","MRx","Unknown status","No Results Available","Inflammatory Arthritis","Other: MRI|Other: Radiography|Other: Standard of Care","The frequency of antirheumatic treatment escalations.|Change in van der Heijde-modified Sharp score of the hands and feet.|Change in 28-joint disease activity score (DAS28)|Change in health assessment questionnaire (HAQ) score|Change in Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS)|Change in health utility index - mark 3 (HUI-III)|Change in EQ-5D|Number of smallest detectable changes|Change in the proportion of participants with radiography-determined erosions of the hands, wrists, or feet|Change in the number of radiography-determined erosions of the hands, wrists or feet","McMaster University","All","18 Years and older   (Adult, Older Adult)","Phase 4","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","200901","June 2009","October 2012","April 2013","December 15, 2008",,"October 7, 2011","McMaster University, Division of Rheumatology, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00808496"
286,"NCT03623984","Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers",,"Recruiting","No Results Available","Neuroendocrine Carcinoma of Pancreas|Carcinoid","Drug: Gallium Dotatate","Comparison of intraoperative findings to preoperative PET scan findings|Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement","University of Alabama at Birmingham","All","19 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001980","June 7, 2019","June 7, 2020","June 7, 2021","August 9, 2018",,"October 10, 2019","UAB Kirklin Clinic, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03623984"
287,"NCT00582530","Men Undergoing Radical Prostatectomy",,"Active, not recruiting","No Results Available","Prostate Cancer","Other: Whole Blood Draw","To determine if men with pathologically latent prostate cancer have a different preoperative proteomic profile than men with a pathologically significant cancer.|To determine the effect of radical prostatectomy on the proteomic profile in blood samples from men with a pathologically latent cancer. This should suggest the contribution of 'benign'prostate to the small peptide proteomic profile in blood.|To determine the effect of radical prostatectomy on the protein profile in blood samples from men with pathologically significant cancer. This should (in combination with 2) suggest the contribution of prostate cancer to the proteome in blood samples.|Determine if pre-tx small peptide proteomic profile in blood collected prior to rad. prostatectomy can ident men at increased risk for recurrence, compared to only using the postop nomogram to assess risk of biochem recur after radical prostatectomy|Determine the impact of sample type on proteomic results, will obtain both coagulated & anti-coagulated samples & perform these studies in parallel to examine which collect method might prove the optimal source for improving our predictive models.","Memorial Sloan Kettering Cancer Center","Male","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","04-132","December 2004","December 2021","December 2021","December 28, 2007",,"June 9, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00582530"
288,"NCT03289793","NEUROFEEDBACK on Event-Related Potential (ERP)","MyB","Completed","No Results Available","Attention Deficit Disorder With Hyperactivity","Other: Neurofeedback training|Other: Active Sham control|Other: Baseline control group","Evaluation of the relative effect on symptoms of inattention between the two proposed training techniques, A and B, with the ADHD Rating Scale in children with ADHD|Neuropsychological assessments of effects of training on the symptoms of inattention in ADHD children|Neuropsychological assessments of the effects of the lack of training on the symptoms of inattention in ADHD children|Compare the effects of the two types of trainings on the hyperactivity symptoms in ADHD children using neuropsychological assessments.|neuropsychological assessments of the effects of the two types of trainings on the hyperactivity symptoms in ADHD children|neuropsychological assessments of the effects of the lack of training on the impulsivity symptoms in ADHD children|neuropsychological assessments of the effects of the lack of training on the hyperactivity symptoms in ADHD children|Quantify whether the changes in inattentive symptoms in groups A (Neurofeedback training) correlate with changes in specific EEG parameter, namely the P300 wave.|Quantify whether the changes in inattentive symptoms in groups B (Neurofeedback training) correlate with changes in specific EEG parameter, namely the P300 wave.|Quantify whether the changes in inattentive symptoms in groups C (Neurofeedback training) correlate with changes in specific EEG parameter, namely the P300 wave.|Quantify the evolution of the classical Neurofeedback biomarkers Slow Cortical Potential (SCP))|Assess whether the classical Neurofeedback biomarkers correlate with the evolution of behavioral and primary neurophysiological measures (P300) in all groups.|Quantify the evolution of the classical Neurofeedback biomarkers Theta/Beta Ratio (TBR)|Assess whether the classical Neurofeedback biomarkers TBR correlate with the evolution of behavioral and primary neurophysiological measures (P300) in all groups.|Quantify the evolution of the classical Neurofeedback biomarkers Sensori-Moteur Rythm (SMR)|Assess whether the Neurofeedback biomarkers SMR correlate with the evolution of behavioral and primary neurophysiological measures (P300) in all groups.|Evaluate the impact of the trainings on the sleep quality in ADHD children.|Evaluating the impact of the trainings on the quality of life in ADHD children.","Hospices Civils de Lyon","All","8 Years to 17 Years   (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research","69HCL15_0214","February 2, 2017","September 9, 2019","September 9, 2019","September 21, 2017",,"October 29, 2019","Hospices Civils de Lyon, Bron, France",,"https://ClinicalTrials.gov/show/NCT03289793"
289,"NCT00076596","Brain Control of Movements in Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","6 Years to 30 Years   (Child, Adult)",,"130","NIH","Observational",,"040098|04-N-0098","January 23, 2004",,"December 10, 2007","January 27, 2004",,"July 2, 2017","Childrens National Medical Center, Washington, D.C., District of Columbia, United States|Georgetown University Medical Center, Washington, D.C., District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00076596"
290,"NCT00417040","Collection of Patient-Reported Symptoms and Performance Status Via the Internet",,"Completed","No Results Available","Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer|Leukemia|Multiple Myeloma","Other: internet-based intervention|Other: assessment of therapy complications|Other: Questionnaire Administration","Willingness of approached patients to participate in this study this study|Proportion of enrolled patients who submit an online questionnaire at any given follow-up visit any given follow-up visit|Proportion of total attended visits during the study period at which a questionnaire was completed (completers:visits) which a questionnaire was completed (completers:visits)|Patient-reported CTCAE symptoms using symptom severity data|Clinician-reported CTCAE symptoms using symptom severity data clinician reporting at day 43 (when patients report before clinicians; clinicians view those reports) vs at day 22 (patients report symptoms after the clinical encounter)|Mean severity scores for patient reporting at day 43","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","325","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CALGB-70501|CDR0000521898|NCI-2009-00489|UG1CA189823|U10CA037447","December 2006","March 2013","June 1, 2017","December 28, 2006",,"June 27, 2017","East Bay Radiation Oncology Center, Castro Valley, California, United States|Valley Medical Oncology Consultants - Castro Valley, Castro Valley, California, United States|Valley Medical Oncology, Fremont, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|El Camino Hospital Cancer Center, Mountain View, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Breast Surgeons, Incorporated, Oakland, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Larry G Strieff MD Medical Corporation, Oakland, California, United States|Tom K Lee, Incorporated, Oakland, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Doctors Medical Center - San Pablo Campus, San Pablo, California, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|La Grange Memorial Hospital, La Grange, Illinois, United States|Center for Cancer Care at OSF Saint Anthony Medical Center, Rockford, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Veterans Affairs Medical Center - Iowa City, Iowa City, Iowa, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's Hospital - South, Overland Park, Kansas, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Michiana Hematology Oncology PC - Niles, Niles, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|St. Joseph Medical Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Parvin Radiation Oncology, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|Comprehensive Cancer Care, PC, Saint Louis, Missouri, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Lakes Region General Hospital, Laconia, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center at Catholic Medical Center, Manchester, New Hampshire, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|CCOP - Hematology-Oncology Associates of Central New York, East Syracuse, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|Monter Cancer Center of the North Shore-LIJ Health System, Lake Success, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center, Pinehurst, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States|Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|Bon Secours St. Francis Health System, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Self Regional Cancer Center at Self Regional Medical Center, Greenwood, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Mountainview Medical, Berlin Corners, Vermont, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00417040"
291,"NCT03759756","Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma",,"Completed","No Results Available","Artificial Intelligence|Optical Enhancement Endoscopy|Magnifying Endoscopy","Other: AI presentation|Other: no AI presentation","the diagnosis efficiency of the AI model","Shandong University","All","18 Years and older   (Adult, Older Adult)",,"119","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","2018SDU-QILU-2","December 1, 2018","March 1, 2020","April 1, 2020","November 30, 2018",,"April 28, 2020","Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03759756"
292,"NCT03430570","An Emotion Regulation Intervention for Early Adolescent Risk Prevention",,"Completed","No Results Available","Risk Behavior|Risk Reduction|Emotion Regulation","Behavioral: Tablet TRAC Emotion Regulation Intervention","Emotion Regulation/Difficulties in Emotion Regulation Scale|Emotion Recognition/DANVA|Emotion Regulation/Emotion Regulation Checklist|Emotion Regulation/ The Regulation of Emotions Questionnaire|Emotion Regulation/Self Efficacy Questionnaire for Children|Emotion Regulation/Emotion Regulation Behavior Scale|Emotion Regulation/Affect Dysregulation Scale|Assessment Risk Behavior/Youth Risk Behavior Surveillance System|Distress Tolerance","Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 14 Years   (Child)","Not Applicable","85","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R21HD089979","February 19, 2019","October 31, 2019","October 31, 2019","February 13, 2018",,"December 6, 2019","Rhode Island Hospital- Bradley Hasbro Children's Research Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT03430570"
293,"NCT00076271","Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases",,"Completed","No Results Available","Eye Diseases",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"350","NIH","Observational",,"040039|04-EI-0039","January 14, 2004",,"October 28, 2008","January 19, 2004",,"July 2, 2017","Rocky Mountain Lions Eye Institute, Denver, Colorado, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00076271"
294,"NCT03764969","Modification of Goal-directed and Habitual Behavior in Addiction",,"Recruiting","No Results Available","Tobacco Use Disorder","Behavioral: standard smoking cessation program (SCP)|Behavioral: Cognitive remediation treatment (CRT)|Behavioral: Implicit computer-based habit-modifying training (ICHT)","Change in imbalance between goal-directed and habitual behavior|Change in implicit smoking-related associations|Change in attentional bias to smoking cues|Change in smoking urges|Change in working memory capacity|Change in planning ability|Change in cognitive flexibility|nicotine consumption|Change in neural PIT effect|Change in neural cue reactivity","Central Institute of Mental Health, Mannheim","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRR265 C01","January 7, 2020","July 2023","July 2023","December 5, 2018",,"January 10, 2020","Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit, Mannheim, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03764969"
295,"NCT00852852","Computerized Assessment for Patients With Cancer","ESRA-C_II","Completed","No Results Available","Cancer","Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C)","Symptom burden and quality of life 2-4 weeks post treatment|To assess the feasibility of delivering a patient oriented, patient-controlled ESRA-C directly to patients outside clinically settings.","Dana-Farber Cancer Institute|Fred Hutchinson Cancer Research Center|University of Washington|National Institute of Nursing Research (NINR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","779","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","08-284|R01NR008726","October 2008","July 2011","December 2013","February 27, 2009",,"February 1, 2018","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00852852"
296,"NCT03525158","A Brief Cognitive Intervention After Intrusive Memories of Trauma With Young Refugees",,"Completed","No Results Available","Intrusive Memories of Trauma, Symptom of Post Traumatic Stress Disorder (Criterion B1)","Behavioral: Brief cognitive intervention","Change in the occurrence of intrusive memories of trauma from baseline week to intervention week|Feasibility and acceptability ratings for using a smartphone game-play intervention|Self-guided intervention adherence - usage of the gameplay intervention in daily life|Impact of intrusive memories on concentration, control, sleep and stress","Karolinska Institutet","All","16 Years to 25 Years   (Child, Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2017/978-31","June 20, 2017","February 26, 2018","February 26, 2018","May 15, 2018",,"May 15, 2018","Residental care home for young people, Stockholm, Sweden|Swedish Language Classes for Refugees, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03525158"
297,"NCT03159325","The Healing Circles Project",,"Recruiting","No Results Available","Heart Diseases|Cardiovascular Diseases","Behavioral: Healing Circles","Changes from baseline in patient self-management (Health Education Impact Questionnaire v3.0) every 6 months until study end.|Health-related Quality of Life (EuroQol 5D5L)|Subjective Quality of Life (ICECAP-A)|Health Resource Use (study specific questionnaire)","Simon Fraser University|Canadian Institutes of Health Research (CIHR)","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","H16-03203","August 20, 2017","December 2020","April 2021","May 18, 2017",,"April 9, 2019","Northern Health Authority, Prince George, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03159325"
298,"NCT01142609","Improving Substance Abuse Counseling Adherence Using Web-based Videoconferencing",,"Completed","No Results Available","Substance Abuse Disorder","Behavioral: eGet","Counseling efficacy|Reinforcement value (eGetgoing)|Reinforcement value (on-site)|Program Satisfaction|Treatment cost|Therapeutic relationship","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","85","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1RC1DA028189-01","December 2009","August 2012","August 2012","June 11, 2010",,"April 4, 2013","Addiction Treatment Services, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01142609"
299,"NCT02658682","Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure",,"Completed","No Results Available","Major Depression","Behavioral: Attention Bias Modification|Behavioral: Sham Attention Bias Modification","Change in residual symptoms of depression. Self report.|Change in residual symptoms of depression. Clinician rating|Recurrence of major depressive episodes|Changes in Emotion Regulation|Changes in Rumination|Changes in cortisol response.|Changes in symptoms of anxiety","University of Oslo|University of Oxford|Sorlandet Hospital HF|Diakonhjemmet Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NFR-229135","January 2015","October 2016","December 2017","January 20, 2016",,"April 26, 2019","Sørlandet Hospital, Department of Psychiatry, Arendal, Aust-Agder, Norway|University of Oslo, Department of Psychology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02658682"
300,"NCT04037501","Effectiveness of a Care Management System to Reduce Unmet Needs of Informal Caregivers of People With Dementia","GAIN","Not yet recruiting","No Results Available","Dementia|Caregiver Burnout|Carer Stress Syndrome|Relatives|Partner, Domestic","Other: Care Management","Change in number of Unmet Needs|Change in Quality of Life|Change in Caregiver Burden|Social Support|Use of medical and non-medical services","German Center for Neurodegenerative Diseases (DZNE)|Gemeinsamer Bundesausschuss (GBA)|University Medicine Greifswald","All","18 Years and older   (Adult, Older Adult)","Not Applicable","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","01VSF18030","July 1, 2020","August 2021","March 2022","July 30, 2019",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04037501"
301,"NCT00001675","The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics",,"Completed","No Results Available","Alcoholism|Healthy",,,"National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","12 Years to 65 Years   (Child, Adult, Older Adult)",,"1194","NIH","Observational",,"980056|98-AA-0056","January 23, 1998",,"December 23, 2015","April 20, 2006",,"December 9, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001675"
302,"NCT00672048","Partnership for Glaucoma",,"Completed","No Results Available","Glaucoma","Other: Computer Tablet|Other: Continuing Education Course|Other: Continuing education","To determine if innovative technology will improve process quality of care & important outcomes of care by optometrists in a cost-efficient manner while simultaneously empowering & including patients as part of the care process.","Duke University|University of Alabama at Birmingham","All","Child, Adult, Older Adult","Not Applicable","721","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00002593|R01EY018405-01","October 2007","July 2013","July 2013","May 6, 2008",,"January 6, 2014","University of Alabama, Birmingham, Alabama, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00672048"
303,"NCT00064896","Technical Development of Cardiovascular Magnetic Resonance Imaging",,"Completed","No Results Available","Peripheral Artery Disease","Procedure: MRI","To develop, test, and provide adjunctive information to the operator derived from MRI during the management of patients being considered for, or undergoing, invasive procedures.|This protocol aims to develop and test novel MRI techniques in patients being treated for cardiovascular disease.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","NIH","Interventional","Primary Purpose: Treatment","030250|03-H-0250","July 14, 2003","October 26, 2017","October 26, 2017","July 15, 2003",,"October 30, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00064896"
304,"NCT03289572","Microgrid II - Electrocorticography Signals for Human Hand Prosthetics",,"Recruiting","No Results Available","Epilepsy Intractable",,"This is an observational study and the outcome is successful measurement of motor-related corticography signals.","University of Washington","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","STUDY00003073","November 2015","December 2020","December 2022","September 21, 2017",,"May 22, 2019","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03289572"
305,"NCT00416754","Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations",,"Completed","No Results Available","Breast Cancer","Other: counseling intervention","patient satisfaction","Georgetown University|National Cancer Institute (NCI)","Female","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","1109","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CDR0000450754|R01CA082346|P30CA051008|GUMC-2000-305","December 2000","December 2006","December 2006","December 28, 2006",,"April 7, 2017",,,"https://ClinicalTrials.gov/show/NCT00416754"
306,"NCT01629056","The Contact PVI Study: Use of Tissue Contact Data to Guide Atrial Fibrillation Ablation",,"Completed","No Results Available","Atrial Fibrillation","Procedure: ablation|Procedure: RF ablation","The primary outcome measure will be the proportion (%) of pulmonary vein pairs found to be reconnected electrically to the left atrium at a subsequent redo ablation procedure|Proportion of acute venous electrical reconnections|touch-up ablation requirements|procedure time|RF time|anatomical location of reconnections at repeat procedure|amount of RF required to achieve re-isolation at repeat ablation procedure|complications","Oxford University Hospitals NHS Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","77431/244334/1/228|11/SC/0398","January 2012","December 2013","February 3, 2014","June 27, 2012",,"October 13, 2017","John Radcliffe Hospital, Headington, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01629056"
307,"NCT01745588","Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Procedure: stem cell|Drug: Dexamethasone|Drug: Clarithromycin","overall response rate|safety analyses|overall survival|progression free survival|Determine the rates of ≥ Grade 3 toxicities","Memorial Sloan Kettering Cancer Center|Celgene Corporation|Weill Medical College of Cornell University|North Shore University Hospital|Rutgers Cancer Institute of New Jersey|State University of New York - Upstate Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-138","December 2012","December 2020","December 2020","December 10, 2012",,"October 29, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|North Shore LIJ, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01745588"
308,"NCT02844543","EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1","ETA-TV","Completed","Has Results","Eye-tracking","Device: EYE-SYNC eye-tracking device|Other: SCAT-3|Device: Desktop Eye-Tracker","Changes in the Eye-tracking Score Before and After Practice or Game: Phase Error|Changes in the Eye-tracking Score Before and After Practice or Game: Tangential and Radial Error|Changes in the Eye-tracking Score Before and After Practice or Game: Vertical and Horizontal Gain|Changes in Sport Concussion Assessment Tool (SCAT-3) Standardized Assessment of Concussion (SAC) Score","Stanford University|Brain Trauma Foundation|United States Department of Defense|Food and Drug Administration (FDA)|U.S. Army Medical Research and Development Command|Department of Health and Human Services","All","18 Years to 25 Years   (Adult)","Not Applicable","155","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","34662","January 2016","December 2016","December 2016","July 26, 2016","April 30, 2018","May 30, 2018","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02844543"
309,"NCT01817582","Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)",,"Completed","Has Results","Keratoconjunctivitis Sicca","Drug: Lotemax|Drug: Restasis|Drug: Soothe® Lubricant Eye Drops","Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4|Change From Baseline in Mean Ocular Surface Disease Index (OSDI) Questionnaire Total Score at Week 4|Percentage of Participants With Adverse Events (AEs)|Mean Grade for Participant-Reported Post-Dosing Ocular Comfort Values|Change From Baseline in Mean OSDI Questionnaire Total Score and Individual Question Scores at Week 12|Change From Baseline in Mean Corneal Total Fluorescein Staining Score for the Study Eye and Averaged for Both Eyes at Week 12|Change From Baseline in Mean Value of Participant Worst Eye Score for Each Symptom (Including the Pre-Specified Worst Symptom) in the List of Possible Worst Symptoms at Week 12|Change From Baseline in Mean Total Combined Lissamine Green (LG) Staining (Nasal Plus Temporal Conjunctival) Score for the Study Eye and Averaged for Both Eyes at Week 12|Change From Baseline in Mean Tear Osmolarity of Participant Worst Eye Value at Week 12|Change From Baseline in Mean Tear Osmolarity Between Two Eyes of Participant at Week 12|Change From Baseline in Mean Eye Comfort Index Questionnaire Total Score and Individual Question Scores at Week 12|Change From Baseline in Mean Eye Dryness Questionnaire Total and Individual Question Scores at Week 12|Change From Baseline in Mean Tear Film Breakup Time (TFBUT) (by Fluorescein Staining) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12|Change From Baseline in Mean Non-Invasive Keratographic Tear Film Breakup Time (NIKBUT) of the Study Eye and Averaged for Both Eyes of a Participant at Week 12|Change From Baseline in Mean Anesthetized Schirmer's Test Values (Distance of Strips Wetting) in the Study Eye and Averaged for Both Eyes of a Participant at Week 13|Averaged Daily Soothe Lubricant Eye Drops Usage|Number of Participants With Overall Change From Baseline in Dry Symptoms at Week 12 as Assessed Independently by Investigators and Participants|Change From Baseline in Ocular Redness Score for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator|Change From Baseline in Non-Invasive Keratographic Limbal and Bulbar Ocular Redness Scores for Study Eye and Averaged for Both Eyes at Week 12, as Assessed by Investigator","Bausch & Lomb Incorporated|Synteract, Inc.","All","40 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","813","May 17, 2013","January 10, 2014","January 10, 2014","March 25, 2013","August 30, 2019","August 30, 2019","Bausch & Lomb Incorporated, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT01817582"
310,"NCT04428931","Attentional Performance in Parkinson Disease",,"Recruiting","No Results Available","Parkinson's Disease",,"Attentional asymmetry|Feedback learning and visuospatial attention performance","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","35 Years to 80 Years   (Adult, Older Adult)",,"60","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200102|20-N-0102","July 14, 2020","March 4, 2030","March 4, 2030","June 11, 2020",,"July 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04428931"
311,"NCT03952624","Patient-Centered Assessment of Symptoms and Outcomes",,"Enrolling by invitation","No Results Available","Fatigue",,"The primary outcome will be the fatigue level using the Fatigue Numeric Rating Scale (FNS) score.|Secondary outcomes of the study will obtain common fatigue dimension information from participants that will allow us to better define phenotypic clusters that ultimately can be used for hypothesis generation, these include patient-reported outc...","National Institute of Nursing Research (NINR)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"4","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","190098|19-NR-0098","September 13, 2019","June 1, 2024","July 1, 2024","May 16, 2019",,"May 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03952624"
312,"NCT02617420","Monitoring Adherence Using Mobile Technology",,"Completed","No Results Available","Asthma","Device: Propeller Health Monitoring Device","Number of patient participants that rate the devices as easy to use|Number of provider participants that rate the devices as easy to use|Number of patients/parents that exhibit behavioral changes with respect to taking asthma medications as a result of information gained from the monitoring devices.|Number of pediatric pulmonary providers that exhibit behavioral changes with respect to prescribing asthma medications as a result of information gained from the monitoring devices.|Correlation of lung function to percent use of controller medications as measured by adherence devices.","University of Colorado, Denver","All","6 Years to 17 Years   (Child)",,"25","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","15-0211","December 2015","September 2016","September 2016","December 1, 2015",,"September 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02617420"
313,"NCT01135407","Visual Selective Attention in Parkinson's Disease","VSA-PD","Completed","No Results Available","Visual Attention in Parkinson's Disease","Other: Recording during computerized tests","reaction time in trials of the computerized tests|responses accuracy in trials of the computerized tests","University Hospital, Grenoble","All","21 Years and older   (Adult, Older Adult)",,"36","Other","Observational","Time Perspective: Prospective","0914","October 2009","July 2010","July 2010","June 2, 2010",,"November 22, 2010","Unité des Troubles du Mouvement, Clinique de Neurologie, Grenoble University Hospital, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT01135407"
314,"NCT02987257","NATIENS: Optimal Management and Mechanisms of SJS/TEN","NATIENS","Not yet recruiting","No Results Available","Stevens-Johnson Syndrome|Toxic Epidermal Necrolyses","Drug: Harmonized supportive care|Drug: Cyclosporine 5 mg/kg bid days 0-14|Drug: Etanercept 50 mg sc day 0 and day 3","Time to complete re-epithelialization|Time to halting of progression of SJS/TEN skin disease|Mortality|Ocular involvement|Infections|Hospital length of stay|Proportion of patients with Adverse events due to assigned treatment arm","Vanderbilt University Medical Center|University of Ottawa|University of Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 3","267","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200662","April 2021","May 2025","July 2027","December 8, 2016",,"May 6, 2020","Vanderblt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02987257"
315,"NCT04359745","Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression",,"Recruiting","No Results Available","Glioblastoma",,"Accuracy of the artificial intelligence model|Failure rate of the artificial intelligence model","Guy's and St Thomas' NHS Foundation Trust|King's College London","All","18 Years to 80 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3.0 04/09/18","March 21, 2019","May 26, 2023","May 26, 2023","April 24, 2020",,"April 27, 2020","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04359745"
316,"NCT03538652","Just-In-Time Adaptive Interventions for Addictive Behaviors",,"Recruiting","No Results Available","Addiction","Behavioral: JITAI|Other: Placebo","Strategy-situation fit|Distal effects of JITAI on self-efficacy and coping flexibility|Proximal effects of CBT and ACT messages in a JITAI|whether the intervention types that benefit participants most when pushed by the app are the same ones participants choose when subsequently given the opportunity to pull interventions.|Time courses of responsiveness to ACT vs. CBT, in the JITAI group|Group differences in frequency of opioid-positive urine over time|Trait predictors of differential responses to CBT and ACT","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","185","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999918095|18-DA-N095","February 19, 2020","May 1, 2023","May 1, 2023","May 29, 2018",,"July 1, 2020","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03538652"
317,"NCT00564902","The Zeaxanthin and Visual Function Study","ZVF","Completed","Has Results","Age Related Macular Degeneration|Cognition Disorders","Drug: 3R 3'R Zeaxanthin|Dietary Supplement: Lutein|Dietary Supplement: Lutein and Zeaxanthin","Macular Pigment Optical Density|SHAPE Discrimination|Early Treatment Diabetic Retinopathy Study Distance Visual Acuity|Glare Recovery|Contrast Sensitivity Function Photopic Distance|6.5 Degrees Tritan Threshold|100% Kinetic Field","Chrysantis, Inc.|Kowa Company, Ltd.|IMAGE TECHNOLOGIES INC.","All","45 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","CHRY1|IRB 07-046","November 2007","May 2009","June 2009","November 29, 2007","March 29, 2012","March 29, 2012","North Chicago VA Medical Center, North Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00564902"
318,"NCT00334360","Dexmed/Buspirone Synergism on Shivering",,"Completed","No Results Available","Hypothermia","Drug: dexmedetomidine|Drug: buspirone|Drug: Bus and Dex|Drug: Control","Shivering threshold|maximum intensity of shivering|gain of shivering|hemodynamic responses","The Cleveland Clinic","Male","18 Years to 40 Years   (Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Dexmed/Buspirone","September 2004","August 2007","August 2007","June 7, 2006",,"June 29, 2016","Outcomes Research Institute, University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00334360"
319,"NCT01945099","Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy",,"Completed","No Results Available","Type 1 Diabetes","Device: ePID closed loop system|Drug: hyaluronidase|Drug: Lispro-PH20","Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20|Peak post-prandial insulin levels following meals","Eda Cengiz|Yale University","All","12 Years to 40 Years   (Child, Adult)","Early Phase 1","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1307012334","September 2013","December 2015","July 2016","September 18, 2013",,"March 19, 2020","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01945099"
320,"NCT02035176","Novel Measure of Social Deficits in Children","OATS","Completed","No Results Available","Autism Spectrum Disorders|ADHD",,"Eye gaze in response to animated social situations|Facial expressions in response to animated social situations","Oregon Health and Science University","All","6 Years to 11 Years   (Child)",,"92","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","eIRB 9747","February 2014","December 2018","December 2018","January 14, 2014",,"August 28, 2019","OHSU, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02035176"
321,"NCT01536379","A Study of Belimumab in the Prevention of Kidney Transplant Rejection",,"Completed","Has Results","Transplantation, Organ","Drug: Belimumab|Drug: Placebo","Change From Baseline in naïve B Cells From Baseline to Week 24|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)|Number of Incidence of All Infections and Serious Infections|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52|Change From Baseline in Heart Rate From Baseline at Week 24 and Week 52|Change From Baseline in Body Temperature From Baseline at Week 24 and Week 52|Number of Participants Outside the Normal Range (NR) for SBP and DBP at Week 24 and Week 52|Number of Participants Outside the Normal Range (NR) for Heart Rate at Week 24 and Week 52|Number of Participants Outside the Normal Range (NR) for Body Temperature at Week 24 and Week 52|Change From Baseline in the Indicated Hematology Parameters at Week 24 and Week 52|Change From Baseline in the Haematology Parameter- Hemoglobin at Week 24 and Week 52|Change From Baseline in the Hematology Parameter- Hematocrit at Week 24 and Week 52|Change From Baseline in Haematology Parameter- Mean Corposcular Hemoglobin (MCH) at Week 24 and Week 52|Change From Baseline in Haematology Parameter- Mean Corposcular Volume (MCV) at Week 24 and Week 52|Change From Baseline in Haematology Parameter- Red Blood Cell (RBC) at Week 24 and Week 52|Change From Baseline in Clinical Chemistry Parameter- Albumin at Week 24 and Week 52|Change From Baseline in Clinical Chemistry Parameter- ALP, ALT, AST at Week 24 and Week 52|Change From Baseline in Clinical Chemistry Parameter- Direct Bilirubin, Total Bilirubin and Creatinine at Week 24 and Week 52|Change From Baseline in Clinical Chemistry Parameter- Ca, CO2/Bicar, Gl, K, Na, PhI, U/BUN at Week 24 and Week 52|Change From Baseline in Clinical Chemistry Parameter- Glomerular Filtration Rate (GFR) at Week 24 and Week 52|Change From Baseline in Immunoglobulin A (IgA), Immunoglobulin G (IgG) and Immunoglobulin M (IgM) at Week 24 and Week 52|Median Percent Change From Baseline in Memory B Cell Count at Week 24 and Week 52|Activated Memory B Cells Count at Week 24 and Week 52|Activated Memory B Cells Percentage at Week 24 and Week 52|Transitional B Cells Count at Week 24 and Week 52|Transitional B Cells Percentage at Week 24 and Week 52|Activated T Cell Count at Week 24 and Week 52|Activated T Cell Percentage at Week 24 and Week 52|Regulatory T Cell Count at Week 24 and Week 52|Regulatory T Cell (%CD4) at Week 24 and Week 52|Mean Activated: Regulatory T Cell Ratio at Week 24 and Week 52|Proportion of Participants With Episodes of Acute Rejection at Week 24 and Week 52|Mean Serum Creatinine at Week 24 and Week 52|Mean eGFR at Week 24 and Week 52|Mean Prednisolone Use at Week 24","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","114424","September 2013","February 2016","February 2016","February 22, 2012","April 25, 2017","April 25, 2017","GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01536379"
322,"NCT01856790","Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Device: ePID closed loop system|Drug: liraglutide","Peak Post-prandial Venous Glucose Levels|the Incremental Meal-related Glucose Area Under Curve (AUC)","Jennifer Sherr|Juvenile Diabetes Research Foundation|Yale University","All","18 Years to 40 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1211011156","February 2013","November 2015","November 2015","May 17, 2013","January 30, 2020","January 30, 2020","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01856790"
323,"NCT00005911","Magnetic Resonance Imaging to Study the Normal Eye",,"Completed","No Results Available","Cataract|Lens Disease",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"20","NIH","Observational",,"000151|00-EI-0151","June 2000",,"August 2002","June 14, 2000",,"March 4, 2008","National Eye Institute (NEI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00005911"
324,"NCT01315730","The Effects of Tactile Speech Feedback on Stuttering Frequency",,"Withdrawn","No Results Available","Stuttering","Device: Tactile Stimulation","Speech Fluency","University of Mississippi, Oxford|West Virginia University|Auburn University|University of Louisiana at Lafayette","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UMO-0001","March 2011",,,"March 15, 2011",,"May 12, 2014","The University of Mississippi, University, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT01315730"
325,"NCT00204893","Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects",,"Completed","No Results Available","Healthy","Drug: calcium formate","Vision Testing (refraction) over baseline|Change in Serum Formate Levels over baseline|Change in Visual Acuity over baseline|Change in 100 Hue Vision Testing results over baseline|Change in ERG/VEP over baseline|Change in Visual Fields over baseline|Fundus Photography","University of Wisconsin, Madison|Nephro-Tech 1, LLC","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2003-297","July 2003","March 2007","March 2007","September 20, 2005",,"March 7, 2019","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00204893"
326,"NCT02767388","Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery","Chemobrain","Completed","Has Results","Myelodysplastic Syndrome|Effects of Chemotherapy|Mild Cognitive Impairment|Multiple Myeloma|Non-hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia",,"Change From Baseline Capture Task Performance at 1- and 3- Months|Change From Baseline N2pc Amplitude at 1- and 3- Months|Change From Baseline Filter Task Performance at 1- and 3- Months|Change From Baseline CDA Amplitude at 1- and 3- Months","University of Nebraska","All","19 Years to 80 Years   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","137-16-FB","September 1, 2016","December 11, 2017","March 15, 2018","May 10, 2016","September 6, 2019","September 6, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02767388/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02767388"
327,"NCT01313130","Advanced MRI In Acute Military TBI",,"Unknown status","No Results Available","Traumatic Brain Injury",,"Cognitive dysfunction|Post-traumatic stress disorder|Depression|Neurological deficits","Washington University School of Medicine|Landstuhl Regional Medical Center","All","18 Years and older   (Adult, Older Adult)",,"400","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","PT090444","October 2010","December 2013","August 2016","March 11, 2011",,"December 10, 2014","Washington University, St Louis, Missouri, United States|Landstuhl Regional Medical Center, Landstuhl, Germany",,"https://ClinicalTrials.gov/show/NCT01313130"
328,"NCT04037215","Exploration of the Mechanisms of Vulnerability of Anorexia Nervosa at an Early Age : Study of the Cognitive Treatment of Food Stimuli and Body Image","AMDP","Recruiting","No Results Available","Anorexia Nervosa","Other: STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE","cognitive processing|fixing a region of interest|body mass index|total score on the Morgan and Russell scale","Assistance Publique - Hôpitaux de Paris","All","8 Years to 14 Years   (Child)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","K170607J","November 19, 2019","May 19, 2021","May 19, 2021","July 30, 2019",,"November 27, 2019","Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT04037215"
329,"NCT03158519","iMETX (Individualized Metabolic RX): a Pilot Study",,"Completed","No Results Available","Breast Cancer","Behavioral: iMETX intervention","Feasibility of intervention","Indiana University|Susan G. Komen Breast Cancer Foundation|University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IUSCC-0590","May 15, 2017","April 1, 2019","April 1, 2019","May 18, 2017",,"February 17, 2020","Indiana University Health North Hospital, Carmel, Indiana, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Spring Mill Medical Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03158519"
330,"NCT01492439","Effectiveness of Cognitive Remediation in a Supported Education Setting",,"Completed","Has Results","Psychosis","Behavioral: Cognitive Remediation|Behavioral: Supported Education","Completion of Academic Semesters|Positive and Negative Symptoms Scale (PANSS) Score at 3 Months|The Rosenberg Self-Esteem Scale Score at 3 Months|The Positive and Negative Symptoms Scale (PANSS) Score at 6 Months|The Rosenberg Self-Esteem Scale Score at 6 Months|The California Verbal Learning Test at 3 Months|The California Verbal Learning Test at 6 Months|The Trail Making Test Part A at 3 Months|The Trail Making Test Part A at 6 Months|The Digit Span Subtest of the Wechsler Adult Intelligence Scale - III at 3 Months|The Digit Span Subtest of the Wechsler Adult Intelligence Scale - III at 6 Months|The Trail Making Test Part B at 3 Months|The Trail Making Part B at 6 Months|The Wisconsin Card Sorting Test at 3 Months|The Wisconsin Card Sorting Task at 6 Months|The Digit Vigilance Test at 3 Months|The Digit Vigilance Test at 6 Months","Centre for Addiction and Mental Health|George Brown College","All","18 Years and older   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","143/2011","December 2011","July 2013","July 2013","December 15, 2011","June 11, 2014","June 11, 2014","George Brown College, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01492439"
331,"NCT02200211","Study of Binocular Computer Activities for Treatment of Amblyopia","ATS18","Completed","Has Results","Amblyopia","Device: iPad®|Other: Patching 2 hours per day, 7 days per week","Change in Distance Visual Acuity From Baseline in the Younger Cohort (5 to <13 Years)|Mean Amblyopic Eye Visual Acuity (Younger Cohort)|Mean Change in Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years)|Mean Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years)|Distribution of Change in Amblyopic-eye Visual Acuity|Distribution of Amblyopic-eye Visual Acuity|Number of Participants With Amblyopic-eye VA Improvement of 2 or More logMAR Lines (10 or More Letters if E-ETDRS) From Baseline|Number of Participants With Resolution of Amblyopia|Time Course of Visual Acuity Improvement|Younger Cohort: Change in Distance Visual Acuity From Baseline According to Subgroups|Older Cohort: Change in Distance Visual Acuity From Baseline According to Subgroups|Distribution of Stereoacuity Scores|Median Stereoacuity Score (Seconds of Arc)|Distribution of Stereoacuity Scores (Participants With no History of Strabismus)|Distribution of Change in Stereoacuity Scores From Baseline|Distribution of Change in Stereoacuity Scores From Baseline (Participants With no History of Strabismus)|Binocular Treatment Group: Adherence and Fellow-eye Contrast (iPad Log File Data)|Binocular Treatment Group: Median Adherence With Prescribed Game Play (iPad Log File Data)","Jaeb Center for Health Research|Pediatric Eye Disease Investigator Group|National Eye Institute (NEI)","All","5 Years to 16 Years   (Child)","Not Applicable","485","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ATS18|2U10EY011751","September 11, 2014","August 19, 2016","August 19, 2016","July 25, 2014","October 15, 2018","February 27, 2019","Mayo Clinic, Rochester, Minnesota, United States|Seattle Children's Hospital, University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02200211"
332,"NCT04420728","Closed-Loop Insulin in Mothers With Type 1 Diabetes and Baby Feeding Practices","CLIMB","Not yet recruiting","No Results Available","Diabetes Mellitus Type 1 Pre-Existing|Pregnancy Related|Feeding Behavior|Infant Development","Combination Product: Early auto-mode|Combination Product: Delayed auto mode","Effect of Auto vs. Manual Mode of MiniMed 670G on Time in Target Range Assessed via CGM|Effect of Auto vs. Manual Mode of MiniMed 670G on Time Spent Below Target Range Assessed via CGM|Effect of Auto vs. Manual Mode of MiniMed 670G on Time Spent Above Target Range Assessed via CGM|Effect of Auto vs. Manual Mode of MiniMed 670G on Glycemic Variability Assessed via CGM|Effect of Auto vs. Manual Mode of MiniMed 670G on Diabetes Self-Care Assessed via Diabetes Distress Scale 3|Effect of Auto vs. Manual Mode of MiniMed 670G on Quality of Life Assessed via Diabetes Distress Scale 3 and the Hypoglycemia Fear Survey Questionnaire II|Effect of Auto vs. Manual Mode of MiniMed 670G on Sleep Assessed via Pittsburgh Sleep Quality Index|Assess Acceptability of Auto-mode MiniMed 360 via qualitative interviews.|Assess Feasibility of Auto-mode MiniMed 360 via study recruitment, retention and completion rates.","University of Calgary|Calgary Health Trust|Medtronic|Ward of the 21st Century","Female","18 Years to 45 Years   (Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10027445","June 2020","August 2022","August 2022","June 9, 2020",,"June 9, 2020","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04420728"
333,"NCT00339508","Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics",,"Completed","No Results Available","Data Analysis|Cancer Genetics",,,"National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"13385","NIH","Observational",,"999902152|02-HG-N152","March 19, 2002",,"May 9, 2017","June 21, 2006",,"April 5, 2018","National Human Genome Research Institute (NHGRI), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00339508"
334,"NCT03106012","The Role of Hysterolaparoscopy in Infertile Patients With Normal Hysterosalpingography",,"Unknown status","No Results Available","Infertility, Female","Procedure: Hysteroscopy|Procedure: Laparoscopy","tubal pathology","Cairo University","Female","21 Years to 40 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","163","March 31, 2017","December 2017","December 2017","April 10, 2017",,"April 10, 2017","Kasr Alainy medical school, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03106012"
335,"NCT03911687","(CONCERN) Clinical Decision Support (CDS) System",,"Not yet recruiting","No Results Available","Hospital Acquired Condition","Behavioral: CONCERN CDS system notification","In-hospital mortality rate|Average length of hospital stay|Number of Cardiac Arrest|Number of hospital acquired sepsis|Number of unanticipated transfer to ICU|Hospital readmission rates","Columbia University|National Institute of Nursing Research (NINR)|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","AAAR1389|R01NR016941","June 2020","April 2022","April 2022","April 11, 2019",,"April 24, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|New York Presbyterian Columbia University Medical Center, New York, New York, United States|New York Presbyterian Allen Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03911687"
336,"NCT02292914","Prospective Analysis of Robot-Assisted Surgery",,"Recruiting","No Results Available","Esophageal Cancer|Gastric Cancer|Pancreatic Cancer|Rectal Cancer|Bladder Cancer|Prostate Cancer|Renal Cancer|Uterus Cancer|Head and Neck Cancer|Lung Cancer","Procedure: Robot-assisted surgery|Procedure: Conventional Surgery","Postoperative Complications|ICU and hospital length of stay","Instituto do Cancer do Estado de São Paulo","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","1120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP433/13","March 10, 2014","July 10, 2020","July 10, 2020","November 18, 2014",,"August 8, 2019","Instituto do Câncer de São Paulo - ICESP, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02292914"
337,"NCT03679247","Electronic Tools to Increase Recognition and Improve Primary Care Management for Hypertension in Chronic Kidney Disease",,"Not yet recruiting","No Results Available","Chronic Kidney Diseases|Hypertension","Other: Intervention Phase One|Other: Intervention Phase Two","Systolic Blood Pressure (SBP)|Difference in SBP over 12 month period (difference-in-differences)|Controlled blood pressure rate|Systolic Blood Pressure (secondary)|Physician Use of Clinical Decision Support","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2018P000692","August 1, 2020","September 1, 2024","September 1, 2024","September 20, 2018",,"July 8, 2020",,,"https://ClinicalTrials.gov/show/NCT03679247"
338,"NCT01280877","Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)",,"Completed","No Results Available","Optic Nerve Diseases|Optic Nerve Injuries|Optic Neuropathies","Device: tACS|Device: Sham stimulation","Detection accuracy (DA) change in percent over baseline within defective visual field|DA change in percent over baseline regarding the damage region of the tested visual field (computer-based high-resolution perimetry)|EEG parameters|Reaction time change in ms|Visual acuity (VA)|DA in static and kinetic conventional perimetry","University of Magdeburg|EBS Technologies GmbH","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","EBS-PP-2010-08-10-001","December 2010","February 2012","February 2012","January 21, 2011",,"January 30, 2017","Klinik für Neurologie, Charité Campus Mitte, Universitätsmedizin Berlin, Berlin, Germany|Klinische Neurophysiologie & Abteilung Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Germany|Augenklinik Kassel am Klinikum Kassel GmbH, Kassel, Germany|Inst. f. Medizinische Psychologie, Universitätsklinikum Magdeburg, Magdeburg, Germany",,"https://ClinicalTrials.gov/show/NCT01280877"
339,"NCT00247611","Improving Treatment Adherence in HIV-Infected Individuals",,"Completed","Has Results","HIV Antiretroviral Therapy (ART) Adherence|Health Behavior","Behavioral: LifeWindows Intervention Sessions|Other: Control","AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken|Visual Analog Scale Measure of Adherence to ART|Viral Load Count","University of Connecticut|National Institute of Mental Health (NIMH)","All","18 Years and older   (Adult, Older Adult)","Phase 2","594","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01MH066684|DAHBR 9A-ASPG","October 2005","March 2008","March 2008","November 2, 2005","December 20, 2013","December 20, 2013","University of Connecticut Health Center, Farmington, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale-New Haven Hospital Nathan Smith Clinic, New Haven, Connecticut, United States|Hospital of Saint Raphael, New Haven, Connecticut, United States|Waterbury Hospital, Waterbury, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00247611"
340,"NCT04290689","Can Gait Analysis and Ultrasound Detect a Change in Calf Musculature in Children With Cerebral Palsy?",,"Recruiting","No Results Available","Cerebral Palsy","Drug: Botulinum Toxin-A injection|Procedure: Serial casting stretching","Are there gait (kinetic) differences pre and post intervention in toe walking cerebral palsy subjects?|Are there gait (kinematic) differences pre and post intervention in toe walking cerebral palsy subjects?|Triceps Surae muscle activation during the gait cycle (Electromyography)|Are there morphological differences in the calf muscle pre and post serial casting/botulinum toxin-A intervention in toe walking cerebral palsy subjects?|Difference in the muscle stiffness values (using elastography) in the calf muscle pre and post intervention.","Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust","All","4 Years to 16 Years   (Child)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RL1 777","March 14, 2018","August 2020","December 2020","March 2, 2020",,"March 2, 2020","ORLAU, RJAH Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04290689"
341,"NCT03819907","The Use of Virtual Reality for Lumbar Pain Management in an Outpatient Spine Clinic",,"Recruiting","No Results Available","Chronic Low Back Pain","Combination Product: Audiovisual Guided Relaxation|Combination Product: Virtual Reality Guided Relaxation","Change is being assessed between two time points by The Numeric Pain Rating Scale|Change is being assessed between two time points by The Anxiety Thermometer|Virtual Reality Symptom Questionnaire","Spaulding Rehabilitation Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2018P003042Final","April 8, 2019","September 2019","September 2019","January 29, 2019",,"April 24, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03819907"
342,"NCT01905839","A Study of Movement Disorders Using the QMAT At-Home Testing Device",,"Terminated","No Results Available","Movement Disorders|Parkinson's Disease",,"Mean speed of keystrokes on a repetitive finger movement|Mean speed of movement on a peg movement task","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)",,"3","NIH","Observational","Time Perspective: Prospective","130167|13-N-0167","June 18, 2013","April 15, 2015","April 15, 2015","July 23, 2013",,"September 25, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01905839"
343,"NCT00526942","Behavioral and Physiological Effects of Visual Training",,"Unknown status","No Results Available","Healthy","Behavioral: SAAGE-designed, visual memory-based cognitive training","Improvement in visual memory assessment after training or no-contact period.|Improvement on at least 1 of the Computerized Visual Attention, Speed and Memory Tests conducted.|Improvement on the computerized cognitive assessments.|Improvement on exercise-based assessments.","Posit Science Corporation|University of San Francisco","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","54","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RES-203-2007","August 2007",,"August 2008","September 10, 2007",,"September 11, 2007","Posit Science Corporation, San Francisco Bay Area, California, United States",,"https://ClinicalTrials.gov/show/NCT00526942"
344,"NCT03050801","Functional Connectivity as a Biomarker of rTMS",,"Recruiting","No Results Available","Traumatic Brain Injury","Device: rTMS","Functional connectivity|Memory tests","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","101","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","170055|17-N-0055","March 24, 2017","March 10, 2020","May 1, 2021","February 13, 2017",,"June 25, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03050801"
345,"NCT02010320","Computer Guided Doing of Tacrolimus in Renal Transplantation","OPTIMAL","Completed","No Results Available","Renal Transplantation","Other: Computer dosing|Other: Standard dose determination","Predictive error (Cpred-Cobs)|Reaching the target concentration","University of Oslo School of Pharmacy|Rikshospitalet University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPTIMAL-13","January 2014","July 2014","July 2014","December 12, 2013",,"December 3, 2014","Olso university hospital - Rikshospitalet, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02010320"
346,"NCT01730079","Near Infrared Spectroscopy in Children With Autism and ADHD",,"Terminated","No Results Available","Attention Deficit Disorder With Hyperactivity|Attention Deficit Disorder|Attention Deficit Hyperactivity Disorder|Autism|Autism Spectrum Disorders",,"Graded changes in blood flow and oxygen, measured with NIRS, in response to different functional tasks.|Differential activity according to region of the frontal cortext and task elements.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","4 Years to 8 Years   (Child)",,"42","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","130007|13-M-0007","October 23, 2012","April 11, 2017","April 11, 2017","November 21, 2012",,"October 18, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01730079"
347,"NCT02226848","Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury",,"Withdrawn","No Results Available","Traumatic Brain Injury","Drug: Erythropoeitin","Effect of 4 weeks of EPO administration on numbers of circulating EPCs in patients with persistent symptons during the subacute period after TBI.|Safety of 4 weeks of EPO administration to TBI participants|Effect of 4 weeks of EPO administration on MRI biomarkers of TBI recovery|Effect of 4 weeks of EPO administration on biomarkers|Relationship between EPC levels at baseline after 4 weeks and neuropsychological performance following TBI.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","140174|14-N-0174","August 15, 2014","May 31, 2017","May 31, 2017","August 27, 2014",,"July 5, 2018",,,"https://ClinicalTrials.gov/show/NCT02226848"
348,"NCT04131530","Automatic Evaluation of Inflammation Activity in Ulcerative Colitis Using pCLE With Artificial Intelligence",,"Recruiting","No Results Available","Ulcerative Colitis|Artificial Intelligence|Confocal Laser Endomicroscopy","Diagnostic Test: The diagnosis of Artificial Intelligence and endoscopist","The diagnosis efficiency of Artificial Intelligence|Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists","Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019SDU-QILU-10","October 2019","December 2019","December 2019","October 18, 2019",,"October 18, 2019","Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04131530"
349,"NCT03784209","Automatic Real-time Diagnosis of Gastric Mucosal Disease Using pCLE With Artificial Intelligence",,"Recruiting","No Results Available","Gastric Diseases|Artificial Intelligence|Confocal Laser Endomicroscopy","Diagnostic Test: The diagnosis of Artificial Intelligence and endoscopist","The diagnosis efficiency of Artificial Intelligence|Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists","Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018SDU-QILU-12","July 1, 2018","November 1, 2019","November 1, 2019","December 21, 2018",,"October 18, 2019","Endoscopic unit of Qilu Hospital Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03784209"
350,"NCT03341780","Standard Amblyopia Therapy in Adult Amblyopes",,"Completed","No Results Available","Amblyopia","Procedure: amblyopia therapy","visual acuity","Southern California College of Optometry|Allergan","All","18 Years and older   (Adult, Older Adult)",,"9","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SoutherCCO","December 16, 2014","October 24, 2016","October 24, 2016","November 14, 2017",,"November 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03341780"
351,"NCT03297554","Healthy Kids Pilot",,"Recruiting","No Results Available","Childhood Obesity","Behavioral: m-Health Intervention","Acceptability/feasibility of the mHealth approach","Pennington Biomedical Research Center","All","6 Years to 10 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-044-PBRC","November 13, 2017","April 30, 2021","April 30, 2021","September 29, 2017",,"May 22, 2020","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03297554"
352,"NCT04136236","Automatic Diagnosis of Early Esophageal Squamous Neoplasia Using pCLE With AI",,"Recruiting","No Results Available","Esophageal Neoplasms|Artificial Intelligence|Confocal Laser Endomicroscopy","Diagnostic Test: The diagnosis of Artificial Intelligence and endoscopist","The diagnosis efficiency of Artificial Intelligence|Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists","Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2019SDU-QILU-66","August 1, 2019","December 1, 2019","December 1, 2019","October 23, 2019",,"October 23, 2019","Qilu Hospital, Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04136236"
353,"NCT03896490","Attention Control Training (ACT) and Very Preterm Infants","ACT","Recruiting","No Results Available","Very Premature Baby","Behavioral: ACT|Behavioral: Control","Recruitment and Retention|Percentage of training/control sessions attended by infants|Percentage of training/control sessions completed by infants|Duration of tasks administered to infants during training/control sessions|Percentage of tasks completed at post-test|Quality of eye-tracker data collected during baseline and post-test attention assessments|Quality of eye-tracker data collected during training","Queen's University, Belfast|Public Health Agency, Health and Social Care Research and Development|TinyLife","All","11 Months to 13 Months   (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","R4798NUR","March 11, 2018","June 30, 2019","March 11, 2020","April 1, 2019",,"November 29, 2019","Queen's University Belfast, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03896490"
354,"NCT01613911","Study of Human Sensory Perception",,"Completed","No Results Available","Epilepsy",,"Reveal induced neuronal activity|Calculate evoked response potentials.","Swedish Medical Center|Weizmann Institute of Science","All","10 Years to 65 Years   (Child, Adult, Older Adult)",,"6","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","5146S-11","March 2012","November 2014","November 2014","June 7, 2012",,"December 8, 2014","Swedish Medical Center Epilepsy Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01613911"
355,"NCT03065218","Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients",,"Suspended","No Results Available","Thyroid Cancer","Radiation: 99mTc sestamibi","Lesion detection on 99mTc Sestamibi Study","Washington Hospital Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-166","October 2016","July 2019","December 2020","February 27, 2017",,"July 2, 2019","Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT03065218"
356,"NCT02829554","Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making",,"Completed","No Results Available","Cancer|Overweight|Obesity",,"Risk perceptions|Intentions","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)",,"6242","NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","999916142|16-C-N142","July 8, 2016","August 29, 2016","May 15, 2020","July 12, 2016",,"May 20, 2020","National Cancer Institute (NCI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02829554"
357,"NCT01591681","Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study",,"Completed","Has Results","Type 1 Diabetes","Device: Pump suspension","Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl|Percentage of Sensor Glucose Values 71 to 180 mg/dL|Percentage of Nights With a Sensor Glucose Value </= 70 mg/dL|Proportion of Nights With a Sensor Glucose Value </= 50 mg/dL|Median Morning Blood Glucose|Percent of Mornings With Glucose >250 mg/dL|Percent of Mornings With Blood Ketones >1.0 mmol/L|Percent of Mornings With Urine Ketones >/= 15 mg/dl|Overall Mean Sensor Glucose Overnight|Overnight Area Under the Curve 250 mg/dl Per 8 Hour|Percent of Nights With Sensor Glucose >250 mg/dL","Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","15 Years to 45 Years   (Child, Adult)","Phase 2","49","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PSO3|1R01DK085591-01","November 2012","July 2013","July 2013","May 4, 2012","June 5, 2014","August 30, 2016","Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|St. Joseph's Health Care, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01591681"
358,"NCT03733080","Large-Scale Online Studies of Early Motor Skill Learning",,"Completed","No Results Available","Healthy Volunteers","Behavioral: repetitive sequence keyboard typing task|Behavioral: Questionnaire","The primary outcome measures for the keyboard typing task were correct sequence typing speed and typing accuracy.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2529","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","999919012|19-N-N012","January 9, 2019","September 23, 2019","October 17, 2019","November 7, 2018",,"January 9, 2020","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03733080"
359,"NCT03235466","A Prospective Trial of Behavioral Therapy for Chronic Cough",,"Recruiting","No Results Available","Cough","Behavioral: Voice Therapy|Behavioral: Voice Therapy and Heart Rate Variability Biofeedback|Behavioral: Heart Rate Variability Biofeedback","Percentage of Cough reduction|Durability of cough remediation|Changes in dyspnea|Change in voice","University of California, San Diego","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","170581","February 1, 2018","June 1, 2020","December 1, 2020","August 1, 2017",,"July 10, 2019","UCSD Center for Voice and Swallowing, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03235466"
360,"NCT02858752","Memory and Attention in Healthy Children","MASK","Recruiting","No Results Available","Healthy Volunteers","Other: Experience 1 : Auditory and Visual Discrimination|Other: Experience 2 : Passive and Active Auditory Perception|Other: Experience 3 : Visual Attention Training|Other: Experience 4 : Attention and Distractibility|Other: Experience 5 : Sustained Visual Attention","Neuropsychological tests: Proportion of accurate answers|Neuropsychological tests: reaction time of answers (seconds)|Neurophysiological tests: Event-related potentials in response to auditory and visual stimulations|Proportion of accurate answers according to age range of children|reaction time of answers (seconds) according to age range of children|Event-related potentials in response to auditory and visual stimulations according to age range of children","Hospices Civils de Lyon","All","5 Years to 17 Years   (Child)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL15_0711","October 6, 2016","October 6, 2020","October 6, 2020","August 8, 2016",,"August 9, 2017","Hopital Femme Mère Enfant, Lyon, France",,"https://ClinicalTrials.gov/show/NCT02858752"
361,"NCT04431011","Layer-specific Contribution to Consolidation of Skill Learning in the Primary Motor Cortex",,"Recruiting","No Results Available","Normal Physiology",,"The primary aim is to determine the role of superficial and deep cortical layers of M1 in the consolidation of motor skill learning.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"30","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","200105|20-N-0105","July 14, 2020","January 2, 2025","April 1, 2025","June 16, 2020",,"July 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04431011"
362,"NCT01747200","Effects of Transcranial Magnetic Stimulation on Object Recognition",,"Completed","No Results Available","Repetitive TMS (rTMS)|Sham rTMS|Bilateral rTMS|Unilateral rTMS","Procedure: Sham rTMS|Procedure: Bilateral rTMS at same frequency and in phase|Procedure: Bilateral rTMS at different frequencies|Procedure: Bilateral rTMSat same frequency and out of phase|Procedure: rTMS over TP8|Procedure: rTMS over TP7","Percentage of correct responses in the midline object recognition task.|Threshold intensity for blocking object recognition","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","13","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science","130035|13-N-0035","November 16, 2012","January 26, 2017","January 26, 2017","December 11, 2012",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01747200"
363,"NCT00692653","Personal Patient Profile Prostate (P4) Randomized, Multisite Trial","P4","Completed","No Results Available","Prostate Cancer","Behavioral: P4","Decisional Conflict|Decisional Satisfaction|Satisfaction with Preparation for Decision Making|Shift in decisional control preference from pre-decision to 1 month post-treatment|Resource utilization","Dana-Farber Cancer Institute|National Institute of Nursing Research (NINR)|University of Washington","Male","21 Years and older   (Adult, Older Adult)","Not Applicable","498","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1R01NR009692|R01NR009692","February 2007","October 2009","December 2009","June 6, 2008",,"May 4, 2015","VA Medical Center / Medical College of Georgia, Augusta, Georgia, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, United States|Seattle Prostate Institute, Seattle, Washington, United States|Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00692653"
364,"NCT02153957","Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Behavioral: Physical Activity","Efficacy|Examine test scores pre- to post- intervention|Effects of lab treadmill on neurobehavioral functioning|compare cognitive test scores between groups|effects of 12wk PA on fatigue, sleep and QOL|Effects of 12wk PA on cognitive functions|Feasibility","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)","Phase 2","156","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","140116|14-C-0116","August 21, 2014","December 31, 2020","July 1, 2021","June 3, 2014",,"February 25, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02153957"
365,"NCT01906151","IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI",,"Withdrawn","No Results Available","Glaucoma","Device: SENSIMED Triggerfish®","To evaluate the differences between the nycthemeral intraocular pressure patterns recorded with Triggerfish during two 24-hour periods, in patients with Primary angle closure and Primary angle closure glaucoma, before and after laser peripheral iridotomy|To assess the nycthemeral intraocular pressure patterns specific to primary angle closure and primary angle closure glaucoma|To assess the effect of laser peripheral iridotomy on diurnal and nocturnal intraocular pressure pattern in primary angle closure and primary angle closure glaucoma","Sensimed AG","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TF-1306","January 2014","March 2014","March 2014","July 23, 2013",,"May 13, 2014","CHNO des Quinze-Vingts, 28 rue Charenton, Paris, France",,"https://ClinicalTrials.gov/show/NCT01906151"
366,"NCT00785304","Advanced MRI in Blast-related TBI",,"Unknown status","No Results Available","Traumatic Brain Injury",,"Comparison of the overall extent of abnormalities apparent on DTI vs conventional MRI.|Identification of specific injured white matter tracts.|Assessment of the correlations in fMRI signal fluctuations between brain regions.|Prediction of the 6-12 month global clinical outcome (GOS-E) based on the acutely apparent DTI abnormalities.|Prediction of the 6-12 month global clinical outcome (GOS-E) based on the acutely apparent resting fMRI correlation abnormalities.|Prediction of the presence and clinical severity of specific post-traumatic sequelae, including i. Spastic hemi/tetraparesis:ii. Short-term learning and memory deficits:iii. Attention deficit:iv. Depression:v. Post-traumatic stress disorder:|Comparison of acute and 6-12 month scans.|Evaluation of the predictive value of the Military Acute Concussion Evaluation (MACE)","Washington University School of Medicine|Landstuhl Regional Medical Center|U.S. Army Medical Research and Development Command","All","18 Years and older   (Adult, Older Adult)",,"100","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","PT075299","November 2008","July 2011","July 2016","November 5, 2008",,"December 10, 2014","Washington University, St Louis, Missouri, United States|Landstuhl Regional Medical Center, Landstuhl, Kirchberg, Germany",,"https://ClinicalTrials.gov/show/NCT00785304"
367,"NCT01823341","Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children","PSO4","Completed","Has Results","Type 1 Diabetes","Device: Pump suspension algorithm","Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.|Percentage of Nights With 1 or More Sensor Glucose Values <70 mg/dL (<3.9 mmol/L)|Percentage of Nights With 1 or More Sensor Glucose Values <50 mg/dL (<2.8 mmol/L)|Mean Sensor Glucose Overnight|Percentage of Time Overnight Sensor Glucose Values 71 to 180 mg/dL (3.9 to 10.0 mmol/L), Normalized to an 8-hour Period.|Percentage of Overnight Time Spent With CGM Value >250 mg/dL (13.9 mmol/L), Normalized to an 8-hour Period.|Mean Morning Blood Glucose|Percentage of Mornings With Blood Glucose >250 mg/dL (>13.9 mmol/L)|Morning Blood Ketones >=1.0 mmol/L|Percent of Mornings With Urine Ketones >/= 15 mg/dl","Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation","All","3 Years to 14 Years   (Child)","Phase 2","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PSO4|5R01DK085591","May 2013","September 2014","September 2014","April 4, 2013","August 24, 2015","August 30, 2016","Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|St. Joseph's Health Care, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01823341"
368,"NCT02639273","Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation",,"Recruiting","No Results Available","AUD","Drug: Nalmefene|Other: Placebo","Nalmefene-induced BOLD signal changes in neural regions associated with alcohol reward processing, including ventral striatum, amygdala, and insula|Nalmefene-induced changes in IV alcohol self-administration|Nalmefene-induced BOLD signal changes in neural processing of aversive stimuli during fMRI|Genotypic modulation (at the OPRM1 118 location) of Nalmafene's effects on primary outcome measures (BOLD signal change during alcohol reward processing and IV alcohol self-administration).","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 60 Years   (Adult)","Phase 1","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","160037|16-AA-0037","June 8, 2016","December 31, 2020","December 31, 2021","December 24, 2015",,"July 8, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02639273"
369,"NCT01237353","Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers",,"Completed","Has Results","Pharmacodynamic","Dietary Supplement: betaine hydrochloride|Drug: Rabeprazole","Change in Gastric pH After Administration of Betaine Hydrochloride (HCl)|Duration of Gastric pH Status","University of California, San Francisco","All","18 Years to 59 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GastricpH-6264","March 2011","July 2011","July 2011","November 9, 2010","July 2, 2013","July 2, 2013","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01237353"
370,"NCT03294460","Nicotinic Receptor Genetic Variation and Alcohol Reward",,"Recruiting","No Results Available","Alcohol Drinking","Drug: Alcohol (Oral)|Drug: Alcohol (IV)|Drug: Alcohol (Ethanol)","To examine the effect of CHRNA5 (rs16969968) genetic variation on neural correlates of incentive salience for alcohol, as measured by BOLD response during the Alcohol-Food Incentive Delay (AFID) task using fMRI.|To examine the effect of CHRNA5 (rs16969968) genetic variation on IV alcohol self-administration, as measured by BrAC exposure (peak BrAC, number of infusions, time to binge-level) in non-smoking, non-dependent drinkers.|To examine the effect of CHRNA5 (rs16969968) genetic variation on resting-state functional connectivity (rsFC) among brain regions associated with the salience network, including dorsal anterior cingulate cortex, ventral striatum and extended am...|To examine the effect of CHRNA5 (rs16969968) genetic variation on the rate of IV alcohol self-administration, as measured by the preferred rate during the second IV-ASA session in non-smoking, non-dependent drinkers.|To examine the relationship between fMRI measures (BOLD response during AFID and rsFC measures) and IV alcohol self-administration, and any differences in the degree of association among these measures by CHRNA5 genotype.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 60 Years   (Adult)","Phase 1","128","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170171|17-AA-0171","June 10, 2019","December 31, 2023","December 31, 2023","September 27, 2017",,"June 5, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03294460"
371,"NCT01087281","Top-Down Attentional Control of Visual-Processing",,"Recruiting","No Results Available","Focal Brain Lesion|Focal Lesions|fMRI",,"MRI signal across the whole brain during the MRI scans|To determine the differential top-down contributions of prefrontal and parietal regions in processes selective and sustain attention, filtering of distracter information, orienting of attention, and attention engagement and disengagement.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"132","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","100047|10-M-0047","July 23, 2012",,,"March 16, 2010",,"June 18, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087281"
372,"NCT02711189","Oxytocin in Alcohol Use Disorder",,"Withdrawn","No Results Available","Alcoholism","Drug: Oxytocin|Other: Placebo","Alcohol Craving, Self-Administration|Stimulation Sedation; Cognitive Performance|BOLD response cognitive tasks and cues","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","Male","21 Years to 55 Years   (Adult)","Phase 1","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","160082|16-AA-0082","March 8, 2016","February 22, 2019","February 22, 2019","March 17, 2016",,"April 11, 2019",,,"https://ClinicalTrials.gov/show/NCT02711189"
373,"NCT02471339","Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain",,"Active, not recruiting","No Results Available","Neurofibromatosis Type 1|Plexiform Neurofibromas","Behavioral: Acceptance and Commitment Therapy (ACT)","Feasibility|Quality of life|Variability|Pattern of change|Examine mediators|Reliability and Validity","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","16 Years to 59 Years   (Child, Adult)","Phase 3","67","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","150142|15-C-0142","July 7, 2015","April 30, 2021","April 30, 2021","June 15, 2015",,"July 2, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02471339"
374,"NCT04055207","VA Video Connect in HIV Care",,"Not yet recruiting","No Results Available","HIV","Other: VVC","Constancy retention in care measure|Adherence retention in care measure|Completed visits for adherence counseling|HIV suppression|Adherence to ART medications","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","390","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IIR 18-077|I01HX002645","July 1, 2020","September 30, 2023","December 31, 2023","August 13, 2019",,"June 11, 2020","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04055207"
375,"NCT02669225","Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People",,"Completed","No Results Available","Normal Physiology","Other: [18F]florbetaben","(1) To assess if there are differences in [18F] florbetaben binding(reflecting A load) in subjects after SD compared to RW when measured in the morning.|(2) To assess if there are differences in brain A accumulation during RW and SD and to assess if there are differences in brain Aclearance (comparisons of RW versus SD) between young and older participants.|This is an exploratory aim to assess if there are differences in brain function and neurochemistry between RW and SD using MRI and1H-MRS and determine if the variability on the effects of SD is related to differences in brain glymphatic funct...","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","160059|16-AA-0059","May 2, 2016","January 24, 2017","July 11, 2018","February 1, 2016",,"June 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02669225"
376,"NCT02270671","Attention Bias Modification Training for Young People",,"Completed","Has Results","Anxiety|Depression","Behavioral: ABMT|Other: Placebo","Threat Bias Measurement at 4-week Post-intervention and 12-week Follow-up|Social Phobia and Anxiety at 4-week Post-intervention and 12-week Follow-up|Fear of Negative Evaluation at 4-week Post-Intervention and 12-week Follow-Up|Anxiety Related Disorders at 4-week Post-intervention and 12-week Follow-up|Depression Symptoms at 4-week Post-intervention and 12-week Follow-up","University College Dublin|Tel Aviv University","All","15 Years to 18 Years   (Child, Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HS-14-49-Fitzgerald","October 2014","May 2015","May 2015","October 21, 2014","November 20, 2018","November 20, 2018",,,"https://ClinicalTrials.gov/show/NCT02270671"
377,"NCT01086670","Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy|Children|Adolescents","Other: Physical Exercise","Coordination as measured by fast cadence during device and walking|3D Motion Capture of walking, cycling and elliptical, Surface electromyography, Selective Control Assessment of Lower Extremities, Physical examination, Muscle Ultrasound. strength and spasticity, Questionnaires, Magnetic Resonance Imaging","National Institutes of Health Clinical Center (CC)","All","5 Years to 17 Years   (Child)","Phase 1|Phase 2","55","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100073|10-CC-0073","March 30, 2010","January 12, 2015","May 9, 2016","March 15, 2010",,"July 2, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01086670"
378,"NCT03181763","""Evaluation of MDMA on Startle Response",,"Recruiting","No Results Available","Startle Response","Drug: Placebo|Drug: MDMA|Behavioral: Acoustic startle","EMG of right orbicularis oculi muscle|Systolic blood pressure pre-drug|Systolic blood pressure 45 min post-drug|Systolic blood pressure 1 h 15 min post-drug|Systolic blood pressure 1 h 45 min post-drug|Systolic blood pressure 3 h post-drug|Systolic blood pressure 4 h post-drug|Systolic blood pressure 5 h post-drug|Systolic blood pressure 6 h post-drug|Diastolic blood pressure pre-drug|Diastolic blood pressure 45 min post-drug|Diastolic blood pressure 1 h 15 min post-drug|Diastolic blood pressure 1 h 45 min post-drug|Diastolic blood pressure 3 h post-drug|Diastolic blood pressure 4 hours post-drug|Diastolic blood pressure 5 hours post-drug|Diastolic blood pressure 6 hours post-drug|Pulse pre-drug|Pulse 45 min post-drug|Pulse 1 h 15 min post-drug|Pulse 1 h 45 min post-drug|Pulse 3 h post-drug|Pulse 4 h post-drug|Pulse 5 h post-drug|Pulse 6 h post-drug|Body temperature pre-drug|Body temperature 45 minutes post-drug|Body temperature 1 h 15 minutes post-drug|Body temperature 1 h 45 minutes post-drug|Body temperature 3 hours post-drug|Body temperature 4 hours post-drug|Body temperature 5 hours post-drug|Body temperature 6 hours post-drug|Plasma oxytocin (OT) levels predrug|Plasma oxytocin (OT) levels 5 min post-drug|Plasma oxytocin (OT) levels 20 min post-drug|Plasma oxytocin (OT) levels 95 min post-drug|Plasma oxytocin (OT) levels 110 min post-drug|Plasma oxytocin (OT) levels 185 min post-drug|Plasma oxytocin (OT) levels 200 min post-drug|Plasma oxytocin (OT) levels 240 min post-drug|Plasma oxytocin (OT) levels 300 min post-drug","Multidisciplinary Association for Psychedelic Studies","All","21 Years to 55 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","MPVA-4","September 21, 2017","July 10, 2020","July 10, 2020","June 9, 2017",,"February 19, 2020","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03181763"
379,"NCT01721304","Decisionmaking for Abnormal Uterine Bleeding (AUB)",,"Completed","No Results Available","Abnormal Uterine Bleeding","Other: Adaptive Conjoint Analysis","Differences in patient-reported satisfaction between treatment groups|Differences in decision regret between treatment groups","Indiana University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1009001853 (0904-66B)","May 2009","August 2012","August 2012","November 4, 2012",,"April 22, 2015","Indiana University, Indianapolis, Indiana, United States|Southern Pines Women's Health Center, Southern Pines, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01721304"
380,"NCT04139980","Virtual Reality Device for Rehabilitation of Stroke Patients",,"Suspended","No Results Available","Stroke","Device: Virtual Reality (VR)","Change in Upper-limb and hand motor function|Change in upper-limb and hand motor function|Change in cognitive function|Change in activities of daily living (ADL) and quality of life|Change in depression","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB-300003889","January 1, 2020","December 2022","December 2022","October 25, 2019",,"June 4, 2020","UAB Spain Rehabilitation Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04139980"
381,"NCT03588845","The Small Intestine Bacterial Overgrowth Study Pilot","SIBO","Recruiting","No Results Available","Systemic Sclerosis|Small Intestinal Bacterial Overgrowth","Other: Treatment Protocol|Other: Standard of Care","Determine if protocol treatment is effective","Canadian Scleroderma Research Group|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","CODIM-MBM-16-282","February 15, 2019","April 1, 2021","September 1, 2021","July 17, 2018",,"October 17, 2019","John's Hopkins, Baltimore, Maryland, United States|Saint Vincent's, Melbourne, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03588845/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03588845"
382,"NCT01924468","Brain Networks and Addiction Susceptibility",,"Completed","No Results Available","Nicotine Dependence","Drug: Oral methylphenidate and Oral haloperidol","The impact of rs16969968 genotype on the BOLD fMRI signal and functional connectivity (FC) within and between the three networks of interests (SN, ECN, DMN) at rest and during task performance.","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","76","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Prevention","999913483|13-DA-N483","August 14, 2013","September 5, 2018","May 14, 2019","August 16, 2013",,"May 16, 2019","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01924468"
383,"NCT03519919","Somofilcon A 1-Day Multifocal Study - Real World Subjective Acceptance Study",,"Completed","Has Results","Presbyopia","Device: somofilcon A multifocal lens","Vision Clarity During the Day - Distance Vision|Number of Participants With Lens Centration|Visual Acuity|Post-blink Lens Movement|Corneal Staining|Conjunctival Staining|Bulbar Hyperemia|Subjective Vision Satisfaction - Driving at Night|Subjective Vision Satisfaction - Long Intermediate Vision|Subjective Vision Satisfaction - Short Intermediate Tasks|Subjective Vision Satisfaction - Near Vision|Ease of Insertion|Ease of Removal|Overall Satisfaction With Speed of Changing Focus|Overall Satisfaction Preference Between Study and Habitual Contact Lenses|Overall Comfort|Overall Preference Between Study and Habitual Contact Lenses for Lifestyle","Coopervision, Inc.","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","51","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EX-MKTG-81","August 21, 2017","September 22, 2018","February 15, 2019","May 9, 2018","December 10, 2019","December 19, 2019","Center for Contact Lens Research, University of Waterloo, Waterloo, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03519919/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03519919"
384,"NCT01603862","ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)","ThinkingFit","Completed","No Results Available","Mild Cognitive Impairment","Procedure: ThinkingFit programme","Activity Compliance|Cardiovascular fitness measure|Cognitive measures|Measures of quality of life and everyday activities","Dr Thomas Dannhauser|University College, London|North Essex Partnership NHS Foundation Trust","All","40 Years and older   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ThinkingFit 1","January 2010","November 2012","November 2012","May 23, 2012",,"April 28, 2014","North Essex Partnership Foundation NHS Trust, Harlow, Essex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01603862"
385,"NCT01418040","PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)","PROCITT","Completed","No Results Available","Prostate Cancer",,"Prediction of ADT induced bone mineral density loss|Feasibility, toxicity and efficacy of multimodality therapy with hypofractionated radiotherapy|To correlate marrow changes on MR with changes in blood counts and patient reported fatigue|Prognostic value of circulating tumour cells|Implementation of a risk adapted duration of neoadjuvant hormonal therapy|Implementation of a nomogram based radiotherapy target delineation algorithm","Calvary Mater Newcastle, Australia|Abbott","Male","Child, Adult, Older Adult",,"28","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IIS MET-10-0030","November 28, 2012","July 20, 2017","July 20, 2017","August 16, 2011",,"February 5, 2018","Calvary Mater Newcastle, Waratah, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01418040"
386,"NCT02355912","Adaptive Recalibration of Prosthetic Leg Neural Control System",,"Recruiting","No Results Available","Amputation","Device: Powered knee and ankle prosthesis","Decreased error rates for pattern recognition system used to predict ambulation modes","Shirley Ryan AbilityLab","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STU00101767","January 2015","January 2020","January 2021","February 4, 2015",,"May 20, 2019","Rehabilitation Institute of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02355912"
387,"NCT00059189","Brain Plasticity of Verbal Memory in the Blind",,"Completed","No Results Available","Blindness","Device: Magstim Rapid Magnetic Stimulator",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"85","NIH","Observational",,"030163|03-N-0163","April 2003",,"April 2005","April 21, 2003",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00059189"
388,"NCT00179322","Effects of Sleep Deprivation and Recovery on Cognitive Functions",,"Completed","No Results Available","Sleep Deprivation",,,"National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC)","All","20 Years to 40 Years   (Adult)",,"29","NIH","Observational",,"050238|05-DC-0238","September 10, 2005",,"September 30, 2016","September 15, 2005",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00179322"
389,"NCT02550379","Emotion Recognition Training for Young People",,"Completed","No Results Available","Anxiety|Depression","Behavioral: Intervention|Other: Placebo","Change from baseline in social anxiety at post-intervention|Change from baseline in social anxiety at 2-week follow-up|Change from baseline in emotion sensitivity measurement at post-intervention and 2-week follow-up|Change from baseline in fear of negative evaluation at post-intervention and 2-week follow-up|Change from baseline in anxiety related disorders at post-intervention and 2-week follow-up|Change from baseline in depression symptoms at post-intervention and 2-week follow-up","University College Dublin|University of Bristol","All","15 Years to 18 Years   (Child, Adult)","Not Applicable","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HS-15-41-Fitzgerald","September 2015","March 2016","March 2016","September 15, 2015",,"November 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02550379"
390,"NCT01779024","Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers",,"Completed","Has Results","fMRI|Alcohol Drinking|Alcoholism","Drug: Ghrelin|Drug: Placebo|Procedure: fMRI|Drug: Alcohol","Alcohol Infusions Self-administered","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 60 Years   (Adult)","Phase 2","17","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","130043|13-AA-0043","December 13, 2012","June 1, 2017","June 1, 2017","January 29, 2013","August 3, 2018","August 3, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01779024/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01779024"
391,"NCT01087346","Parents Thoughts About Kids and Eating",,"Completed","No Results Available","Overweight","Behavioral: Reading Information","The number of calories selected for participant's index child in a virtual buffet food selection task","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1148","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","100076|10-HG-0076","November 19, 2010","July 12, 2019","July 12, 2019","March 16, 2010",,"June 16, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087346"
392,"NCT04323254","Language of Sleepiness",,"Not yet recruiting","No Results Available","Sleep|Sleep Disorder|Sleepiness",,"Language of Sleepiness Questionniare|Work Productivity Impairement Questionnaire|San Diego Wisdom Scale (SD-WISE)|Functional Outcomes of Sleep Questionnaire|Beck Depression Index II","University of California, San Diego|Jazz Pharmaceuticals","All","18 Years to 89 Years   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","190489","March 23, 2020","March 23, 2021","March 23, 2021","March 26, 2020",,"March 26, 2020","UCSD Health - Pulmonary and Sleep Clinic, La Jolla, California, United States|Altman Clinical and Translational Research Institute, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04323254"
393,"NCT01473238","Desktop Versus Mobile Data Collection in Clinical Trial",,"Unknown status","No Results Available","User Experience","Other: Evaluation form","Evaluation score|Recruitment rate|Cost-effectiveness analysis|Cost-benefit analysis|Cost-utility analysis","University of Zurich","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PSP_Appendix_2","January 2014","June 2014","August 2014","November 17, 2011",,"August 23, 2013","University of St. Gallen, Institute of Information Managemen, St. Gallen, Switzerland|University Hospital Zurich, Department of Surgery, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01473238"
394,"NCT00060593","MRI Study of Self-Perception of Postural Stability",,"Completed","No Results Available","Healthy|Postural Stability",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"40","NIH","Observational",,"030183|03-N-0183","May 2003",,"May 2005","May 8, 2003",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00060593"
395,"NCT00757497","Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia",,"Terminated","No Results Available","Childhood Onset Psychotic Disorders|Schizophrenia|Psychosis|Mental Disorders","Behavioral: Electrical Polarization","TDCS treatment is safe in childhood onset schizophrenia|Improvement in cognition and psychosis","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1","20","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","080211|08-M-0211","September 17, 2008",,"August 18, 2015","September 23, 2008",,"December 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00757497"
396,"NCT01139541","Testing Strategies for Increasing Exercise",,"Completed","No Results Available","Sedentary Lifestyle|Obesity","Behavioral: Social walking intervention","WalkStation usage|Creativity|Focus|Health Behaviors Survey|WalkStation Usage","Harvard University|Blue Cross Blue Shield","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","224","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WalkStation1","June 2010","January 2011","January 2011","June 8, 2010",,"August 19, 2015","Blue Cross Blue Shield Massachusetts, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01139541"
397,"NCT01373372","Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia",,"Withdrawn","No Results Available","Functional Dyspepsia","Drug: Acthrel","Heart rate variability|Stress profile|plasma protein levels|BASC 2 profile|STICSA-C|GI symptom severity scale","Children's Mercy Hospital Kansas City","All","8 Years to 17 Years   (Child)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11 05-069","December 2016","December 2016","March 2017","June 15, 2011",,"May 16, 2019","Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01373372"
398,"NCT00051870","Brain Encoding for Memory",,"Completed","No Results Available","Healthy","Device: Magstim Rapid Magnetic Stimulator",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"50","NIH","Observational",,"030081|03-N-0081","January 2003",,"January 2005","January 17, 2003",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00051870"
399,"NCT00695500","Varenicline to Reduce Alcohol Consumption in Heavy Drinkers",,"Completed","Has Results","Alcohol Drinking","Drug: Varenicline|Drug: Placebo","Alcohol Consumption|Alcohol Urges","Vijay Ramchandani, Ph.D.|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 60 Years   (Adult)","Phase 1|Phase 2","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","080137|08-AA-0137","June 2008","July 2014","June 2015","June 12, 2008","August 15, 2016","August 15, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00695500"
400,"NCT00989105","Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer",,"Terminated","No Results Available","Prostate Cancer","Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: computed tomography|Procedure: magnetic resonance imaging|Procedure: single photon emission computed tomography|Radiation: technetium Tc 99m demobesin-4","Causality of each adverse events as assessed by NCI CTCAE v. 3.0|Biodistribution of radioactivity of 99mTc DB4 by gamma-camera imaging|Pharmacokinetics of 99mTc DB4 in blood and urine and assessment of decline over 6 hours|Performance of 99mTc DB4 gamma-camera imaging compared with conventional imaging (CT scan and/or MRI)|Levels of expression in gastrin-releasing peptide in prostate tumor samples and lymph node specimens","Cancer Research UK","Male","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Diagnostic","CDR0000650867|UKM-ICRF-CR0402-11|CRUK-CR0402-11|EUDRACT-2007-005324-32|EU-20981","June 2009","December 2011","December 2011","October 2, 2009",,"February 28, 2012","Saint Bartholomew's Hospital, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00989105"
401,"NCT03010254","A Clinical Study of the ACRYSOF® IQ EDF Intraocular Lens (IOL)",,"Completed","Has Results","Cataract","Device: ACRYSOF® IQ Extended Depth of Focus IOL|Device: ACRYSOF® IQ Monofocal IOL|Procedure: Cataract surgery","Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeters (cm)|Percentage of Subjects With Ocular Adverse Events|Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) at 4 Meters (m)|Monocular Photopic Distance Corrected Near Visual Acuity (DCNVA) at 40 cm|Monocular Photopic Distance Corrected Depth of Focus Assessed by the Mean Defocus Curve|Monocular Mesopic Contrast Sensitivity at 12 Cycles Per Degree (Cpd)|Percentage of Subjects Who Respond ""Never"" to Question 1 of the Spectacle Use Questionnaire: ""How Often Do You Wear Eyeglasses for Any Purpose?""|Percentage of Subjects Who Respond ""Never"" to Question 3 of the Spectacle Use Questionnaire: ""How Often Do You Wear Eyeglasses for Intermediate Tasks (e.g., Computer)?""","Alcon Research","All","22 Years and older   (Adult, Older Adult)","Not Applicable","322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ILI875-C001","March 21, 2017","August 17, 2018","October 31, 2018","January 5, 2017","March 26, 2020","April 7, 2020","Alcon Investigative Site, Sydney, New South Wales, Australia|Alcon Investigative Site, Southport, Queensland, Australia|Alcon Investigative Site, Footscray, Victoria, Australia|Alcon Investigative Site, Hawthorn East, Victoria, Australia|Alcon Investigative Site, Vancouver, British Columbia, Canada|Alcon Investigative Site, Mississauga, Ontario, Canada|Alcon Investigative Site, Toronto, Ontario, Canada|Alcon Investigative Site, Toronto, Ontario, Canada|Alcon Investigative Site, Boisbriand, QU, Canada|Alcon Investigative Site, Québec, QU, Canada|Alcon Investigative Site, Sant Cugat del Vallès, BCN, Spain|Alcon Investigative Site, Jerez De La Frontera, Cadiz, Spain|Alcon Investigative Site, Barcelona, Spain|Alcon Investigative Site, Barcelona, Spain|Alcon Investigative Site, Barcelona, Spain|Alcon Investigative Site, Madrid, Spain|Alcon Investigative Site, Valencia, Spain|Alcon Investigative Site, Dartford, Kent, United Kingdom|Alcon Investigative Site, Essex, United Kingdom|Alcon Investigative Site, London, United Kingdom|Alcon Investigative Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03010254/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03010254/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03010254"
402,"NCT03077945","A Cognitive Behavioral Stress Intervention for Women Who Smoke",,"Completed","No Results Available","Smoking, Cigarette|Smoking Cessation|Stress|Stress, Emotional|Stress Reaction","Behavioral: heart rate variability biofeedback and cognitive reappraisal|Behavioral: control tasks","Change in cigarette craving|Change in heart rate variability|Performance on a stress task|Changes in smoking behavior at follow-up","Rutgers, The State University of New Jersey|Nepalese Psychological Association|New Jersey Psychological Association","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","16-782M","December 1, 2016","May 30, 2017","May 30, 2017","March 13, 2017",,"March 14, 2018","Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03077945"
403,"NCT00059137","Breathing Cycle Biofeedback During Computed Tomography Procedures",,"Completed","No Results Available","Needle Biopsy|CAT Scan|X-Ray",,,"National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"30","NIH","Observational",,"030166|03-CC-0166","April 2003",,"March 2006","April 18, 2003",,"March 4, 2008","National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00059137"
404,"NCT00396890","Enhancing Brain Activity With Magnetic Stimulation",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"72","NIH","Observational",,"070022|07-N-0022","November 3, 2006",,"December 15, 2008","November 8, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00396890"
405,"NCT03927846","Implementation of Nurse-guided Web-based Cognitive Behavioral Therapy for Pain Management",,"Active, not recruiting","No Results Available","Chronic Musculoskeletal Pain","Behavioral: Nurse-guided Web-based Cognitive Behavioral Therapy","PROMIS (patient reported-outcomes measurement information system) pain intensity|PROMIS pain interference|Completed phone calls|Completed learning modules per treatment arm","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00056912","July 17, 2019","December 2020","February 2021","April 25, 2019",,"April 28, 2020","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03927846"
406,"NCT00069225","Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder",,"Completed","No Results Available","Stress Disorders, Post-Traumatic",,,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"95","NIH","Observational",,"030297|03-M-0297","September 2003",,"September 2005","September 18, 2003",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00069225"
407,"NCT01271023","Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System","CTR","Completed","No Results Available","Type 1 Diabetes","Device: Control-to-Range Automated Insulin Management System","Percent of glucose values 71-180 mg/dL of combined day and night readings during the first admission visit|Percent of subjects with blood glucose reading of 71-180 mg/dL 4 hours following the breakfast with a missed meal bolus|Percent of subjects with blood glucose reading of 71-180 mg/dL 5 hours following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of subjects with a blood glucose nadir <=60 mg/dL following exercise|Overall frequency of hypoglycemia|Overall frequency of hyperglycemia|Percent of blood glucose values 71-180 mg/dL during the day (9:00AM-11:00PM) of the first admission visit|Percent of blood glucose values 70-180 mg/dL during the night (11:00PM-8:00AM) of the first admission visit|Percent of blood glucose values >400 mg/dL during the first admission visit|Percent of blood glucose values <=60 mg/dL during the first admission visit|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a missed meal bolus|Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount|Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount","Jaeb Center for Health Research","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","57","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTR","March 2011","August 2012","August 2012","January 6, 2011",,"September 9, 2016","Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|University of Colorado Health Sciences Center- Barbara Davis, Aurora, Colorado, United States|University of Virginia, Charlottesville, Virginia, United States|Montpellier University Hospital, Montpellier, France|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|University of Padova, Padova, Italy",,"https://ClinicalTrials.gov/show/NCT01271023"
408,"NCT02427100","Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults",,"Completed","Has Results","Dietary Modification|Physical Activity","Behavioral: Diet/Physical Activity","Automated Self-Administered 24-Hour Dietary Recall: Fruit/Vegetable, Cups|Accelerometer-Measured Physical Activity: Moderate to Vigorous Intensity Physical Activity","University of Texas Southwestern Medical Center|The University of Texas Health Science Center, Houston|American Cancer Society, Inc.|Simmons Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STU 062014-031","April 2015","September 2015","September 2015","April 27, 2015","May 6, 2019","May 6, 2019",,,"https://ClinicalTrials.gov/show/NCT02427100"
409,"NCT00766272","Lokomat Training Effects on MS Gait Abnormalities",,"Terminated","No Results Available","Multiple Sclerosis","Device: Lokomat","Frequency of Falls","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","LO-0003","June 2008","June 2008","June 2008","October 3, 2008",,"September 23, 2013","Providence VA Medical Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00766272"
410,"NCT00077038","Brain Activity in Visual-Motor Behavior",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","20 Years and older   (Adult, Older Adult)",,"20","NIH","Observational",,"040117|04-N-0117","February 6, 2004",,"March 31, 2007","February 10, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00077038"
411,"NCT02395874","tDCS and Speech Therapy to Improve Aphasia","MP-LOGA","Unknown status","No Results Available","Aphasia, Global|Stroke|Transcranial Direct Current Stimulation|Speech Therapy","Procedure: tDCS + speech therapy","Goodglass-Kaplan communication scale (GKS, 0-5)|Aphasia Check-list (ACL, 0-148)|Aphasic depression rating scale (ADRS, 0-32)|Alterskonzentrationstest (AKT, 0-35)|Barthel-Index (BI,0-100)|Rivermead Motor Assessment - Arm (RMA, 0-15)","Medical Park AG","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MP-LOGA","May 2015","April 2018","October 2018","March 24, 2015",,"September 13, 2016","Medical Park Berlin Humboldtmuehle, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02395874"
412,"NCT02151396","Effect of Working Memory Training on ADHD Brain Function",,"Completed","No Results Available","Attention-Deficit/Hyperactivity Disorder (Combined-subtype)","Behavioral: Working memory training|Device: Functional magnetic resonance imaging (fMRI)","Functional magnetic resonance imaging (fMRI)|Working memory neuropsychological test performance|ADHD clinical dysfunction","Hartford Hospital|National Institutes of Health (NIH)","All","13 Years to 17 Years   (Child)","Phase 3","37","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R21HD061915","July 2009","February 2013","February 2013","May 30, 2014",,"May 30, 2014","Olin Neurospychiatry Research Center, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02151396"
413,"NCT00102570","Clinical and Immunological Evaluation of Children With Allergies",,"Completed","No Results Available","Hypersensitivity, Immediate",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","3 Months to 19 Years   (Child, Adult)",,"270","NIH","Observational",,"050084|05-I-0084","January 26, 2005",,"August 10, 2010","January 31, 2005",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00102570"
414,"NCT01443156","The Effects of Work Schedule and Sleep Patterns on Caregivers' Health",,"Completed","No Results Available","Obesity|Diabetes|Cancer|Metabolic Syndrome|Sleep Deprivation",,"Cognitive performance|Body Composition|Diet|Work Schedule|Blood Pressure|Blood cholesterol, glucose, triglycerides|Breast, skin, and lung cancer prevention behaviors and knowledge|Preventive care habits","Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)",,"211","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OHSU eIRB7542","January 2012","February 2013",,"September 29, 2011",,"February 18, 2013","St. Charles Medical Center, Bend, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01443156"
415,"NCT01785667","Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark","DCPD1987","Completed","No Results Available","Type 1 Diabetes|Diabetic Retinopathy",,"Incidence of diabetic retinopathy and proliferative diabetic retinopathy|Vessel diameters as a predictor of diabetic retinopathy and proliferative diabetic retinopathy","Odense University Hospital|Center for Eye Research Australia|Moorfields Eye Hospital NHS Foundation Trust","All","25 Years to 45 Years   (Adult)",,"132","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S-20100088","January 2011","November 2011","February 2013","February 7, 2013",,"July 30, 2014","Department of Ophthalmology, Odense University Hospital, Odense, Fyn, Denmark",,"https://ClinicalTrials.gov/show/NCT01785667"
416,"NCT02137512","Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use","CTR3","Completed","Has Results","Type 1 Diabetes","Device: Closed-Loop Control System|Device: Sensor-Augmented Pump (SAP)","Time Spent <70 mg/dL - Main Phase, Night Only|Time Spent <70 mg/dL - Main Phase, Day and Night|Time Spent <70 mg/dL - Main Phase, Day Only|Time in Range 70-180 mg/dL - Main Phase, Day and Night|Time in Range 70-180 mg/dL - Main Phase, Night Only|Time in Range 70-180 mg/dL - Main Phase, Day Only|Mean Sensor Glucose - Main Phase, Day and Night|Mean Sensor Glucose - Main Phase, Night Only|Mean Sensor Glucose - Main Phase, Day Only|Glucose Coefficient of Variation - Main Phase, Day and Night|Glucose Coefficient of Variation - Main Phase, Night Only|Glucose Coefficient of Variation - Main Phase, Day Only|Glucose Standard Deviation - Main Phase, Day and Night|Glucose Standard Deviation - Main Phase, Night Only|Glucose Standard Deviation - Main Phase, Day Only|Time Spent >180 mg/dL - Main Phase, Day and Night|Time Spent >180 mg/dL - Main Phase, Night Only|Time Spent >180 mg/dL - Main Phase, Day Only|Time Spent <50 mg/dL - Main Phase, Day and Night|Time Spent <50 mg/dL - Main Phase, Night Only|Time Spent <50 mg/dL - Main Phase, Day Only|Time Spent <60 mg/dL - Main Phase, Day and Night|Time Spent <60 mg/dL - Main Phase, Night Only|Time Spent <60 mg/dL - Main Phase, Day Only|LBGI - Main Phase, Day and Night|LBGI - Main Phase, Night Only|LBGI - Main Phase, Day Only|AOC 70 mg/dL - Main Phase, Day and Night|AOC 70 mg/dL - Main Phase, Night Only|AOC 70 mg/dL - Main Phase, Day Only|HBGI - Main Phase, Day and Night|HBGI - Main Phase, Night Only|HBGI - Main Phase, Day Only|ADRR - Main Phase, Day and Night|AUC 180 mg/dL - Main Phase, Day and Night|AUC 180 mg/dL - Main Phase, Night Only|AUC 180 mg/dL - Main Phase, Day Only|Time Spent >250 mg/dL - Main Phase, Day and Night|Time Spent >250 mg/dL - Main Phase, Night Only|Time Spent >250 mg/dL - Main Phase, Day Only|Time Spent >300 mg/dL - Main Phase, Day and Night|Time Spent >300 mg/dL - Main Phase, Night Only|Time Spent >300 mg/dL - Main Phase, Day Only","Jaeb Center for Health Research","All","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pilot 3 Outpatient CTR","August 2014","November 2015","November 2015","May 13, 2014","October 19, 2016","October 29, 2018","Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|University of Virginia, Charlottesville, Virginia, United States|Montpellier University Hospital, Montpellier, France|National Center for Childhood Diabetes- Schneider Children's Medical Center, Petah Tikva, Israel|University of Padova, Padova, Italy",,"https://ClinicalTrials.gov/show/NCT02137512"
417,"NCT03326934","Impact of Dark Chocolate on Visual Performance",,"Completed","No Results Available","Dietary Supplementation","Dietary Supplement: Dark chocolate|Dietary Supplement: Milk Chocolate","Visual acuity, contrast sensitivity and color vision.|Effects of distraction on visual performance during simulated hands-free phone calls.|Visual-electrodiagnostic testing.|Simulated marksmanship.","University of the Incarnate Word","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","17-06-002","June 25, 2017","August 30, 2018","August 30, 2018","October 31, 2017",,"April 18, 2019","University of the Incarnate Word Rosenberg School of Optometry, San Antonio, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03326934/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03326934/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03326934"
418,"NCT00663013","Virtual Reality for Burn Wound Care Pain Control",,"Unknown status","No Results Available","Pain|Anxiety","Other: Virtual Reality","pain perception|anticipatory anxiety|current psychiatric diagnosis, is related to pain|""pain catastrophizing"" is related to higher pain perception and greater benefits from the VR","Weill Medical College of Cornell University","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0701008961","October 2007","May 2010","May 2010","April 21, 2008",,"January 4, 2011","New York Presbyterian Hospital, WRH Burn Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00663013"
419,"NCT03447548","Neurofeedback Training for High Risk Psychosis",,"Recruiting","No Results Available","Prodromal Schizophrenia","Behavioral: Neurofeedback processing speed training|Behavioral: Active control","Change on the Wechsler Intelligence Scale Processing Speed Index","Hartford Hospital|National Institute of Mental Health (NIMH)","All","12 Years to 25 Years   (Child, Adult)","Not Applicable","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HHC-2017-0190|1R33MH111850-01A1","March 1, 2018","December 1, 2020","January 1, 2021","February 27, 2018",,"October 29, 2019","Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program, Hartford, Connecticut, United States|Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03447548"
420,"NCT01596959","The Contact-CTI Study: Use of Tissue Contact Data to Guide Atrial Flutter Ablation",,"Completed","No Results Available","Atrial Flutter","Procedure: Radiofrequency ablation utilising the ECI contact software|Procedure: Radiofrequency ablation without the use of ECI contact data","The primary outcome measure is the mean ablation time required to achieve the acute procedural endpoint of cavotricuspid isthmus conduction block","Oxford University Hospitals NHS Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","79426/244082/1/568|11/SC/0394","January 2012","April 2013","April 2013","May 11, 2012",,"October 13, 2017","John Radcliffe Hospital, Headington, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01596959"
421,"NCT01853930","Translation of Eye Movement Reading Training to Clinical Practice",,"Completed","Has Results","Macular Disease","Behavioral: Platform for Administering Eye-movement Control Training","Change in Reading Performance and Accuracy Using MNREAD.","VA Office of Research and Development","All","55 Years and older   (Adult, Older Adult)","Not Applicable","33","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","C0849-R","January 1, 2014","June 30, 2017","June 30, 2017","May 15, 2013","November 13, 2019","November 13, 2019","Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT01853930/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01853930"
422,"NCT04018092","The Revitalize Study",,"Not yet recruiting","No Results Available","Cognitive Aging|Alzheimer Disease, Protection Against","Device: Active NIR-PBM|Device: Sham NIR-PBM","Change in Active group ARENA scores compared to Sham group ARENA scores","University of Florida|University of Arizona|National Institute on Aging (NIA)","All","65 Years to 89 Years   (Older Adult)","Phase 2","168","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB201901780 -N|R01AG064587","August 2020","January 2025","January 2025","July 12, 2019",,"July 8, 2020","University of Arizona, Tucson, Arizona, United States|University of Florida McKnight Brain Institute, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04018092"
423,"NCT01796158","Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use",,"Withdrawn","No Results Available","Alcohol Abuse","Behavioral: cASBI+cMET|Behavioral: cASBI","cMET completion|cMET satisfaction","Boston Children’s Hospital","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JKR34_PA-13-078","September 2013","March 2016","March 2016","February 21, 2013",,"October 7, 2016","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01796158"
424,"NCT01442467","Study of Echocardiogram Accuracy in Patients With Mitral Valve Calcification",,"Terminated","No Results Available","Mitral Annulus Calcification",,"Agreement between invasive and non-invasive measures of LVEDP","Creighton University","All","19 Years and older   (Adult, Older Adult)",,"4","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","11-16085","June 2011","January 2013","January 2013","September 28, 2011",,"April 1, 2013","Creighton Unviversity Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01442467"
425,"NCT04429945","Immersive VR in Stroke Pilot Study",,"Not yet recruiting","No Results Available","Stroke","Device: Virtual Reality","Action Research Arm Test|Fugl-Meyer Assessment Upper Extremity|Pain Outcomes Questionnaire-VA:Intake|Pain Outcomes Questionnnaire-VA: Discharge","VA Office of Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N3449-P|I21 RX003449","January 1, 2021","October 31, 2022","October 31, 2022","June 12, 2020",,"June 17, 2020","James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04429945"
426,"NCT02458365","A Stage-Based Expert System for Teen Dating Violence Prevention",,"Completed","Has Results","Violence|Bullying","Behavioral: Teen Choices: A Program for Healthy Nonviolent Relationships|Behavioral: Health In Motion","Number of Participants Perpetrating Physical Dating Violence During Follow-up|Number of Participants Experiencing Physical Dating Violence During Follow-up|Number of Participants Perpetrating Emotional Dating Violence During Follow-up|Number of Participants Experiencing Emotional Dating Violence During Follow-up","Pro-Change Behavior Systems","All","Child, Adult, Older Adult","Phase 2","3901","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R44MH086129","September 2009","December 2010","December 2010","June 1, 2015","July 9, 2015","April 21, 2016",,,"https://ClinicalTrials.gov/show/NCT02458365"
427,"NCT01148056","Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer",,"Terminated","Has Results","Rectal Cancer","Radiation: Intensity Modulated Radiation Therapy","Bowel Quality of Life|Pelvic Control Rate|Surgical Complication Rate|Tissue Microarray|Quantity of Circulating Tumor Cells|Accuracy","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-157","March 2010","April 2014","April 2014","June 22, 2010","February 15, 2017","February 15, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01148056"
428,"NCT02355223","Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission","FAST","Unknown status","No Results Available","Tuberculosis","Other: FAST","Reduction of time to TB diagnosis and treatment for patients and TB infection rates in health care workers.|Sensitivity and specificity of a novel exhaled breath test (EBT) and digital chest X-ray with computer assisted detection (dCXR/CAD4TB) as ""rule-out"" screening tests for tuberculosis in coughing patients|Costs and cost-effectiveness of FAST|Acceptability of FAST, novel screening strategies, and health care worker testing for latent tuberculosis.","Brigham and Women's Hospital|Hospital Nacional Hipólito Unanue|Socios En Salud Sucursal, Peru|Hospital Nacional Arzobispo Loayza|Hospital Nacional Sergio Bernales","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11060","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2014P002396","August 2016","February 2020","February 2020","February 4, 2015",,"January 12, 2018","Hospital Nacional Hipolito Unanue, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT02355223"
429,"NCT01248390","""Interactive Metronome Technology for Blast-Related Traumatic Brain Injury""",,"Completed","No Results Available","Traumatic Brain Injury|Post-Concussion Syndrome","Behavioral: Interactive metronome","Outcome Measure","The Defense and Veterans Brain Injury Center","All","18 Years to 55 Years   (Adult)","Not Applicable","48","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","A-14853.22","August 2010","May 2014","October 3, 2016","November 25, 2010",,"June 20, 2017","Warrior Recovery Center, Colorado Springs, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01248390"
430,"NCT02181114","Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant",,"Completed","No Results Available","End Stage Renal Disease","Behavioral: Expert System Coaching","Patient LDKT Attitude & Decision-Making Measure: Readiness|Patient LDKT Attitude & Decision Making Measure: Decisional Balance|Patient LDKT Attitude & Decision Making Measure: Self-efficacy|Patient LDKT Attitude & Decision Making Measure: Small Steps towards LDKT and DDKT|Patient LDKT Attitude & Decision Making Measure: Transplant Knowledge|Final Outcome: Pursuit of Transplant","University of California, Los Angeles|University of Rhode Island","All","18 Years and older   (Adult, Older Adult)","Not Applicable","815","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DK088711-1","May 2014","December 2017","December 2017","July 3, 2014",,"May 1, 2018","UCLA Division of Nephrology, Los Angeles, California, United States|University of Rhode Island, Kingston, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02181114"
431,"NCT01993316","Neurofeedback Using TMS as an Assessment Tool",,"Unknown status","No Results Available","Brain Diseases","Device: Mitsar 201 neurofeedback","EEG","Beersheva Mental Health Center","All","22 Years to 28 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","neurofeedbackTMS1","December 2013","December 2014","December 2014","November 25, 2013",,"November 25, 2013","Beersheva Mental Health Center, Beersheva, Israel",,"https://ClinicalTrials.gov/show/NCT01993316"
432,"NCT01094132","Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection","MDC_Algo","Completed","No Results Available","Cervical Cancer|Precancerous Condition","Device: Multispectral Digital Colposcope (MDC)","Detection of cancer or pre-cancerous abnormalities of the cervix by multispectral digital colposcope.","British Columbia Cancer Agency|National Cancer Institute (NCI)|Texas Tech University Health Sciences Center|Brookdale University Hospital Medical Center|William Marsh Rice University|The University of Texas Health Science Center, Houston|M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","551","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BCCR-H09-03303|P01CA082710|H09-03303","December 2012","September 1, 2016","November 9, 2016","March 26, 2010",,"July 5, 2019","Brookdale Hospital and Medical Center, Brooklyn, New York, United States|Texas Tech Health Sciences Center, El Paso, Texas, United States|Vancouver General Hospital - Women's Clinic (G&L Diamond Centre), Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01094132"
433,"NCT03397836","Health TAPESTRY Ontario",,"Recruiting","No Results Available","Aging","Other: Health TAPESTRY Intervention|Other: Usual Care","Change in Hospitalizations|Change in Physical activity|Emergency department and urgent care visits|Falls|Hours sitting|Patient enablement|Quality of life|Treatment burden|Disease burden|Medications|Negative effects (unmet expectations)|Negative effects (effects of labeling)|Negative effects (serious adverse events)|Primary care visits|Reason for hospitalization","McMaster University|Canadian Red Cross|Ontario Ministry of Health and Long Term Care|David Braley","All","70 Years and older   (Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","3967","March 15, 2018","August 1, 2020","November 1, 2020","January 12, 2018",,"August 14, 2019","Department of Family Medicine, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03397836"
434,"NCT01165463","Iowa Healthy and Active Minds Study","IHAMS","Completed","No Results Available","Visual Processing Speed","Behavioral: SOPT basic training|Behavioral: Crossword Puzzles|Behavioral: SOPT booster training","Useful Field of View Test|Digit Vigilance Test|Symbol Digit Modalities Test|Controlled Oral Word Association Test|Comprehensive Trail Making Test|Stroop","Fredric D Wolinsky|National Institute on Aging (NIA)|University of Iowa","All","50 Years and older   (Adult, Older Adult)","Not Applicable","681","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","200908789|1RC1AG035546-01","September 2009","December 2011","March 2012","July 19, 2010",,"June 21, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01165463"
435,"NCT00468195","Optimizing Image Quality in Obese Patients Undergoing Coronary Computed Tomography (CT) Angiography","BMI40","Completed","No Results Available","Coronary Angiography|Obesity|Coronary Disease",,,"William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)",,"175","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007-002","May 2007",,"September 2010","May 2, 2007",,"March 21, 2012","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00468195"
436,"NCT03231488","The Effect of Mindfulness on Cognition and Emotion Following Acquired Brain Injury",,"Unknown status","No Results Available","Injuries, Brain","Other: Mindfulness intervention|Other: Control intervention (unfocused attention)","Emotional Stroop|Over-selectivity task.|Hospital Anxiety and Depression Scale (HADS)|The Five Facet Mindfulness Questionnaire (FFMQ)|Test of Everyday Attention (TEA)|Weschler Test of Adult Reading (WTAR)","University of East Anglia|Cambridge University Hospitals NHS Foundation Trust|Cambridgeshire Community Services NHS Trust|Cambridgeshire and Peterborough NHS Foundation Trust|NORFOLK COMMUNITY HEALTH AND CARE NHS TRUST|NORTHAMPTONSHIRE HEALTHCARE NHS FOUNDATION TRUST|Headway Cambridgeshire|Headway Essex|Headway Norfolk and Waveney|Icanho, Livability|Brain Injury Rehabilitation Trust|St Andrews Healthcare|Partnerships in Care","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRAS project ID: 213205","July 31, 2017","January 2018","January 2018","July 27, 2017",,"August 11, 2017","Cambridge University Hospitals Nhs Foundation Trust, Cambridge, United Kingdom|Cambridgeshire Community Services Nhs Trust, Cambridge, United Kingdom|Headway Cambridgeshire, Cambridge, United Kingdom|Brain Injury Rehabilitation Trust, Ely, United Kingdom|Headway Essex, Essex, United Kingdom|Headway Norfolk & Waveney, Norfolk, United Kingdom|Norfolk Community Health and Care Nhs Trust, Norfolk, United Kingdom|Northamptonshire Healthcare Nhs Foundation Trust, Northampton, United Kingdom|Partnerships in Care, Northampton, United Kingdom|St Andrews Healthcare, Northampton, United Kingdom|Cambridgeshire and Peterborough Nhs Foundation Trust, Peterborough, United Kingdom|Icanho, Livability, Stowmarket, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03231488"
437,"NCT03007485","A Comprehensive Disease Management Program to Improve Quality of Life in Disparity Hispanic and African-American Patients Admitted With Exacerbation of Chronic Pulmonary Diseases",,"Active, not recruiting","No Results Available","COPD Exacerbation","Other: Telehealth Pulmonary Rehabilitation","Change in the rate of rehospitalizations in patients with COPD|Change in functional capacity after pulmonary rehabilitation|Change in self-reported quality of life after pulmonary rehabilitation|Measure of patients' adherence to completing pulmonary rehabilitation","Northwell Health|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","AD-1511-33066","April 1, 2017","June 15, 2019","November 15, 2020","January 2, 2017",,"March 9, 2020","Northwell Health, Manhasset, New York, United States",,"https://ClinicalTrials.gov/show/NCT03007485"
438,"NCT03627208","Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch",,"Enrolling by invitation","No Results Available","Leukemia, Lymphoblastic, Acute|ALL, Childhood",,"To identify the frequency and degree of disease discrepancies in identification of bone marrow involvement by ALL when comparing bone marrow biopsy to bone marrow aspirate to flow cytometric disease detection.|To identify the frequency of discrepancies in identification of CNS involvement by leukemia when comparing flow cytometry to cytopathology.|To identify and characterize immunophenotypic changes in leukemic cells over time and in response to targeted therapy.|To comprehensively characterize EM disease including incidence, presentation, risk factors for and radiographic presentation of disease.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 40 Years   (Child, Adult)",,"150","NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","999918131|18-C-N131","August 2, 2018","December 31, 2021","December 31, 2021","August 13, 2018",,"July 9, 2020","National Cancer Institute (NCI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03627208"
439,"NCT00995709","Phase III Study in Refractory Behcet's Disease","SHIELD","Completed","Has Results","Behcet Disease","Drug: AIN457|Drug: Placebo","Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment|Change From Baseline for Composite Immunosuppressive Medication Score at Week 24 by Treatment (Full Analysis Set)|To Determine the Effect of AIN457 on Macular Edema and Visual Acuity in Patients With Posterior Segment Uveitis Secondary to Behçet's Disease as Determined by Optical Coherence Tomography.|To Establish the Impact of AIN457 on Quality of Life of Posterior Segment Uveitis Patients Secondary to Behçet's Disease Refractory to Systemic Immunomodulatory Therapy as Measured by National Eye Institute Visual Function Questionaire-25 and Euroqol.|To Observe the Effect of AIN457 on the Systemic Non-ocular Manifestations of Behçet's Disease in Patients With Posterior Segment Uveitis Requiring Systemic Immunosuppression as Measured by the Bechet's Disease Current Activity Form.","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAIN457C2303|2009-011237-27","October 2009","July 2010","July 2010","October 15, 2009","August 31, 2015","August 31, 2015","Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Dessau-Rosslau, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Heraklion - Crete, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Ioannina, Greece|Novartis Investigative Site, Larisa, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Madurai, Tamil Nadu, India|Novartis Investigative Site, Angamaly, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Irbid, Jordan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Lin-Ko, Taiwan|Novartis Investigative Site, Monastir, Tunisia|Novartis Investigative Site, Sfax, Tunisia|Novartis Investigative Site, Tunis, Tunisia|Novartis Investigative Site, Altindag / Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT00995709"
440,"NCT01875055","Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU","NIRS-ICU","Completed","No Results Available","Cerebral Ischemia","Device: NIRS and Algorithm|Device: NIRS derived cerebral oximetry","The incidence in the two groups of postoperative cerebral desaturation","University of Manitoba","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","B2012:118","May 2013","June 30, 2014","June 30, 2014","June 11, 2013",,"April 10, 2019","St. Boniface Hospital, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01875055"
441,"NCT02419664","Ga-68-DOTATOC -PET in the Management of Pituitary Tumours",,"Recruiting","No Results Available","Pituitary Tumours","Procedure: Gallium-68 DOTATOC PET","SUV max in GA-68 DOTATOC in pituitary tumours in comparison to normal pituitary|Ga-PET uptake in correlation to sst expression in pituitary tumours, measured as SUVmax which is then used to establish statistical relationship with a cell membrane-based sst-immunohistochemistry (IHC) score""|Adverse event registration in association to Ga-68 PET|Detection of tumour recurrence with Ga-PET","Göteborg University|Sahlgrenska University Hospital, Sweden|Uppsala University","All","18 Years and older   (Adult, Older Adult)","Phase 3","45","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Ga-PET version 8 (141017)|2010-020482-24","January 2015","May 2019","December 2019","April 17, 2015",,"November 2, 2018","Center of Endocrinology and Metabolism, Sahlgrenska university Hospital, Göteborg, Sweden",,"https://ClinicalTrials.gov/show/NCT02419664"
442,"NCT04427631","Exploring Interventions for Glue Ear During Covid-19","BIG-C","Not yet recruiting","No Results Available","Hearing Impaired Children|Glue Ear|Hearing Loss, Conductive","Device: Bone conduction headphones","acceptability of management strategy, questionnaire|quality of life questionnaire OMQ-14","Cambridgeshire Community Services NHS Trust|Cambridge University Hospitals NHS Foundation Trust","All","3 Years to 11 Years   (Child)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","262816","June 22, 2020","January 1, 2021","June 1, 2021","June 11, 2020",,"June 11, 2020","Peacock Children's centre. Brookfields Hospital, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04427631"
443,"NCT04417140","A Prospective, Double-Blinded, Randomized Controlled Trial of dHACM for Incisional Hernia Prophylaxis","NO-HERNIA","Recruiting","No Results Available","Incisional Hernia","Biological: dHACM (AmnioWrap)","Incidence of IH as determined by physical exam or abdominal ultrasound demonstrating a midline fascial defect and hernia sac> 4mm diameter|Intraoperative and postoperative complications","Louisiana State University Health Sciences Center in New Orleans|LSUHSC-NO","All","18 Years and older   (Adult, Older Adult)","Phase 4","533","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LSUHSC-NO IRB # 19-174","May 20, 2020","May 20, 2022","May 20, 2022","June 4, 2020",,"June 4, 2020","University Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04417140"
444,"NCT02298361","IMPACCT for Kids' Care","IMPACCT","Completed","Has Results","Insurance Status/Stability","Other: Health insurance outreach IT tools","Percent of Study Period Covered by Medicaid|Proportion of Patients Who Gained Medicaid Coverage|Proportion of Patients Who Lost Medicaid Coverage","Ochin, Inc.|Oregon Health and Science University","All","up to 19 Years   (Child, Adult)",,"27251","Other","Observational","Time Perspective: Prospective","PCORI Award (308)","March 2013","February 2016","February 2016","November 21, 2014","June 2, 2016","June 2, 2016",,,"https://ClinicalTrials.gov/show/NCT02298361"
445,"NCT02290353","Functional Engagement in Assisted Therapy Through Exercise Robotics","FEATHERS","Completed","No Results Available","Stroke|Cerebral Palsy|Traumatic Brain Injury","Device: FEATHERS","Wolf Motor Function Test WMFT|Motricity index, grip/pinch index|Canadian Occupational Performance Measure COPM|Confidence scale|Paediatric Motivation Scale|Usability of the System|Modified Rankin Test|Reach Performance Scale|Game-based kinematic test","University of British Columbia|UBC Peter Wall Institute for Advanced Studies","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","H12-00220","April 2015","November 16, 2015","November 16, 2015","November 14, 2014",,"April 4, 2017","University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02290353"
446,"NCT03027414","Effect of Transcranial Magnetic Stimulation to the Frontoparietal Attention Network on Anxiety Potentiated Startle",,"Completed","No Results Available","Healthy Volunteers","Drug: Transcranial Magnetic Stimulatin Sham|Device: Transcranial Magnetic Stimulation","Anxiety-potentiated startle","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Not Applicable","61","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","170042|17-M-0042","January 23, 2017","July 19, 2019","June 29, 2020","January 23, 2017",,"July 1, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03027414"
447,"NCT03745339","Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder",,"Recruiting","No Results Available","Opiod-Related Disorders|Drug Addiction",,"Outcome inferencing in the probe test|Percentage of trials in which the odor prediction is correct.|Response latency per cue type|Amplitude of respiratory (sniff) responses per cue type|Latency of respiratory (sniff) responses per cue type|Drug use at follow-up","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 50 Years   (Adult)",,"150","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","999919019|19-DA-N019","June 7, 2019","October 1, 2021","October 1, 2021","November 19, 2018",,"March 16, 2020","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03745339"
448,"NCT03992976","Development of an Online Program to Help Manage Chronic Pain in Children and Teenagers",,"Recruiting","No Results Available","Chronic Pain","Other: Online Chronic Pain Management Intervention for Teenagers","8-item interview schedule","University of Southampton|Great Ormond Street Hospital for Children NHS Foundation Trust","All","12 Years to 17 Years   (Child)",,"60","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","45429|19BO01","December 12, 2019","March 1, 2021","March 1, 2021","June 20, 2019",,"March 25, 2020","University of Southampton, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03992976/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03992976"
449,"NCT00257296","Evaluation of an Intimate Partner Violence Screening-Intervention",,"Completed","No Results Available","Domestic Violence","Other: Screening and Intervention|Other: Usual Care",,"University at Albany|Johns Hopkins University","Female","18 Years to 45 Years   (Adult)","Not Applicable","471","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","S1751","August 1, 2004","October 15, 2005","October 15, 2005","November 22, 2005",,"February 13, 2018",,,"https://ClinicalTrials.gov/show/NCT00257296"
450,"NCT01981538","Web-based Patient Reported Outcome Measurement Information System (PROMIS ) to Explore Burden and Stress in Cancer Caregivers (BaSiC2)",,"Completed","No Results Available","Stress",,"Feasibility of collecting web-based PROs,|To explore differences among caregivers across cancer populations","National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","18 Years to 100 Years   (Adult, Older Adult)",,"139","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999914006|14-CC-N006","November 7, 2013","August 23, 2016","August 23, 2016","November 11, 2013",,"June 25, 2020","National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01981538"
451,"NCT03394404","ECG-I Phenotyping of Persistent AF Based on Driver Distribution to Predict Response to Pulmonary Vein Isolation","PHENOTYPE-AF","Recruiting","No Results Available","Atrial Fibrillation","Device: ECG-I mapping and PVI","Freedom from Atrial Arrhythmia and association with distribution of drivers of AF|Impact of pulmonary vein isolation on drivers of AF","Barts & The London NHS Trust","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","218367-1","January 8, 2018","December 2019","December 2020","January 9, 2018",,"July 11, 2018","Barts Heart Centre, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03394404"
452,"NCT03896516","Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder",,"Not yet recruiting","No Results Available","Alcohol Use Disorder","Other: Placebo|Drug: GLWL-01","The co-primary aims will be 1) AE's and alcohol craving|The effects of GLWL-01 on food choices using a ""virtual buffet"" experimental procedure. We will also monitor a wide range of behavioral measures including e.g., pain, anxiety, depression, alcohol craving, withdrawal, smoking","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","43","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","999919075|19-DA-N075","July 14, 2020","November 26, 2022","December 31, 2022","April 1, 2019",,"July 9, 2020","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03896516"
453,"NCT04312126","The Beneficial Effects of Naps on Motor Learning",,"Recruiting","No Results Available","Stroke",,"The degree to which motor skill consolidation is predicted by replay rates during wakeful rest and sleep, and spindle rates during sleep.|Spatial and time-frequency maps of neural replay during wakeful rest and sleep.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"138","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","200060|20-N-0060","July 14, 2020","March 1, 2024","December 31, 2024","March 18, 2020",,"July 9, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04312126"
454,"NCT03996031","Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic","PTT","Recruiting","No Results Available","Cancer, Breast|Cancer of Colon|Cancer of Rectum|Cancer","Device: Plan to Thrive smartphone application","Rate of enrollment|Rate of retention|Rate of app usage|Patient knowledge and adherence to follow-up care recommendations and health behaviors|Patient activation|Symptom burden|Health-related quality of life (HRQoL)|Patient satisfaction","Northwestern University|Vignet, Inc.","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU00209558","August 19, 2019","December 31, 2019","December 31, 2019","June 24, 2019",,"August 28, 2019","Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03996031"
455,"NCT02795806","NLM Scrubber: NLM s Software Application to De-identify Clinical Text Documents",,"Enrolling by invitation","No Results Available","Personally Identifiable Information",,"The rate of de-identification of PII|The rate of erroneously redacted clinical information","National Library of Medicine (NLM)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1","NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","999916122|16-LM-N122","June 9, 2016","May 4, 2020","January 31, 2027","June 10, 2016",,"May 8, 2020","National Library of Medicine, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02795806"
456,"NCT03255031","Ketogenic Diet (KD) in Alcoholism",,"Recruiting","No Results Available","Alcoholism","Dietary Supplement: Ketogenic Diet (KD) / Standard American (SA) Snacks and Shakes","Assessment of ketogenic diet|To assess the effects of a ketogenic diet in alcohol use disorder (AUD) subjects.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","170152|17-AA-0152","October 24, 2017","December 31, 2023","December 31, 2024","August 21, 2017",,"June 18, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03255031"
457,"NCT01862744","Imaging Studies of Cognitive Impairment in Parkinson s Disease",,"Completed","No Results Available","Parkinson Disease|Dementia",,"Functional connectivity of cognitive networks using resting-state fMRI between patients with PD-CogNL, PD-MCI or PDD, and HVs.|Correlate MMSE score with functional connectivity of the default mode network in PD patients.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","40 Years and older   (Adult, Older Adult)",,"76","NIH","Observational","Time Perspective: Prospective","130115|13-N-0115","April 4, 2013","January 30, 2015","February 3, 2015","May 24, 2013",,"December 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01862744"
458,"NCT01404247","Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates","OCT","Completed","No Results Available","Retinal Diseases|Optic Nerve Diseases","Other: Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|Procedure: OCT imaging.","Specific eye measurements by SD-OCT, including retinal nerve fiber layer thickness per quadrant, foveal depth, optic cup area and depth, optic nerve/foveal distance and depth of various layers within the retina to determine neonatal baseline values.","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","38 Weeks to 42 Weeks   (Child)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","14069-01","January 2011","December 2015","December 2015","July 28, 2011",,"July 13, 2017","Los Angeles Biomedical Research Institute atHarbor-UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01404247"
459,"NCT02707029","Clinical and Scientific Assessment of Pain and Painful Disorders",,"Recruiting","No Results Available","Normal Physiology|Pain",,"To enable for the deep, broad, and targeted phenotyping of individuals, in particular those with rare and unusual pain disorders.|To facilitate obtaining information relevant to determining potential eligibility in IRB-approved NIH protocols, in particular those of the Clinical Investigations Branch of NCCIH.","National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)",,"10000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160077|16-AT-0077","July 22, 2016","February 9, 2026","February 9, 2026","March 14, 2016",,"June 24, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02707029"
460,"NCT01950377","Imaging and Genetic Investigation of Learning and Decision Making",,"Completed","No Results Available","Polymorphism- Genetic|Reward Mediating System",,"Outcome measures include performance in the behavioral tasks, effects in the magnetic resonance imaging data, and the genotype of individual participants.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)",,"78","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","130190|13-M-0190","February 11, 2014","February 12, 2018","March 5, 2020","September 25, 2013",,"June 17, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01950377"
461,"NCT02231892","Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study",,"Completed","Has Results","Healthy Volunteer","Device: TMS","Behavioral Outcome Measure|Imaging Outcome Measures","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Not Applicable","104","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","999914186|14-DA-N186","September 3, 2014","January 3, 2019","September 18, 2019","September 4, 2014","February 24, 2020","February 24, 2020","National Institute on Drug Abuse, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02231892/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02231892"
462,"NCT03289923","Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes",,"Recruiting","No Results Available","Major Depressive Disorder","Other: Sham TMS + Sham Therapy|Device: TMS|Behavioral: Cogntive Therapy","Change in magnitude of Bold signal|Electrophysiological changes using MEG and EEG measures|Clinical Rating Scales: BSL, C-SSRS, CTQ, HAM-A, NIH-BFI, PANAS, RBANS, RRS, SHAPS, and TLEQ","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","170147|17-M-0147","May 17, 2018","March 1, 2029","March 1, 2029","September 21, 2017",,"June 11, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03289923"
463,"NCT00076583","Spinal Reflexes in Motor Skill Learning",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"22","NIH","Observational",,"040107|04-N-0107","January 2004",,"November 2005","January 27, 2004",,"March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00076583"
464,"NCT02408874","Inhaled Nanosilver Study",,"Withdrawn","No Results Available","Inflammatory Disease",,"To evaluate the impact of nanosilver exposure on ex vivo inflammatory response of bronchoscopy-derived cells (i.e. alveolar macrophage and epithelial cells) to challenge with a TLR agonist","National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)",,"0","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150104|15-E-0104","April 3, 2015","November 20, 2017","November 20, 2017","April 6, 2015",,"December 17, 2019",,,"https://ClinicalTrials.gov/show/NCT02408874"
465,"NCT03968094","Early Detection of Respiratory Compromise to Prevent Harm of the Hospitalized Opioid Treated Patient",,"Enrolling by invitation","No Results Available","Pain",,"Opioid Induced Respiratory Depression","State University of New York at Buffalo","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MOD00005932","June 1, 2019","September 2019","March 30, 2020","May 30, 2019",,"May 30, 2019","Buffalo General Medical Center, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03968094"
466,"NCT01295775","Diabetic Retinopathy Sulodexide Study","DRESS","Completed","No Results Available","Diabetic Retinopathy","Drug: sulodexide","Hard exudates|microaneurysms|Vascular leakage|Haemorrhages|Intraretinal microvascular abnormalities (IRMA)","Ajou University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","127","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRESS_Korea","February 2009","April 2011","May 2011","February 15, 2011",,"November 6, 2012","Kangnam Sacred Heart Hospital, Colloge of Medicine, Hallym University, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01295775"
467,"NCT03139578","Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Test 8.5BC|Device: Test 9.0BC|Device: Control 8.5BC|Device: Control 9.0BC","Overall Fit Acceptance|Lens Power Requirement|Subjective Comfort at Lens Insertion|Subjective Comfort After Lens Settling|Subjective Vision Quality|Subjective Handling|Monocular High Contrast Visual Acuity (VA)","Johnson & Johnson Vision Care, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5932","April 28, 2017","October 22, 2017","October 22, 2017","May 4, 2017","December 11, 2018","February 1, 2019","Aston University Optometry and Vision Science, Birmingham, United Kingdom|Visioncare Research, Farnham, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03139578/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03139578"
468,"NCT01369901","Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy",,"Completed","No Results Available","Motor Neuron Disease","Behavioral: A functional exercise program|Behavioral: A stretching exercise program","Adult Myopathy Assessment Tool (AMAT)|To assess the effect of functional exercise on muscle strength as measured by quantitative muscle analysis (QMA), and the Timed up and go test (TUG), and progressive height sit-to-stand.|Several exploratory biomarkers that may be affected by exercise will be evaluated, including insulin-like growth factor-1 (IGF-1), testosterone, growth hormone, and creatine kinase.|To assess the ability of patients to maintain exercise compliance as measured by accelerometer measurements.|To assess the effect of functional exercise on balance as measured by Computerized Dynamic Posturography (CDP) evaluation.|To assess the effect of functional exercise on adverse outcomes as measured by an adverse event questionnaire.|Beck Depression Inventory (BDI) testing will also be used to determine if the subjects mood is affected by exercise.|To assess the effect of functional exercise on quality of life as measured by the SF36v2.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","61","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","110171|11-N-0171","June 8, 2011",,"February 28, 2018","June 9, 2011",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01369901"
469,"NCT04040465","Asprin Dosing Estimator in Healthy Adults",,"Not yet recruiting","No Results Available","Aspirin Sensitivity","Drug: Aspirin","Height|Weight|Urine TBX2 Collection (Thromboxane levels)|Salicylate Levels|Aspirin Reaction Units (ARU)|Complete Blood Count (CBC)|High-sensitivity C-reactive protein (hs-CRP)|Blood Pressure (mmHg)|Heart Rate (BPM)|Respiratory Rate (breaths per minute)","University of Utah|University of Colorado, Denver","All","18 Years to 55 Years   (Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB_00117303","February 1, 2020","May 1, 2020","May 1, 2020","July 31, 2019",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04040465"
470,"NCT01517048","Brain-Derived Neurotrophic Factor in Obesity and Brain Function",,"Completed","No Results Available","Obesity|Genetic Disorder|Mental Retardation|Developmental Delay",,"Serum brain-derived neurotrophic factor concentration|Body Composition, Cognitive Function","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Older Adult)",,"93","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","120051|12-CH-0051","January 9, 2012",,"December 12, 2014","January 25, 2012",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|University of Alberta, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01517048"
471,"NCT00321568","Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"60","NIH","Observational",,"060154|06-N-0154","May 1, 2006",,"April 19, 2011","May 4, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00321568"
472,"NCT03859999","PRediction of Outcome With ED Intervention for Colles Type Wrist Fractures [PREDICT]","PREDICT","Completed","No Results Available","Colles' Fracture|Colles' Fracture of Unspecified Radius, Sequela","Diagnostic Test: Analysis of primary radiograph and available demographics","Subsequent surgery|Unsatisfactory position and recommended surgery","Royal Devon and Exeter NHS Foundation Trust|University of Exeter|City, University of London","All","18 Years and older   (Adult, Older Adult)",,"279","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","1802595","November 1, 2017","February 1, 2018","May 1, 2018","March 1, 2019",,"March 1, 2019","Emergency Department, Exeter, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03859999"
473,"NCT02199483","Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain",,"Withdrawn","No Results Available","Healthy Volunteers",,"To measure metabolic and neural adaptations after 4-12 weeks, 6-10 months, and 22-26 months following the start of a lifestyle intervention resulting in weight loss.|To determine whether the degree of metabolic or neural adaptation at 4-12 weeks is correlated with the weight plateau at 6-10 months or the rate of weight regain in the subsequent months.|To investigate changes in circulating hormone and metabolites that correlate with metabolic and neural adaptations as well as changes in appetitive behaviors following a lifestyle intervention resulting in weight loss.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)",,"0","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140154|14-DK-0154","July 21, 2014","June 29, 2017","June 29, 2017","July 24, 2014",,"December 12, 2019",,,"https://ClinicalTrials.gov/show/NCT02199483"
474,"NCT04208490","Implementation and Effectiveness Trial of HN-STAR","HN-STAR","Not yet recruiting","No Results Available","Head and Neck Cancer","Other: HN-STAR Intervention","Change in HNC-Specific QOL|Change in QoL|Change symptom burden|Change in symptom burden|Change in pain|Change in patient activation|Change in perceived quality of cancer care|Adherence and surveillance of guideline concordant care","Wake Forest University Health Sciences|National Cancer Institute (NCI)|Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","470","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00060694","August 2020","December 2022","December 2022","December 23, 2019",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04208490"
475,"NCT01880359","AF CRT +/- Nimorazole in HNSCC",,"Active, not recruiting","No Results Available","Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers","Drug: Cisplatin|Radiation: Radiotherapy|Drug: Placebo|Drug: Nimorazole","locoregional control rate|Time to distant metastasis|Time to second cancer|Overall survival|Disease-specific free survival|Acute and late morbidity","European Organisation for Research and Treatment of Cancer - EORTC|Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EORTC-1219|2013-002441-12","July 2014","March 2020","December 2020","June 19, 2013",,"January 22, 2020","Royal Brisbane And Women's Hospital, Brisbane, Australia|Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia|Royal North Shore Hospital, St Leonards, Australia|Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium|Centre Georges-Francois-Leclerc, Dijon, France|CHU de Tours - Hopital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France|Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany|Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern, Muenchen, Germany|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Radboud University Medical Center Nijmegen, Nijmegen, Netherlands|Medical University Of Gdansk, Gdansk, Poland|The Great Poland Cancer Centre, Poznan, Poland|Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland|Lower Silesian Oncology Centre, Wrocław, Poland|Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneva, Switzerland|UniversitaetsSpital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01880359"
476,"NCT02363309","Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)",,"Completed","No Results Available","Fatty Liver",,"Measure rates of fatty acid oxidation in patients with non alcoholic fatty liver disease","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","21 Years and older   (Adult, Older Adult)",,"74","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","150080|15-DK-0080","March 27, 2015","November 29, 2018","November 29, 2018","February 16, 2015",,"July 8, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02363309"
477,"NCT01348633","Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye",,"Unknown status","No Results Available","Branch Retinal Artery Occlusion|Central Retinal Artery Occlusion|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion",,"Validation and calibration of the Quantitative, Doppler SD-OCT Blood Flow Technology","University of Toronto|Ontario Research Fund","All","20 Years to 80 Years   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ORF1","March 2012","August 2015","August 2015","May 5, 2011",,"January 17, 2013","Department of Ophthalmology and Vision Science, Toronto Western Research Institute, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01348633"
478,"NCT04300504","Muscle in Obesity: Imaging, Function and microRNA",,"Not yet recruiting","No Results Available","Muscle Function","Other: observational study","Differential microRNA expression between normal weight and obese, further stratified by dynapenia|mean difference in distance walked during 6 minute walk test between normal weight and obese, further stratified by dynapenia|mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia MRI|mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia DXA|mean difference in muscle strength between normal weight and obese, further stratified by dynapenia|mean difference in fatigue between normal weight and obese, further stratified by dynapenia","Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield|University of Liverpool","Female","60 Years to 80 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","STH21022","April 1, 2020","April 1, 2022","April 1, 2022","March 9, 2020",,"March 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04300504"
479,"NCT01925196","Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation",,"Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis|Frontotemporal Lobar Degeneration",,"ALS Functional Rating Scale-revised|Verbal Fluency Score|Fronto behavioral Index (FBI)","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"50","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","130188|13-N-0188","September 30, 2013","December 31, 2020","November 30, 2021","August 19, 2013",,"November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01925196"
480,"NCT02965924","Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes",,"Completed","Has Results","Assess Phenylephrine on EVP and IOP","Drug: Phenylephrine 2.5%","Change in Episcleral Venous Pressure (EVP)|Change in Intraocular Pressure (IOP)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-007077","October 2016","October 1, 2018","October 1, 2018","November 17, 2016","October 23, 2019","October 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02965924/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02965924"
481,"NCT01521507","Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye",,"Completed","Has Results","Meibomian Gland Dysfunction|Dry Eye","Device: LipiFlow System|Device: Warm Compress Therapy + Lid Scrub","Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months|Stage 2 Mean Total Meibomian Gland Score at 12 Months|Stage 1 Mean Change in Total OSDI Score From Baseline to 3 Months|Stage 2 Mean Total OSDI Score at 12 Months","TearScience, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LF-004","January 2012","November 2013","January 2014","January 30, 2012","February 23, 2015","February 23, 2015","McDonald Eye Associates, Fayetteville, Arkansas, United States|Harvard Eye Associates, Laguna Hills, California, United States|Center for Excellence in Eye Care, Miami, Florida, United States|Chicago Cornea Consultants, Ltd., Hoffman Estates, Illinois, United States|Jackson Eye, Lake Villa, Illinois, United States|Cincinnati Eye Institute - Northern Kentucky, Edgewood, Kentucky, United States|Charles River Eye Associates, Winchester, Massachusetts, United States|Associated Eye Care, Stillwater, Minnesota, United States|Ophthalmology Consultants, Ltd., St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01521507"
482,"NCT02744846","Short- and Long-Term Effects of Antibiotics on Childhood Growth","ABX","Completed","Has Results","Obesity","Drug: Antibiotics exposure","Body Mass Index Z-score Difference at 48-72 Months, Exposed vs. No Antibiotics Less Than 24 Months|Body Mass Index Z-score Difference at 10 Years, Exposed vs. No Antibiotics Less Than 24 Months","Harvard Pilgrim Health Care|Patient-Centered Outcomes Research Institute|National Patient-Centered Clinical Research Network|ADVANCE CDRN|Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN)|Greater Plains Collaborative Clinical Data Research Network|Mid-South Clinical Data Research Network|New York City Clinical Data Research Network|OneFlorida Clinical Research Consortium|PEDSnet: A Pediatric Learning Health System CDRN|PORTAL CDRN|Research Action for Health Network (REACHnet)|Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS)|Genetic Alliance|StatLog","All","up to 11 Years   (Child)",,"681739","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","OBS-1505-30699","February 2016","December 2018","December 2018","April 20, 2016","December 20, 2019","December 20, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02744846/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02744846"
483,"NCT00728741","Brain Activity During Strategic Planning",,"Completed","No Results Available","Healthy Volunteers",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)",,"16","NIH","Observational","Time Perspective: Prospective","080192|08-N-0192","August 1, 2008",,"May 26, 2010","August 6, 2008",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00728741"
484,"NCT03844178","Pupil Centroid Shift Compensation in Photorefractive Keratectomy Candidates",,"Recruiting","No Results Available","Pupil Centroid Shift","Procedure: The option for compensation of Pupil centroid shift was ON|Procedure: The option for compensation of Pupil centroid shift was OFF|Drug: installation of Tetracaine 1%|Procedure: Photorefractive keratectomy (PRK)","Postoperative refractive error|Root Mean Square (RMS) of higher order aberration","Shahid Beheshti University of Medical Sciences","All","18 Years to 40 Years   (Adult)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","97362","February 10, 2019","June 1, 2019","July 1, 2019","February 18, 2019",,"February 18, 2019","Ophthalmic Research Center, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03844178"
485,"NCT00480441","Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal",,"Completed","Has Results","Marijuana Dependence","Drug: Dronabinol|Behavioral: BRENDA therapy|Drug: Placebo","Physiological Changes in Response to Cue-induced Craving.|Tolerability of Treatment","University of Pennsylvania|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Phase 2","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5P60DA005186-19","August 2006","June 2009","July 2009","May 31, 2007","July 29, 2019","July 29, 2019","Treatment Research Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00480441"
486,"NCT00078364","Pain Pathways in the Brain",,"Completed","No Results Available","Healthy|Tooth Extraction","Procedure: MRI",,"National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","30","NIH","Interventional","Primary Purpose: Treatment","040125|04-D-0125","February 2004",,"August 2005","February 24, 2004",,"March 4, 2008","National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00078364"
487,"NCT00541593","Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts",,"Terminated","Has Results","Pancreatic Pseudocyst","Procedure: Pancreatic Pseudocystgastrostomy","Mortality","Baystate Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-164","September 2007","March 2011","June 2011","October 10, 2007","November 7, 2013","November 7, 2013","Baystate Medical Center, Springfield, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00541593"
488,"NCT00214669","Can Education for South Asians With Asthma and Their Clinicians Reduce Unscheduled Care? A Randomised Trial","OEDIPUS","Completed","No Results Available","Asthma","Behavioral: PACE (Professional Asthma Care Education)|Behavioral: Lay Led Expert Patient Programme|Behavioral: Asthma self management education by a specialist nurse","Primary outcomes are time to first unscheduled contact with acute asthma, and proportion of participants with unscheduled care, assessed from patient records 12 months after recruitment.|Secondary outcomes are generic (EQ5D) and disease specific quality of life (AQ20 and North of England scales), prescribing and costs.","Barts & The London NHS Trust|Asthma UK|Social Action for Health|Department of Health (Service Support)|Noreen Clarke, Professor of Public Health, Michigan University","All","3 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","375","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","CG-09-05-IHS|04/060","November 2005","April 2008","April 2009","September 22, 2005",,"June 4, 2009","Barts and TheLondon, Queen Marys's School of Medicine and Dentistry, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00214669"
489,"NCT01906502","24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population",,"Completed","No Results Available","Healthy Subject","Device: Sensimed Triggerfish","The 24-hour IOP pattern recorded with Sensimed Triggerfish (TF) in healthy subjects, aged between 40 and 80 years Secondary|Diurnal and nocturnal IOP patterns in healthy subjects|Assessment of corneal biomechanical properties in healthy population (if available)|Relationship between the 24-hour IOP pattern monitored by TF and the 24-hour blood pressure pattern in healthy subjects (if available)|Assessment of Safety and tolerability through adverse events","Sensimed AG","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","115","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TF-1217","July 2013","April 2014","April 2014","July 24, 2013",,"August 26, 2014","Meir Medical Center, Kfar Saba, Israel|The Western Galilee Hospital in Naharya, Naharya, Israel|Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Sourasky Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01906502"
490,"NCT00056888","Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders",,"Completed","No Results Available","Movement Disorders",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)",,"115","NIH","Observational",,"030134|03-N-0134","March 21, 2003",,"February 17, 2009","March 26, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00056888"
491,"NCT02821741","Effects of External Ear Stimulation on Pain Perception and Mood",,"Recruiting","No Results Available","Pain","Device: Transcutaneous Electrical Nerve Stimulator","The difference in pain ratings collected for each subject during the two types of left ear stimulation (cymba conchae and earlobe).|The effect of tVNS on pain threshold, pain unpleasantness, and mood as measured by visual analogue scales (VAS).|Mood and anxiety, as measured by questionnaires taken at the beginning and end of both study sessions.|Autonomic measures will be analyzed to determine whether tVNS has an effect on heart rate variability.","National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Early Phase 1","76","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","160136|16-AT-0136","October 18, 2016","December 30, 2020","December 30, 2020","July 4, 2016",,"May 8, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02821741"
492,"NCT02861820","Functional Connectivity Changes During Early Recovery as a Marker for Relapse",,"Recruiting","No Results Available","Substance Use Disorder","Device: MRI: Brain Imaging Data Collection","Brain connectivity","University of Minnesota|National Institute on Drug Abuse (NIDA)","All","18 Years to 45 Years   (Adult)",,"160","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1101M95345|1R01DA038984-01A1","July 1, 2015","June 30, 2020","June 30, 2020","August 10, 2016",,"February 5, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02861820"
493,"NCT01944514","Implantable Cardioverter Defibrillators - Improving Risk Stratification","ICD-IRS","Completed","No Results Available","Sudden Cardiac Death|Implantable Defibrillator User|Myocardial Infarction|Arrhythmias, Cardiac",,"Regional Restitution Instability Index|Peri-infarct zone","University Hospitals, Leicester|University of Leicester|Da Vinci Health Technology Innovation Network|LivaNova","All","18 Years and older   (Adult, Older Adult)",,"92","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","UHL-10824: ICD-IRS","January 2010","November 2012",,"September 17, 2013",,"September 20, 2013",,,"https://ClinicalTrials.gov/show/NCT01944514"
494,"NCT03181711","Is DIAGNOcam Comparable to Bitewing Radiographs as a Diagnostic Method for Approximal Caries in Primary Teeth?","Diagncamera","Unknown status","No Results Available","Caries",,"number of surfaces with manifest approximal caries lesions|Children´s perception of pain during examination with radiographs (bitewings) and DIAGNOcam.","Malmö University","All","4 Years to 8 Years   (Child)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","DIAGNOcam Malmo U","June 1, 2017","October 1, 2018","October 2018","June 9, 2017",,"April 9, 2018","Malmö University, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT03181711"
495,"NCT02953080","Improving Outcomes in HIV Patients Using Mobile Phone Based Interactive Software Support",,"Unknown status","No Results Available","M Hhealth Technology","Behavioral: Call for life using M health SMS","1. Change in quality of life physical health score in those accessing Call for Life UgandaTM between baseline, 6 , 12 and 24 months of Call for Life UgandaTM use, and comparison to those with no access to Call for Life UgandaTM at 6 and 12 months|1. Change in quality of life mental health score in those accessing Call for Life UgandaTM between baseline, 6 , 12 and 24 months of Call for Life","Makerere University","All","18 Years to 77 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ST/163/2016","November 2016","April 2018","April 2019","November 2, 2016",,"November 2, 2016",,,"https://ClinicalTrials.gov/show/NCT02953080"
496,"NCT01147913","Computerized Information-Processing Bias Retraining in Depressed Adolescents",,"Completed","No Results Available","Major Depression","Behavioral: Computerized Information-Processing Bias Retraining|Behavioral: Attention Control Training","Test of Interpretation Bias (TIB)|Test of Interpretation Bias|Kiddie-Schedule of Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; Orvaschek & Puig-Antich, 1987)|Beck Depression Inventory, 2nd Version|State-Trait Anxiety Scale (STAI)|Structured Clinical Interview for DSM-IV (SCID-IV; First et al, 1997), Mood Disorder Modules only|Dysfunctional Attitudes Scale (DAS)|CANTAB Affective Go-No Go Task (AGN)","Massachusetts General Hospital","All","14 Years to 21 Years   (Child, Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","F32MH088065-01","March 2010","April 2012","April 2012","June 22, 2010",,"May 3, 2012","Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01147913"
497,"NCT01232686","Snow Disease Surveillance System Study","Snow","Completed","No Results Available","Communicable Diseases","Other: Online disease surveillance data access","Earlier diagnosis and treatment for communicable diseases|Earlier detection of local disease outbreaks|Lower number of infected during disease outbreaks|Impact on health service costs","University Hospital of North Norway|University of Tromso|The Royal Norwegian Ministry of Health|Norwegian Health Network (state owned enterprise)","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","ID 3746/ HST954-10","October 2010","December 2012","December 2012","November 2, 2010",,"February 16, 2017",,,"https://ClinicalTrials.gov/show/NCT01232686"
498,"NCT00268476","Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","STAMPEDE","Recruiting","No Results Available","Prostate Cancer","Drug: Celecoxib|Drug: Docetaxel|Drug: Prednisolone|Drug: ADT|Drug: Zoledronic Acid|Drug: Abiraterone|Radiation: Radiotherapy to the prostate|Drug: Enzalutamide|Drug: Metformin|Drug: Transdermal Oestradiol","Overall survival|Failure-free survival|Cost effectiveness by EuroQol|Quality of life (QOL) by EORTC QOL Questionnaire C30 and prostate specific 25-item|Number of participants with treatment-related side effects as assessed by CTCAE v4.0|Skeletal related events|Biochemical failure|Progression-free survival|Lymph node progression|Distant metastases|Treatment for progression|Disease-specific survival|Non-prostate cancer death|Metabolic effects","Medical Research Council","Male","up to 120 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","12200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000455008|MRC-STAMPEDE|EU-205102|PR08|ISRCTN78818544|2004-000193-31","July 8, 2005","September 2024","September 2024","December 22, 2005",,"February 21, 2020","Kantonsspital Graubuenden, Chur, Graubunden, Switzerland|Lausanne Centre Hospitalier Universitaire, Lausanne, Vaud, Switzerland|Winterthur Hospital, Winterthur, Zurich, Switzerland|Hirslanden Klinik Aarau, Aarau, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Inselspital Bern, Berne, Switzerland|Liestal Hospital, Liestal, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|City Hospital Triemli, Zurich, Switzerland|Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, Berkshire, United Kingdom|Royal Bolton Hospital, Farnworth, Bolton, United Kingdom|Wycombe General Hospital, High Wycombe, Buckinghamshire, United Kingdom|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Broomfield Hospital, Broomfield, Chelmsford, United Kingdom|Countess of Chester Hospital, Chester, Chesire, United Kingdom|James Cook University Hospital, Middlesbrough, County Durham, United Kingdom|Cumberland Infirmary, Carlisle, Cumbria, United Kingdom|North Devon District Hospital, Barnstaple, Devon, United Kingdom|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Dorset County Hospital, Dorchester, Dorset, United Kingdom|Poole Hospital, Poole, Dorset, United Kingdom|Castle Hill Hospital, Cottingham, East Riding Of Yorkshire, United Kingdom|Eastbourne District General Hospital, Eastbourne, East Sussex, United Kingdom|Conquest Hospital, Saint Leonards-on-Sea, East Sussex, United Kingdom|William Harvey Hospital, Ashford, England, United Kingdom|Stoke Mandeville Hospital, Aylesbury, England, United Kingdom|Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom|City Hospital (Birmingham), Birmingham, England, United Kingdom|Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom|Burnley General Hospital, Burnley, England, United Kingdom|Queen's Hospital, Burton-upon-Trent, England, United Kingdom|West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom|Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom|Darlington Memorial, Darlington, England, United Kingdom|Derbyshire Royal Infirmary, Derby, England, United Kingdom|Doncaster Royal Infirmary, Doncaster, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|University Hospital of North Durham, Durham, England, United Kingdom|Gloucestershire Royal Hospital, Gloucester, England, United Kingdom|Hereford County Hospital, Hereford, England, United Kingdom|Kidderminster Hospital, Kidderminster, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Glenfield Hospital, Leicester, England, United Kingdom|Royal Liverpool University Hospital, Liverpool, England, United Kingdom|University Hospital Aintree, Liverpool, England, United Kingdom|Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|St. Mary's Hospital, London, England, United Kingdom|UCL Cancer Institute, London, England, United Kingdom|University College of London Hospitals, London, England, United Kingdom|Withington Hospital, Manchester, England, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|Sunderland Royal Hospital, Sunderland, England, United Kingdom|Torbay Hospital, Torquay, England, United Kingdom|Warrington Hospital NHS Trust, Warrington, England, United Kingdom|West Cumberland Hospital, Whitehaven, England, United Kingdom|Royal Albert Edward Infirmary, Wigan, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|Worthing Hospital, Worthing, England, United Kingdom|Princess Alexandra Hospital, Harlow, Essex, United Kingdom|Queen's Hospital, Romford, Essex, United Kingdom|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, Essex, United Kingdom|South West Wales Cancer Institute At Singleton Hospital, Swansea, Glamorgan, United Kingdom|Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom|St. Bartholomews Hospital, London, Greater London, United Kingdom|Queen Elizabeth Hospital - Woolwich, London, Greater London, United Kingdom|St. George's Hospital, London, Greater London, United Kingdom|Charing Cross Hospital, London, Greater London, United Kingdom|Christie Hospital, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Greater Manchester, United Kingdom|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, United Kingdom|Raigmore Hospital, Inverness, Highland, United Kingdom|St. Mary's Hospital, Newport, Isle Of Wight, United Kingdom|Airedale General Hospital, Steeton, Keighley, United Kingdom|Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, Kent, United Kingdom|Queen Elizabeth The Queen Mother Hospital, Margate, Kent, United Kingdom|Beatson Institute for Cancer Research - Glasgow, Glasgow, Lanarkshire, United Kingdom|Rosemere Cancer Centre at Royal Preston Hospital, Preston, Lancashire, United Kingdom|Southport and Formby District General Hospital, Southport, Merseyside, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, Middlesex, United Kingdom|Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Midlothian, United Kingdom|Freeman Hospital, Newcastle, Newcastle-upon-Tyne, United Kingdom|Scarborough General Hospital, Scarborough, North Yorkshire, United Kingdom|Centre for Cancer Research and Cell Biology at Queen's University Belfast, Belfast, Northern Ireland, United Kingdom|Nottingham City Hospital, Nottingham, Nottinghamshire, United Kingdom|King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Queen Alexandra Hospital, Cosham, Portsmouth, United Kingdom|Ayr Hospital, Ayr, Scotland, United Kingdom|Royal United Hospital, Bath, Somerset, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, Somerset, United Kingdom|Musgrove Park Hospital, Taunton, Somerset, United Kingdom|Weston General Hospital, Weston Super Mare, Somerset, United Kingdom|Yeovil District Hospital, Yeovil, Somerset, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, United Kingdom|Ipswich Hospital, Ipswich, Suffolk, United Kingdom|St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Royal Marsden - Sutton, Sutton, Surrey, United Kingdom|Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle-Upon-Tyne, Tyne & Wear, United Kingdom|South Tyneside District Hospital, South Shields, Tyne & Wear, United Kingdom|Bronglais General Hospital, Aberystwyth, Wales, United Kingdom|Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom|Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom|Good Hope Hospital, Sutton Coldfield, West Midlands, United Kingdom|Bradford Royal Infirmary, Bradford, West Yorkshire, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, West Yorkshire, United Kingdom|Great Western Hospital, Swindon, Wiltshire, United Kingdom|Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom|Barnet General Hospital, Barnet, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|Forth Valley Hospital, Larbert, United Kingdom|Lincoln Hospital, Lincoln, United Kingdom|North Tees Hospital, Stockton-on-Tees, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00268476"
499,"NCT00247689","Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics",,"Terminated","No Results Available","Substance Abuse",,,"National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 50 Years   (Adult)",,"31","NIH","Observational","Time Perspective: Prospective","999905381|05-DA-N381","December 22, 2004",,"February 27, 2015","November 2, 2005",,"December 12, 2019","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00247689"
500,"NCT02291224","Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens","2Gether","Completed","No Results Available","Pregnancy|Sexually Transmitted Diseases","Behavioral: Interactive multimedia platform|Behavioral: Intervention arm counseling|Behavioral: Standard of care counseling","Participant selection of an effective dual protection (DP) strategy|Participant report of adherence to DP strategy|Time to first biologic event (pregnancy or diagnosis with STI) in participants|Incidence of pregnancy and sexually transmitted infections (STIs)|Participant level of reproductive health knowledge (percentage correct of knowledge questions)|Participant intention to use DP strategy|Participant reproductive health self-efficacy|Participant report of STI testing|Participant report of partner communication","Centers for Disease Control and Prevention|Emory University|Grady Health System","Female","14 Years to 19 Years   (Child, Adult)","Not Applicable","709","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCCDPHP-6588|DP12-001","March 2015","August 2018","August 2018","November 14, 2014",,"November 27, 2018","Grady Health System Teen Services Clinic, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02291224"
501,"NCT02436057","Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform",,"Completed","No Results Available","Abdominal Pain|Deglutition Disorders|Fecal Incontinence|Nausea|Diarrhea|Constipation|Gastroesophageal Reflux","Other: AEGIS (Automated Evaluation of Gastrointestinal Symptoms)","Patient satisfaction|Patient Assessment of Physician Interpersonal Skills|Patient Assessment of Shared Decision Making","Cedars-Sinai Medical Center|National Institutes of Health (NIH)|University of California, Los Angeles|VA Medical Center-West Los Angeles|University of Michigan|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","255","Other|NIH|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","0023|7U01AR057936-05","July 2014","December 2015","December 2015","May 6, 2015",,"January 15, 2016","Cedars-Sinai Medical Center, Los Angeles, California, United States|West Los Angeles VA Medical Center, Los Angeles, California, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02436057"
502,"NCT03413631","A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women",,"Completed","No Results Available","Substance-Related Disorders|Pregnancy, High Risk|Prenatal Care|Maternal-Fetal Relations|Parenting|Depression|Anxiety|Perinatal Outcome|Fetal Exposure During Pregnancy","Behavioral: Prenatal mentalization intervention|Other: Prenatal obstetric treatment as usual","Prenatal depressive symptoms post-intervention at 35 gestational weeks|Prenatal parental mentalization post-intervention at 35 gestational weeks|Maternal-fetal attachment post-intervention at 35 gestational weeks|Prenatal maternal substance abuse (health behaviour)|Prenatal anxiety symptoms post-intervention at 35 gestational weeks","Turku University Hospital|Foundation for Paediatric Research, Finland|Academy of Finland|Hospital District of Southwestern Finland|University of Turku","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13924","October 18, 2011","December 31, 2015","December 31, 2015","January 29, 2018",,"January 29, 2018","Department of Obstetrics and Gynecology and Department of Child Psychiatry, Turku University Hospital; Department of Obstetrics and Gynecology and Department of Child Psychiatry, University of Turku, Turku, Finland, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT03413631"
503,"NCT00340093","Diabetes Management Personal Trainer",,"Completed","No Results Available","Diabetes","Behavioral: Managing Diabetes",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","11 Years to 16 Years   (Child)","Phase 1","0","NIH","Interventional","Primary Purpose: Treatment","999902290|02-CH-N290","August 23, 2002",,"March 6, 2007","June 21, 2006",,"July 2, 2017","Johns Hopkins University, Baltimore, Maryland, United States|Mount Washington Pediatric Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00340093"
504,"NCT00309010","Neurophysiology of Task-Specificity of Focal Hand Dystonia",,"Completed","No Results Available","Focal Dystonia",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"115","NIH","Observational",,"060126|06-N-0126","March 28, 2006",,"February 24, 2009","March 30, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00309010"
505,"NCT02132481","Using Smartphones to Provide Recovery Support Services","SRSS","Active, not recruiting","No Results Available","Substance Use Disorder (SUD)|Recovery","Other: EMA Only|Other: EMI Only|Other: EMA+EMI|Other: Neither - RSAU","Days of Abstinence|EMA & EMI utilization|HIV Risk Behavior Index","Chestnut Health Systems|National Institute on Drug Abuse (NIDA)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","401","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SRSS Experiment|R01DA035879","June 2015","October 2018","February 2021","May 7, 2014",,"January 22, 2020","Haymarket, Chicago, Illinois, United States|Chestnut Health Systems, Chicago, Illinois, United States|Chestnut Health Systems, Normal, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02132481"
506,"NCT01402609","Assessing the Efficacy of an Electronic Discharge Communication Tool",,"Completed","No Results Available","Other Diagnoses, Comorbidities, and Complications","Device: electronic discharge communication tool|Device: Usual care","composite of death or readmission|occurrence of post-discharge adverse events and adverse drug events at 1 month post discharge","Ward of the 21st Century|Canadian Institutes of Health Research (CIHR)|Alberta Health Services|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1399","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research","SeamDis2010","September 2011","December 2013","April 2016","July 26, 2011",,"August 1, 2016","Medical Teaching Unit, Foothills Medical Centre, Calgary, Alberta, Canada|The ward of 21st Century (W21C) Foothills Medical Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01402609"
507,"NCT00845052","Survey of Housestaff Attitudes Toward Patient Care and Safety",,"Completed","No Results Available","Safety Issues|Patient Care",,,"Weill Medical College of Cornell University","All","20 Years to 50 Years   (Adult)",,"674","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0807009889","July 2008","June 2011","September 2011","February 16, 2009",,"February 6, 2017","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00845052"
508,"NCT00733421","The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery",,"Completed","Has Results","Postoperative Pain","Drug: etoricoxib|Drug: tramadol","Number of Patients Requiring Rescue Medication|Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain|Compliance to Base Medication|Gastro-intestinal Symptoms|Dizziness/Sleepiness|Wound Healing|Satisfaction With Pain Medication|Patient Assessed Overall Satisfaction With Surgery/Outcome|Patient Assessed Quality of Life","Karolinska Institutet","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2008HV001|EudraCT number 2008-000791-24","October 2008","June 2009","August 2009","August 13, 2008","January 13, 2010","January 20, 2010","Foot & Ancle Surgical Center, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00733421"
509,"NCT01273129","Surgery as a Treatment for Medically Intractable Epilepsy",,"Recruiting","No Results Available","Epilepsy|Epilepsy, Temporal Lobe|Partial Epilepsy",,"Change in seizure frequency|1. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy|2. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy|3. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy|4. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy|5. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy|6. Neurophysiological correlates of human cognitive function and to provide invasive monitoring for patients with tumor related epilepsy","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years to 100 Years   (Child, Adult, Older Adult)",,"300","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","110051|11-N-0051","March 21, 2011",,,"January 10, 2011",,"July 8, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01273129"
510,"NCT00431366","Sequence Effect in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"24","NIH","Observational",,"070088|07-N-0088","February 1, 2007",,"December 24, 2008","February 5, 2007",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00431366"
511,"NCT00508989","Niacin to Improve Blood Flow in People With Sickle Cell Disease",,"Completed","No Results Available","Sickle Cell Disease","Drug: Niacin-ER|Drug: Placebo|Drug: L-NMMA|Drug: Acetylcholine","The Effect of niacin-ER on endothelial dysfunction in the sickle cell.|Effect of niacin therapy on HDL and apo A-I levels in subjects with sickle cell disease.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","070196|07-H-0196","July 24, 2007","December 31, 2010","December 24, 2015","July 30, 2007",,"April 5, 2019","Howard University Hospital, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00508989"
512,"NCT00314769","Long-Term Improvement in Motor Learning by Transcranial Direct Current Stimulation",,"Completed","No Results Available","Healthy Volunteers",,,"National Institute of Neurological Disorders and Stroke (NINDS)|United States Department of Defense|Center for Neuroscience and Regenerative Medicine (CNRM)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"196","NIH|U.S. Fed","Observational",,"060138|06-N-0138","April 7, 2006",,"December 16, 2013","April 14, 2006",,"December 16, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00314769"
513,"NCT01443026","The Effects of Lycopene on High Risk Prostatic Tissue",,"Completed","Has Results","Intraepithelial Prostatic Neoplasia|Prostatic Neoplasms","Drug: Lycopene 30mg|Drug: Placebo","Tissue Biomarkers|Changes in Serum Biomarkers|Changes in Nuclear Morphometry","University of Illinois at Chicago|National Cancer Institute (NCI)","Male","40 Years and older   (Adult, Older Adult)","Phase 2","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2005-0828|R01CA090759","February 2006","April 2009","April 2009","September 29, 2011","June 4, 2015","November 19, 2019","Northwestern Memorial Hospital, Chicago, Illinois, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01443026"
514,"NCT01979471","The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH","RxEACH","Completed","No Results Available","Diabetes|Chronic Kidney Disease|Established Atherosclerotic Vascular Disease|Framingham Risk Score More Than 20 Percent","Other: Advanced Care","The difference in change in estimated cardiovascular risk between advanced care and usual care groups|Difference in change in individual cardiovascular risk factors between advanced care and usual care groups|Achievement of individual and the ""triple target""","University of Alberta|Alberta Health & Wellness|Alberta Health Services|Merck Frosst Canada Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","723","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","pro00041644","January 2014","September 2015","December 2015","November 8, 2013",,"October 30, 2017","EPICORE Centre, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01979471"
515,"NCT00413842","Effects of tDCS Over the Cerebellum on Motor Function",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 40 Years   (Adult)",,"40","NIH","Observational",,"070049|07-N-0049","December 14, 2006",,"August 20, 2008","December 20, 2006",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00413842"
516,"NCT03314129","Remediation of Visual Perceptual Impairments in Schizophrenia","VRiS","Recruiting","No Results Available","Schizophrenia|Schizoaffective Disorder","Behavioral: UltimEyes|Behavioral: Contour Integration Training|Behavioral: UltimEyes + Contour Integration Training|Behavioral: MyBrainSolutions","Contrast sensitivity - behavioral|Contrast sensitivity - electrophysiological|Contour integration|Reading speed|Emotion recognition|Cognition|Community functioning","Rutgers, The State University of New Jersey|New York University","All","18 Years to 60 Years   (Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","20170000922|U.S. NIH Grant # 1R61MH115119","December 15, 2018","July 31, 2022","January 31, 2023","October 19, 2017",,"March 28, 2019","Rutgers University Behavioral Health Care, Piscataway, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|New York Presbyterian Hospital, White Plains, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03314129/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03314129"
517,"NCT01374815","The Online Advocate: Health Related Social Problems And Diet Quality Pilot Study",,"Completed","No Results Available","Children's Diet Quality|Health-related Social Problems","Other: The Online Advocate","Diet quality|Physical activity","Boston Children’s Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","X10-07-335","June 2011","August 2012","August 2012","June 16, 2011",,"March 5, 2014","Children's Hospital, Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01374815"
518,"NCT02347202","Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention",,"Active, not recruiting","No Results Available","Alzheimer's Disease|Dementia","Other: Online counseling via Zoom teleconferencing|Other: Telephone support as needed","Differences in depressive symptoms between groups (One-way analysis of variance, questionnaire)|Differences in reactions to problem behaviors between groups (questionnaire)|Differences in satisfaction with social support between groups (questionnaire)","NYU Langone Health","All","21 Years to 125 Years   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","14-01185","October 2015","March 31, 2020","March 31, 2020","January 27, 2015",,"December 20, 2019","NYU School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02347202"
519,"NCT02121847","Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","IMPACT","Completed","Has Results","Dry Eye Syndromes","Drug: cyclosporine 0.05% ophthalmic emulsion|Drug: carboxymethylcellulose-based lubricant eye drops","Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye|Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye|Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)|Change From Baseline in Driving at Night on the OSDI|Change From Baseline in Working With a Computer or Bank Machine on the OSDI|Change From Baseline in Watching TV on the OSDI|Change From Baseline in Reading Rate|Change From Baseline in Words Read Incorrectly|Change From Baseline in Font Size|Change From Baseline in OSDI|Change From Baseline in Ocular Discomfort on a 4-point Scale|Change From Baseline in Tear Film Break-up Time in the Worse Eye|Change From Baseline in the Interblink Interval in the Worse Eye|Change From Baseline in Conjunctival Redness in the Worse Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMA-RES-014-001","April 3, 2014","September 23, 2014","September 23, 2014","April 24, 2014","April 25, 2016","April 18, 2019","Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02121847"
520,"NCT02132910","Restorative Exercise for Strength Training and Operational Resilience (RESTORE) for Chronic or Recurrent Low Back Pain","RESTORE","Completed","Has Results","Lower Back Pain","Other: RESTORE Intervention","Pain Scores|Disability","Defense and Veterans Center for Integrative Pain Management","All","18 Years to 68 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","380491","December 2013","August 7, 2015","August 7, 2015","May 7, 2014","November 25, 2019","November 25, 2019","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02132910"
521,"NCT04403399","Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3)","UdallP3","Completed","No Results Available","Parkinson's Disease","Drug: Varenicline|Other: Evaluation by Investigator|Other: Placebo","Gait speed|Balance control|Attention","University of Michigan","All","45 Years and older   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HUM00093188-a","June 29, 2017","June 26, 2019","June 26, 2019","May 27, 2020",,"May 29, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04403399"
522,"NCT00095407","The Functional Anatomy of Personality Trait Knowledge: An fMRI Study",,"Completed","No Results Available","Healthy",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","21 Years to 65 Years   (Adult, Older Adult)",,"190","NIH","Observational",,"050018|05-N-0018","October 29, 2004",,"December 29, 2011","November 4, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00095407"
523,"NCT02150577","Implementation Trial of Evidence Based Practices for Mood Disorders",,"Completed","No Results Available","Bipolar Disorder|Treatment Resistant Depression","Behavioral: Evidence Based Quality Improvement","Patient Reach","University of Arkansas","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","291","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MH085104","May 1, 2014","November 1, 2017","November 1, 2017","May 30, 2014",,"December 8, 2017","Mainline Health Systems Inc., Eudora, Arkansas, United States|Boston Mountain Rural Health Center, Huntsville, Arkansas, United States|Lee County Cooperative Clinic, Marianna, Arkansas, United States|ARcare, Melbourne, Arkansas, United States|Jefferson Comprehensive Care System, Pine Bluff, Arkansas, United States|East Arkansas Family Health Center, West Memphis, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02150577"
524,"NCT00108680","Effects of Two Different Kinds of Exercise on Stroke Rehabilitation",,"Completed","No Results Available","Cerebrovacular Accident|Paresis",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"24","NIH","Observational",,"050142|05-N-0142","April 13, 2005",,"January 14, 2011","April 18, 2005",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00108680"
525,"NCT01862796","Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals",,"Completed","Has Results","Obesity|Overweight","Behavioral: Underfeeding diet|Behavioral: Weight maintaining diet","Adherence Score|Change in Weight From Baseline to 6 Weeks","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999913096|13-DK-N096","May 31, 2013","May 22, 2018","May 22, 2018","May 24, 2013","August 15, 2019","August 15, 2019","NIDDK, Phoenix, Phoenix, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT01862796/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01862796"
526,"NCT02471495","RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)",,"Withdrawn","No Results Available","Bladder Cancer","Device: Synergo® RITE + MMC","Recurrence-free survival|Complete Response Rate (CRR)|Rate of serious adverse events|Proportion of patients who discontinue treatment for safety reasons.","Medical Enterprises Europe B.V.","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RITE-2","September 2016","January 2019","January 2020","June 15, 2015",,"May 7, 2018",,,"https://ClinicalTrials.gov/show/NCT02471495"
527,"NCT00069355","Propranolol for the Treatment of Acute Stress Disorder",,"Completed","No Results Available","Stress Disorders, Traumatic, Acute","Drug: Propranolol",,"National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","030296|03-M-0296","September 2003",,"October 2004","September 24, 2003",,"March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00069355"
528,"NCT02137161","Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","REPEX","Completed","No Results Available","Cataract|Pseudoexfoliation Syndrome","Drug: Dexamethasone+Tobramycin eye drop|Drug: Bromfenac eye drop","Change from baseline in anterior chamber inflammation measured by Laser Flare Photometry (photon counts per millisecond)|Proportion of patients with central macular thickness greater than 300 microns|Proportion of subjects with best corrected visual acuity equal to 20/20|Proportion of patients who had no ocular pain","Arcispedale Santa Maria Nuova-IRCCS","All","60 Years and older   (Adult, Older Adult)","Phase 4","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-002066-39","November 2013","October 2014","October 2014","May 13, 2014",,"October 29, 2014","Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy",,"https://ClinicalTrials.gov/show/NCT02137161"
529,"NCT04129021","Multimodal Ophthalmic Imaging","IMA-MODE","Recruiting","No Results Available","Retinitis Pigmentosa|Maculopathy, Age Related|Macular Dystrophy|Macular Edema|Retinal Detachment|Retinal Degeneration|Glaucoma|Vascular Inflammation|Hypertension|Stroke|Diabetes|Corneal Dystrophy|Keratoconus|Dry Eye|Trauma","Device: High-resolution retinal imaging through adaptive optics|Device: High-resolution retinal imaging through holographic systems","Visualization of a structure of interest and measuring the short-term and long-term reproducibility of the data collected compared to routine systems","Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","P19-03|2019-A00942-55","July 15, 2019","June 30, 2023","June 30, 2023","October 16, 2019",,"October 16, 2019","Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France",,"https://ClinicalTrials.gov/show/NCT04129021"
530,"NCT02744534","Targeted Fusion Biopsy of the Prostate",,"Completed","Has Results","Prostatic Neoplasms","Drug: FACBC PET-CT Scan|Procedure: Three-dimensional ultrasound-guided biopsy|Procedure: Standard transrectal ultrasound (TRUS) guided biopsy","Percentage of Cores Positive for Cancer","Emory University|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00080287|R21CA176684|R01CA156775|R01CA204254","November 2015","March 31, 2018","March 31, 2018","April 20, 2016","May 8, 2019","May 8, 2019","Emory University Hospital, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02744534/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02744534"
531,"NCT02008097","Clinical Benefits of B-Flow Ultrasound",,"Completed","No Results Available","Evidence of Liver Transplantation|Arterial Occlusive Diseases|Hypertension|Pregnancy, High Risk|Pregnancy","Device: GE LOGIQ E9 Ultrasound System","Correlating blood flow findings using B-flow imaging with standard clinical ultrasound.|Correlating blood flow findings on B-flow imaging in pregnant women with pathology findings in the placenta.","University of Washington|General Electric","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","180","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","45374","October 2013","August 31, 2015","September 1, 2015","December 11, 2013",,"May 1, 2018","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02008097"
532,"NCT03060291","Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program",,"Active, not recruiting","No Results Available","Substance Use|Conduct Disorders in Adolescence|Depression|Anxiety","Behavioral: FCU-Online, web/ mobile only|Behavioral: FCU-Online, web/ mobile + coach","Change from Baseline in Youth Behavioral Control across 12 months (parent report)|Change from Baseline in Youth Behavioral Control across 12 months (youth report)|Change from Baseline in Youth Substance Use across 12 months (parent report)|Change from Baseline in Youth Substance Use across 12 months (youth report)|Change from Baseline in Youth Problem Behavior across 12 months (parent report)|Change from Baseline in Youth Problem Behavior across 12 months (youth report)|Change from Baseline in Family Conflict across 12 months (parent report)|Change from Baseline in Family Conflict across 12 months (youth report)|Change from Baseline in Positive Family Relationships across 12 months (parent report)|Change from Baseline in Positive Family Relationships across 12 months (youth report)|Change From Baseline in Positive Behavior Support across 12 months (parent report)|Change from Baseline in Limit Setting across 12 months (parent report)|Change from Baseline in Monitoring across 12 months (parent report)|Change from Baseline in School Involvement across 12 months (parent report)|Change from Baseline in Parenting Self-Efficacy across 12 months (parent report)","University of Oregon|National Institute on Drug Abuse (NIDA)","All","Child, Adult, Older Adult","Not Applicable","347","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01DA037628","February 21, 2017","September 30, 2019","September 30, 2019","February 23, 2017",,"October 15, 2018","University of Oregon, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03060291"
533,"NCT00132340","Deep Brain Stimulation to Treat Cervical Dystonia",,"Completed","No Results Available","Cervical Dystonia","Device: Electrodes",,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","NIH","Interventional","Primary Purpose: Treatment","050222|05-N-0222","August 2005",,"July 2006","August 19, 2005",,"July 6, 2006","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00132340"
534,"NCT01892397","Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma",,"Active, not recruiting","No Results Available","Brain Cancer","Device: Optune (NovoTTF-100A)","progression-free survival rate|overall survival|safety and tolerability","Memorial Sloan Kettering Cancer Center|NovoCure Ltd.|Columbia University|University of Cincinnati|University of Colorado, Denver|University of Miami|Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-067","June 2013","June 2021","June 2021","July 4, 2013",,"July 2, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Colorado, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01892397"
535,"NCT01663168","EARNEST Rifabutin Pharmacokinetics (PK) Substudy",,"Unknown status","No Results Available","HIV|Tuberculosis","Drug: Rifabutin","Grade 3/4 adverse events|Rifabutin and its 25-o-desacetyl metabolite pharmacokinetic parameters (from a population PK model)|Lopinavir/ritonavir pharmacokinetic parameters (from a population PK model)|Raltegravir pharmacokinetic parameters (from a population PK model)|Response to TB therapy|Rifamycin resistance","Justine Boles|Abbott|Medical Research Council","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISRCTN13074752","December 2011","January 2014","January 2014","August 13, 2012",,"August 13, 2012","JCRC Fort Portal, Fort Portal, Uganda|JCRC Gulu, Gulu, Uganda|JCRC Kabale, Kabale, Uganda|JCRC Kakira, Kakira, Uganda|Infectious Diseases Institute (IDI), Kampala, Uganda|JCRC Kampala, Kampala, Uganda|San Raphael of St Francis Hospital, Nsambya, Kampala, Uganda|JCRC Mbale, Mbale, Uganda|JCRC Mbarara, Mbarara, Uganda",,"https://ClinicalTrials.gov/show/NCT01663168"
536,"NCT01448408","Corneal Biomechanical Properties and Anterior Segment Parameters, in Forme Fruste Keratoconus",,"Completed","No Results Available","Keratoconus|Forme Fruste Keratoconus",,"Sensitivity, Specificity and Predictive accuracy of CH, CRF, Cyl, ACD,CV, CV3, CV5 CCT, TCT, TCTx, TCTy and of a combination model","Democritus University of Thrace","All","18 Years to 50 Years   (Adult)",,,"Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","26/27-09-2011","May 2007",,"July 2011","October 7, 2011",,"October 7, 2011","Eye Institute of Thrace, Alexandroupolis, Thrace, Greece",,"https://ClinicalTrials.gov/show/NCT01448408"
537,"NCT01561859","Brain Imaging, Cognitive Enhancement and Early Schizophrenia","BICEPS","Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Behavioral: Cognitive Enhancement Therapy|Behavioral: Enriched Supportive Therapy","Confirm the neuroprotective effects of CET on frontal and temporal brain structure|Examine the effects of CET on fronto-temporal brain function.|Examine the durability of CET effects on fronto-temporal brain structure and function, cognition, and functional outcome at 1 year post-treatment|Explore the effects of a fronto-temporal structural and functional reserve on CET treatment response.","Beth Israel Deaconess Medical Center|University of Pittsburgh|Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 35 Years   (Adult)","Not Applicable","102","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2011P000267|R01MH092440","June 2012","June 2018","June 2018","March 23, 2012",,"December 17, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts Institute of Technology, Cambridge, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Psychiatry Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01561859"
538,"NCT00051961","Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome",,"Completed","No Results Available","Restless Legs Syndrome",,,"National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)",,"90","NIH","Observational",,"030075|03-N-0075","January 14, 2003",,"October 18, 2007","January 20, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00051961"
539,"NCT03115710","The K-Map Study, Global Prevalence of KC",,"Recruiting","No Results Available","Keratoconus","Diagnostic Test: Rotating Scheimpflug camera (Pentacam HR)","Prevalence of keratoconus","University Hospital, Geneva|ELZA Institute","All","6 Years to 23 Years   (Child, Adult)",,"700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR-09","December 28, 2015","February 1, 2021","February 1, 2021","April 14, 2017",,"April 19, 2019","USC Roski Eye Institute, Los Angeles, California, United States|Eye Hospital of Wenzhou Medical College, Wenzhou, China|King Saud University, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT03115710"
540,"NCT03094793","Impact of Interictal Electroencephalographic Abnormalities on the Stability of Attention in the Epilepsies","COGNIT-AIC","Unknown status","No Results Available","Epilepsy","Other: abnormal EEGs","Presence of AIC measured by an EEG on attentional performance","University Hospital, Grenoble|Hospices Civils de Lyon","All","6 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","38RC14.374","May 2015","May 2019","May 2020","March 29, 2017",,"June 4, 2018","University Hospital Grenoble, Grenoble, France|HCL, Lyon, France",,"https://ClinicalTrials.gov/show/NCT03094793"
541,"NCT02807480","Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response",,"Recruiting","No Results Available","Generalized Anxiety Disorder","Behavioral: Exposure-based therapy|Behavioral: Behavioral Activation therapy|Behavioral: Computer-based behavioral assessment|Behavioral: Surveys and Interviews|Device: Magnetic resonance imaging (MRI)|Device: Electroencephalography (EEG)","For Aim1: Baseline generalized anxiety disorder symptoms as measured by the Generalized Anxiety Disorder - 7 item scale (GAD-7).|For Aims 2 and 3: Change in generalized anxiety disorder symptoms as measured by the Generalized Anxiety Disorder - 7 item scale (GAD-7).|Change in anxiety symptoms as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale.|Change in depressive symptoms as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale.|Change in level of disability as measured by the Sheehan Disability Scale|Change in depressive symptoms as measured by the Beck Depression Inventory - II.|Change in worry symptoms as measured by the Penn State Worry Questionnaire.","Laureate Institute for Brain Research, Inc.|National Institute of Mental Health (NIMH)","All","18 Years to 55 Years   (Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2015-006-02|1K23MH108707-01A1","June 2016","April 2021","April 2021","June 21, 2016",,"March 18, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02807480"
542,"NCT03385343","Staging of Superficial EAC Using VLE",,"Enrolling by invitation","No Results Available","Esophageal Cancer","Diagnostic Test: VLE imaging for staging EAC","Percentage of subjects whose VLE results correlates with the histology results for T1 EAC depth of invasion|Percentage of subjects whose VLE results correlates with the histology results for staging T1 EAC","Mayo Clinic","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-002723","May 5, 2017","August 1, 2020","February 28, 2021","December 28, 2017",,"September 12, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03385343"
543,"NCT03467490","Self-care Management Program for Dry Eye Disease Patients Using the heiQ","heiQ","Active, not recruiting","No Results Available","Dry Eye Disease","Behavioral: DED self-management","Mean Change score in heiQ subscales|Mean Change scores in OSDI scores|Mean change score in heiQ subscale 1:Health-directed activity|Mean change score in heiQ subscale 1: Health-Directed activity|Mean change score in heiQ subscale 2: Positive and active engagement in life|Mean change score in heiQ subscale 3: Self-monitoring and insight|Mean change score in heiQ subscale 4: Constructive attitudes and approaches|Mean change score in heiQ subscale 5: Skill and technique acquisition|Mean change score in heiQ subscale 6: Social integration and support|Mean change score in the heiQ subscale 7: Health service navigation|Mean change score in heiQ subscale 8: Emotional distress","Lawson Health Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","109377","November 24, 2018","January 19, 2019","July 30, 2020","March 16, 2018",,"March 31, 2020","St. Joseph's Hospital, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03467490"
544,"NCT02980224","Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease",,"Completed","Has Results","Dry Eye","Drug: OmegaD|Drug: Placebo","Change From Baseline in Tear Break up Time(TBUT ) at Day 84|Change From Baseline in Dry Eye Symptom Scores (OSDI Questionnaire)|The Frequency and Severity of Adverse Events","OmegaD LLC","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OmegaD-2016-001","October 2016","February 2017","February 2017","December 2, 2016","September 11, 2019","December 13, 2019","Artesia, California, United States|Mission Hills, California, United States|Rancho Cordova, California, United States|Danbury, Connecticut, United States|Crystal River, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Pittsburg, Kansas, United States|Edgewood, Kentucky, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02980224/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02980224/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02980224"
545,"NCT01691235","SIMpill Medication Dispensing Device in the Treatment of HCV","SIMpill HCV","Withdrawn","No Results Available","Chronic Hepatitis C Virus","Device: SIMpill device","Improved SVR Rates|Improved Patient Adherence Rates","University of Chicago","All","18 Years to 70 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-1293","September 2012","January 2013","January 2013","September 24, 2012",,"October 8, 2014","The University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01691235"
546,"NCT01730625","Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial",,"Completed","No Results Available","Anxiety Disorder","Behavioral: Cognitive behavioral therapy for anxiety|Behavioral: Attention Bias Modification Treatment","Change in frequency of anxiety symptoms (based on ADIS)|Change in severity of anxiety symptoms (based on ADIS)|SCARED parent/child","Tel Aviv University","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","119","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ABMT-RCT","October 2010","July 2012","July 2012","November 21, 2012",,"November 21, 2012",,,"https://ClinicalTrials.gov/show/NCT01730625"
547,"NCT03402932","Administration Method of Cognitive Screening in Older Individuals With Hearing Loss",,"Completed","Has Results","Hearing Loss, Sensorineural|Cognitive Impairment","Other: Auditory amplified|Other: Visual|Other: Auditory unamplified","Cognitive Screening Results (Montreal Cognitive Assessment)|Auditory Working Memory Performance","Northwestern University","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2R01DC012289","April 1, 2018","July 10, 2018","July 10, 2018","January 18, 2018","April 3, 2019","April 3, 2019","Hearing Aid Laboratory, Evanston, Illinois, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03402932/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03402932/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03402932"
548,"NCT03665909","A Proactive Health Monitoring Intervention for Dementia Caregivers",,"Active, not recruiting","No Results Available","Dementia|Alzheimer Disease","Other: Remote activity monitoring system","Nursing home utilization at 18 months for the person with ADRD|Perceptions of change in caregiver self-efficacy|Perceptions of change in caregiver competence|Perceptions of change in caregiver burden|Perceptions of change in caregiver role captivity|Change in caregiver role overload|Change in frequency/perceptions caregiver depressive symptom severity|Perceived acceptability/utility of remote activity monitoring at 6-, 12-, and 18-months","University of Minnesota|Agency for Healthcare Research and Quality (AHRQ)","All","21 Years and older   (Adult, Older Adult)","Phase 3","170","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1401547541|R18HS022836","April 1, 2014","March 3, 2020","March 3, 2020","September 11, 2018",,"November 1, 2019",,,"https://ClinicalTrials.gov/show/NCT03665909"
549,"NCT00578123","Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy",,"Active, not recruiting","No Results Available","Prostate Cancer|Quality of Life","Behavioral: Quality of Life Questionnaires","To compare robotic-assisted radical prostatectomy (RALP), and open radical prostatectomy (ORP) with respect to potency function at 1 year, after adjusting for known confounding variables measured at baseline.|To evaluate the recovery of continence after RALP or ORP.|To evaluate patient convalescence after RALP or ORP.|To evaluate operative details.|To evaluate inpatient (hospital) details|To evaluate post-discharge (home) details.|To evaluate health service utilization, out-of-pocket spending and changes in employment following RALP or ORP.","Memorial Sloan Kettering Cancer Center|The Cleveland Clinic","Male","Child, Adult, Older Adult","Not Applicable","959","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","04-094","July 2005","July 2020","July 2020","December 20, 2007",,"August 7, 2019","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00578123"
550,"NCT02446262","Neural and Psychological Mechanisms of Pain Perception",,"Recruiting","No Results Available","Pain|Normal Physiology|Healthy Volunteers","Behavioral: Instructions|Behavioral: Attention|Behavioral: Thermal Pain|Behavioral: Placebo instructions","Pain perception (pain ratings)|BOLD response in brain regions of interest measured using fMRI|Physiological responses (heart rate, skin conductance, respiration, pupil dilation, eye gaze position)|Questionnaire measures (e.g. State-trait anxiety index, Fear of Pain questionnaire, Intolerance of Uncertainty questionnaire, McGill Pain Questionnaire)","National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Not Applicable","400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","150132|15-AT-0132","June 11, 2015","February 15, 2021","June 15, 2021","May 18, 2015",,"April 29, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02446262"
551,"NCT01088230","The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke",,"Completed","No Results Available","Stroke","Other: Botox®|Other: saline solution","Change scores on Fugl Meyer- Upper Extremity Section|Change on kinematic analysis","New York Presbyterian Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-0904010371","June 2009","September 2010","November 2010","March 17, 2010",,"April 26, 2011","New York Presbyterian Hospital- Weill Cornell campus, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01088230"
552,"NCT02088099","Mayo Clinic Traumatic Brain Injury Model System Center: The CONNECT Trial","CONNECT","Completed","No Results Available","Traumatic Brain Injury","Other: Complex clinical intervention|Other: Treatment as usual","Change in Traumatic Brain Injury - Quality of Life (TBI-QOL)|Change in measure of patient impression of Telemedicine (TMP-Q)|Change in Caregiver Appraisal Scale (CAS)|Change in Clinical Satisfaction and Competency Rating (CSCR)|Change in the Activity Measure for Post-Acute Care™ (AM-PAC™)|Change in self-reported use of health care and other community support services","Mayo Clinic|Minnesota Department of Health|Iowa Department of Public Health|Rapid City Regional Hospital, Inc|Altru Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","12-008525|NIDILRR","March 2014","September 2017","December 2018","March 14, 2014",,"October 1, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02088099"
553,"NCT04099537","Skin Picking Approach Avoidance Task","SPAAT","Recruiting","No Results Available","Skin-Picking","Behavioral: Computerized cognitive training","Changes in Behavioral Approach Tendency After a Single Training Session|Changes in Urges to Pick After Training|Changes in scores on the Skin Picking Scale-Revised (SPS-R).","University of Wisconsin, Milwaukee","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SPAAT2018","July 2, 2018","December 2, 2020","December 2, 2020","September 23, 2019",,"September 23, 2019","Psychology Clinic, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04099537"
554,"NCT01182506","Rehabilitation of Cognitive Changes in Breast Cancer Survivors",,"Active, not recruiting","No Results Available","Breast Cancer","Behavioral: Cogmed Working Memory Training Program","Determine the efficacy of working memory training|Test whether or not working memory training in breast cancer survivors is associated with greater gains in the software's ""Improvement Index"".|Investigate whether breast cancer survivors perceive functional improvement following working memory training.","Memorial Sloan Kettering Cancer Center|MARTELL FOUNDATION","Female","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10-105","August 2010","August 2020","August 2020","August 16, 2010",,"February 17, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01182506"
555,"NCT01721291","Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)",,"Unknown status","No Results Available","CHRONIC OBSTRUCTIVE PULMONARY DISEASE|ASTHMA|HEALTHY SUBJECTS","Drug: SALBUTAMOL","ANALYSIS OF LUNG DEPOSITION - Penetration Index|ANALYSIS OF LUNG PHYSIOLOGY TESTS - Impulse Oscillometry R5 & X5 and Multi-breath Washout tests of S-acin and S-cond","Imperial College London|National Institute for Health Research, United Kingdom","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NIHRCDF|NIHR-CDF-2011-04-053","October 2012","April 2015","February 2016","November 4, 2012",,"August 27, 2015","Royal Brompton Hospital & Imperial College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01721291"
556,"NCT03980119","Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya","PARA","Not yet recruiting","No Results Available","Pediatric HIV Infection","Other: HITSystem 3.0","Pediatric ART Retention|Pediatric Viral Load Suppression|Missed ART|Medication Ratio >90%|Viral Load Testing","Global Health Innovations|London School of Hygiene and Tropical Medicine|Kenya Medical Research Institute","All","up to 16 Years   (Child)","Not Applicable","1160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HITSystem Peds Retention Kenya","August 2019","August 2021","December 2021","June 10, 2019",,"June 10, 2019",,,"https://ClinicalTrials.gov/show/NCT03980119"
557,"NCT04214223","Conception of a Decisional Tool Using a Pre-Anesthesic Numerical Evaluation (PANE) During the 8th Month of Pregnancy","PANE","Not yet recruiting","No Results Available","Pregnancy Related","Other: Pre-Anesthesic Consultation|Other: Pre-Anesthesic Numerical Evaluation","Validated Pre-Anesthesic Numerical Evaluation questionnaire|Elaborate and validate the first version of Pre-Anesthesic Numerical Evaluation questionnaire|Validate the first version of Pre-Anesthesia Numerical Evaluation within the population of pregnant women of Maternity Hospital of Nancy (France)","Central Hospital, Nancy, France","Female","18 Years and older   (Adult, Older Adult)",,"336","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","2019PI140","September 1, 2020","August 31, 2021","February 28, 2022","January 2, 2020",,"January 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04214223"
558,"NCT02153918","Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy",,"Completed","Has Results","Prostate Cancer|Prostatic Neoplasms|Neoplasms, Prostate","Biological: PROSTVAC-V/TRICOM|Biological: PROSTVAC-F/TRICOM","Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates|Count of Participants With Change in Peripheral Prostatic Specific Antigen (PSA)-Specific T Cell Responses|Intraprostatic Treg Cell Infiltration With Cluster of Differentiation 4 (CD4)+Forkhead Box P3 (FOX-P3) Staining|Prostatic Specific Antigen (PSA) Changes Secondary to Vaccination|Magnetic Resonance Imaging (MRI) Changes Secondary to Vaccination|Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","27","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140112|14-C-0112","May 31, 2014","July 28, 2017","January 16, 2018","June 3, 2014","October 12, 2018","October 12, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02153918/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02153918"
559,"NCT01249742","Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet",,"Completed","No Results Available","Diabetes Mellitus","Behavioral: Internet intervention","Patients' Evaluation of Quality of Care|Health Related Quality of Life|Adolescents' disease knowledge|Confidence In Diabetes Selfcare|Glycemic control (HbA1c)|Degree of use of intervention","Radboud University|Dutch Diabetes Research Foundation","All","12 Years to 21 Years   (Child, Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care","2007.13.003","February 2009","April 2010","November 2010","November 30, 2010",,"November 30, 2010","Children's Diabetes Center Nijmegen, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01249742"
560,"NCT00819949","Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Device: Lokomat","Freezing of Gait","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","B4125-K","October 2008","October 2010","October 2010","January 9, 2009",,"September 20, 2013","Providence VA Medical Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00819949"
561,"NCT01546766","Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)",,"Completed","No Results Available","Diabetes|Retinal Disorders","Device: Pupillometry testing.","Pupillary response|Pupillary response.","University of California, Los Angeles|Neuro Kinetics|Jules Stein Eye Institute|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)",,"315","Other|Industry|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UCLA IRB#11-002987|5R44EY018025-03","February 2007","August 2015","August 2015","March 7, 2012",,"October 15, 2018","Jules Stein Eye Institute, Dept. of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Neuro Kinetics Inc., Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01546766"
562,"NCT02019173","Rehabilitation Boot Camp: Intensive Balance and Mobility Therapy for People With Acquired Brain Injury",,"Completed","No Results Available","Brain Injuries","Behavioral: Boot Camp Balance Training","Change from baseline measure of Dual Task Cost of a visual cognitive task on stationery balance|Change from baseline measure in time (seconds) to perform Five Times Sit to Stand Test|Change in score from baseline measure in Chedoke McMaster Stroke Assessment Activity Scale|Change from baseline measure of the Sway Path Length during The Modified Clinical Test of Integration in Balance (mCTSIB)|Change in distance walked (meters) from baseline measure in the Two Minute Walk Test (2 MWT)|Change in score from baseline measure in the Participation Assessment with Recombined Tools - Objective 17 (PART-O 17)","University of Manitoba","All","18 Years to 55 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H2013:403","June 2014","July 2014","July 2014","December 24, 2013",,"March 24, 2015","University of Manitoba, School of Medical Rehabilitation, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02019173"
563,"NCT03286686","Sensori-motor and Perceptual Functions of the PPC.","PPCfonctions","Recruiting","No Results Available","Healthy Volunteers|Optic Ataxia","Behavioral: point targets|Behavioral: tactile stimulation|Behavioral: visual images","response error - number of pointing error|response error -measure of reaction times|response error - percentage of right responses","Hospices Civils de Lyon","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","155","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL17_0341|2017-A02562-51","February 22, 2018","February 22, 2024","February 22, 2024","September 18, 2017",,"August 8, 2019","U1028 INSERM - CNRS UMR 5292 Equipe ImpAct, Bron, France",,"https://ClinicalTrials.gov/show/NCT03286686"
564,"NCT02173119","Can Quantitative MRI After cTACE Help Predict Survival ?",,"Completed","No Results Available","Hepatocellular Carcinoma (HCC)","Other: MRI post-TACE","Imaging response|Clinical response|Adverse Events|Time-to-Tumor Progression|Survival","Medical College of Wisconsin|Guerbet|Northwestern University","All","18 Years to 89 Years   (Adult, Older Adult)",,"23","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO22746","August 2014","March 7, 2018","March 7, 2018","June 24, 2014",,"June 10, 2019","Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02173119"
565,"NCT03468634","Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy","RaPIDE","Not yet recruiting","No Results Available","Barrett Esophagus|Esophageal Cancer","Diagnostic Test: endoscopy","Device safety testing (no detectable damage in biopsy samples when reviewed by histopathology)|Diagnostic model developed (algorithm able to discriminate disease with >50% specificity and >50% sensitivity)","University of Exeter|University of Bristol|Gloucestershire Hospitals NHS Foundation Trust","All","18 Years to 100 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","1516/017/162347","May 2020","August 2020","August 2020","March 16, 2018",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT03468634"
566,"NCT03383848","Evaluation of Patient Experience and Quality of Life During In Vitro Fertilization Treatment",,"Recruiting","No Results Available","Infertility","Device: Medication Management Software","Documented Medication Errors|Number of Phone and Patient Portal Messages to Infertility Nurses|Quantity of Medication Waste|Stress Level|Anxiety Level|Quality of Life","University of Michigan","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HUM00121481","January 10, 2018","September 30, 2020","September 30, 2020","December 26, 2017",,"July 2, 2020","Center for Reproductive Medicine, University of Michigan, Ann Arbor, Michigan, United States|Northville Health Center, Northville, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03383848"
567,"NCT01101724","Effect of Early Rest on Recovery From Pediatric Concussion",,"Completed","No Results Available","Mild Traumatic Brain Injury|Concussion|Post-concussive Syndrome","Behavioral: Mandated Rest, Intervention","Neurocognitive Outcomes|Ancillary Neurocogntive Test Battery|Parental Attitude to Concussion:","Medical College of Wisconsin","All","11 Years to 22 Years   (Child, Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","5520163IRC","April 2010","December 2011","December 2012","April 12, 2010",,"November 5, 2013","Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01101724"
568,"NCT01945333","Personalized and Scalable Cognitive Remediation Approaches",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Behavioral: Cognitive remediation","Feasibility|Change in neurocognition from baseline to treatment end-point|Change in neurocognition from baseline to 3-month follow-up","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","122","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","#6721|1R34MH100317-01","September 2013","October 2, 2017","March 20, 2019","September 18, 2013",,"May 22, 2019","FEGS Bronx Mental Health Clinic, Bronx, New York, United States|Williamsburg Clinic, Brooklyn, New York, United States|Institute for Community Living, Brooklyn, New York, United States|Nyspi/ Cumc, New York, New York, United States|The Bridge Inc, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01945333"
569,"NCT04173806","Evaluation of an Online Telemedicine Course Through Facebook",,"Recruiting","No Results Available","Telemedicine|Training","Other: Facebook intervention|Other: Control Training:","Level of Knowledge about telemedicine|The satisfaction assessment will be carried out through the Wang questionnaire (Likert scale)","Universidad Peruana Cayetano Heredia","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","104043","November 25, 2019","January 4, 2020","January 4, 2020","November 22, 2019",,"November 27, 2019","Universidad Peruana Cayetano Heredia, Medicine School, Lima, San Martín De Porres, Peru",,"https://ClinicalTrials.gov/show/NCT04173806"
570,"NCT02312934","Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study",,"Completed","Has Results","Chemo Brain|Chemotherapy-related Cognitive Impairment|Chemo Fog|Breast Cancer|Chemobrain","Drug: Transdermal nicotine|Other: Placebo Transdermal Patch","Change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) PCI Scale|Conners Continuous Performance Test","Vanderbilt University Medical Center","Female","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","141584","August 2015","May 2018","May 2018","December 9, 2014","January 21, 2020","January 21, 2020","Center for Cognitive Medicine at Vanderbilt University, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02312934/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02312934"
571,"NCT02813473","SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease","SYNTAX III","Completed","Has Results","Coronary Artery Diseases|Multivessel Coronary Artery Disease|Heart Diseases|Cardiovascular Diseases","Radiation: Coronary Angiography|Radiation: Computed Tomography (CT) scan","Inter-rater Agreement on Revascularization Strategy of Two Heart Teams Using an ""Angio-first"" Algorithm or a ""CT First"" Algorithm.|Level of Agreement in the Decision Making Strategy Based on CT Only Without Functional Assessment and the Decision Making Strategy Based on CT With Functional Assessment (""CT First"" Algorithm Group) at Screening.|Level of Agreement in the Decision Making Strategy Based on CT Only (With Functional Assessment) and the Decision Making Strategy Based on CT With Functional Assessment and Conventional Angiography (""CT First"" Algorithm Group) at Screening|Level of Agreement in the Decision Making Strategy Based on Conventional Angiography Only and the Decision Making Strategy Based on CT With Functional Assessment and Conventional Angiography (""Angio First"" Algorithm Group) at Screening|Inter-rater Agreement on Revascularization Strategy (Based on Conventional Angiography and CT With Functional Assessment) of Two Heart Teams Using an ""Angio-first"" Algorithm or a ""CT-first"" Algorithm at Screening|Anatomical SYNTAX Score Calculation Based on Non-invasive GE Revolution CT (Visual by Heart Team Involving an Experienced Coronary CT Reader) and the Resulting SYNTAX Score II at Screening|Anatomical SYNTAX Score Calculation Based on Non-invasive GE Revolution CT (Visual by Core Lab) and the Resulting SYNTAX Score II at Screening|Anatomical SYNTAX Score Calculation Based Invasive Angiography (Visual by Heart Team) and the Resulting SYNTAX Score II at Screening|Anatomical SYNTAX Score Calculation Based on Invasive Angiography (Visual by Core Lab) and the Resulting SYNTAX Score II at Screening|CT Based Functional Anatomy (FFRCT as Assessed by Heartflow) at Screening|Concordance in SYNTAX Score(s) Between and Within Strategies at Screening|Agreement in Coronary Stenosis Segments to be Revascularized Between and Within Strategies at Screening","ECRI bv|GE Healthcare|HeartFlow, Inc.","All","18 Years and older   (Adult, Older Adult)",,"223","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ECRI-004","June 27, 2016","March 26, 2018","March 26, 2018","June 27, 2016","September 27, 2019","September 27, 2019","BE006, Brussel, Belgium|FR013, Nancy, France|FR012, Paris, France|DE011, Jena, Germany|IT008, Milan, Italy|CH003, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02813473/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02813473"
572,"NCT03498651","Interpretation Training to Reduce Anxiety: Evaluating Technology-based Delivery Models and Methods to Reduce Attrition",,"Recruiting","No Results Available","Anxiety","Behavioral: Cognitive Bias Modification - Interpretation training|Behavioral: Coaching|Behavioral: Online psychoeducation about anxiety","Change in Recognition Ratings|Change in Overall Anxiety Severity and Impairment Scale|Change in Brief Bodily Sensations Interpretations Questionnaire|Change in Depression, Anxiety, Stress Scales-Short Form: Anxiety Subscale|Change in Depression Comorbid symptoms|Change in Alcohol Use Comorbid symptoms|Change in Wellness measures - Optimism|Change in Wellness measures - Growth mindset|Change in Wellness measures - Self-efficacy|Change in Wellness measures - Life Satisfaction|Change in Mechanisms underlying bias change - Cognitive flexibility|Change in Mechanisms underlying bias change - Experiential avoidance|Change in Mechanisms underlying bias change - Cognitive reappraisal|Change in Mechanisms underlying bias change - Intolerance of uncertainty|Change in Anxiety and Identity Circles","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 2","840","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2017-0234-00","January 20, 2019","March 2021","March 2022","April 17, 2018",,"April 15, 2020","MindTrails web site: https://mindtrails.virginia.edu/ (thru Univ. of Virginia), Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03498651"
573,"NCT00565864","Neurocognitive and Metabolic Effects of Mild Hypothyroidism",,"Completed","Has Results","Hypothyroidism","Drug: L-thyroxine (L-T4)","Executive Function|Resting Energy Expenditure","Oregon Health and Science University","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 4","173","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00002265","August 2008","August 2013","August 2013","November 30, 2007","August 22, 2018","August 22, 2018","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00565864"
